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SUMMARY 
 
Surfactant replacement therapy is used the treatment of neonatal respiratory distress syndrome 
as surfactant’s biophysical behaviour helps to maintain proper lung function and reduces the 
work associated with breathing. Secondly, surfactant associated proteins are important role 
players in the innate immune response within the pulmonary environment and therefore assist 
in pulmonary host defence. However, natural and synthetic exogenous surfactants have gained 
much interest in other areas of therapy such as possibly aiding in dual-drug delivery systems 
for infectious or inflammatory pulmonary conditions. Both types have been studied extensively 
in animal models and in clinical trials and have elicited positive and negative effects on lung 
function. This thesis aims to determine whether a synthetic peptide containing surfactant, 
Synsurf®, may have potential immunomodulatory effects compared to the naturally derived 
surfactants, Curosurf® and Liposurf®.  
 
Two formulations of Synsurf®, combined with the antibiotic linezolid were tested for its 
efficacy as a respirable compound in a pressurised metered dose inhaler. The outcome of these 
experiments revealed the prospect of Synsurf®’s adaptability as a pulmonary drug carrier. 
Furthermore, the tuberculosis isolates H37Rv and MDR-X51 displayed enhanced 
susceptibility to surfactant-drug micro-particle combinations.  
 
The main findings of this study show that the natural surfactants Curosurf® and Liposurf® as 
well as Synsurf® inhibit secretion of pro-inflammatory cytokines and influence the production 
of reactive oxygen species in NR8383 alveolar macrophages and therefore influence cell 
viability. The inhibitory effects on cytokine secretion was displayed in a dose-dependent 
manner as well as a threshold effect that was seen for all three surfactants. This may result from 
unique mechanisms of decreasing cell signalling or up-regulating anti-inflammatory activity 
that was further elucidated by the employment of proteomics.  
 
The findings in this thesis on the comparison of the two natural and one synthetic surfactant 
led to the following main conclusions: a) Different surfactant compositions modulate the anti-
inflammatory activity in lipopolysaccharide stimulated alveolar macrophages via the possible 
involvement of different signalling pathways. The initial hypothesis regarding the protective 
nature that is linked to the protein content in natural surfactants is challenged and may be 
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deemed as “not fully supported” as these new findings suggest non-specific lipid or synthetic 
peptide protection with alveolar macrophages as seen with Synsurf®. b) Different surfactant 
compositions effect cell viability and morphology in a time and dose-dependent manner 
revealing that the treatment of neonatal respiratory distress syndrome may depend upon the 
specific preparation or dose used. c) All three surfactants displayed an impact on the antibiotic 
activity of linezolid that holds positive ramifications for drug loaded surfactants. d) The data 
shows that linezolid in combination with Synsurf® can be aerosolised in desired particle ranges 
for optimal lung deposition for a possible non-invasive, site-specific, delivery model via 
pressurised metered dose inhaler. 
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OPSOMMING 
 
Surfaktantvervangingsterapie word gebruik in die behandeling van neonatale respiratoriese 
noodsindroom aangesien die biofisiese werking van surfaktant behoorlike longfunksie help 
handhaaf en die inspanning verbonde aan asemhaling verminder. Tweedens is 
surfaktantverwante proteïene belangrike rolspelers in die aangebore immuunreaksie in die 
pulmonêre omgewing, en bevorder dus pulmonêre gasheerverdediging. Tog is daar ook 
toenemende belangstelling in natuurlike en sintetiese eksogene surfaktante op ander 
behandelingsgebiede, soos dat dit moontlik dubbele middelleweringstelsels vir infeksie- of 
inflammatoriese pulmonêre toestande kan ondersteun. Albei tipes surfaktante is reeds 
omvattend in diermodelle en kliniese proewe bestudeer, en blyk sowel positiewe as negatiewe 
uitwerkings op longfunksie te hê. Hierdie tesis beoog om te bepaal of ’n surfaktant wat 
sintetiese peptiede bevat, naamlik Synsurf®, ’n moontlike rol in immuunregulering speel 
vergeleke met die natuurlik afgeleide surfaktante Curosurf® en Liposurf®.  
 
Twee Synsurf®-formules is in kombinasie met die antibiotikum linezolid getoets vir 
doeltreffendheid as ’n inasembare verbinding in ’n drukinhalator met afgemete dosisse. Die 
uitkoms van hierdie eksperimente dui op die moontlike aanpasbaarheid van Synsurf® as ’n 
draer vir pulmonêre middels. Daarbenewens toon die tuberkulose-isolate H37Rv en MDR-X51 
verhoogde vatbaarheid vir mikropartikel surfaktantmiddel kombinasies.  
 
Die hoofbevinding van die studie toon dat die natuurlike surfaktante Curosurf® en Liposurf® 
sowel as Synsurf® die afskeiding van pro-inflammatoriese sitokiene strem en ’n invloed het 
op die produksie van reaktiewe suurstofspesies in NR8383- alveolêre makrofage, en dus op 
sellewensvatbaarheid. Die remmende uitwerking op sitokienafskeiding is op ’n 
dosisafhanklike manier bewys, sowel as deur ’n drempeleffek vir ál drie surfaktante. Dít kan 
dalk spruit uit unieke meganismes wat selseine verminder, of die opregulering van anti-
inflammatoriese aktiwiteit, wat verder met behulp van proteomika toegelig is.  
 
Die hoofgevolgtrekkings na aanleiding van die bevindinge van hierdie tesis oor die vergelyking 
van die twee natuurlike en een sintetiese surfaktant is soos volg: a) Verskillende 
surfaktantsamestellings moduleer anti-inflammatoriese werking in lipopolisakkaried-
gestimuleerde alveolêre makrofage deur die moontlike betrokkenheid van verskillende 
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seinroetes. Die aanvanklike hipotese oor die beskermende funksie van die proteïeninhoud van 
natuurlike surfaktante word bevraagteken. Aangesien hierdie nuwe bevindinge dui op nie-
spesifieke lipied- of sintetiesepeptiedbeskerming by alveolêre makrofage, soos in die geval van 
Synsurf®, kan die hipotese nie ten volle ondersteun word nie. b) Verskillende 
surfaktantsamestellings beïnvloed sellewensvatbaarheid en -morfologie op ’n tyd- en 
dosisafhanklike manier, wat daarop dui dat die behandeling van neonatale respiratoriese 
noodsindroom moontlik kan afhang van die spesifieke preparaat of dosis wat gebruik word. c) 
Ál drie surfaktante het oënskynlik ’n impak op die antibiotiese aktiwiteit van linezolid, wat 
belowend lyk vir surfaktante as middeldraers. d) Die data toon dat linezolid in kombinasie met 
Synsurf® in ’n gewenste partikelgrote verstuif kan word vir optimale longneerslag in ’n 
moontlike nie-ingrypende, terreinspesifieke leweringsmodel, deur middel van ’n drukinhalator 
met afgemete dosisse. 
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1 CHAPTER 1: LITERATURE REVIEW 
1.1 Introduction 
 
The development of inhaled drug delivery systems has gained great interest, as it is an attractive 
route for drug delivery. Supporting reasons for the inhalation route being a preferred means of 
drug delivery alongside reduced incidence of adverse systemic side effects include: (A) Site- 
specific drug delivery for locally acting compounds can lead to a rapid onset of action (Timsina, 
Martin et al. 1994), especially for drugs that undergo extensive first pass metabolism such as 
hormones, peptides and proteins. Furthermore, potent drugs can be administered at lower 
dosages (Newhouse, Corkery 2001). (B) The large surface area of the respiratory tract of 70-
80 m2 with a good blood supply also provides excellent conditions for efficient drug absorption 
(Weibel, Gomez 1962). Moreover, the decreased invasiveness may offer improved patient 
compliance for infectious pulmonary disease. With the advent of novel macromolecular 
medications, the horizon of aerosol drug delivery is expanding to include non-respiratory 
conditions e.g. diabetes, analgesia, thyroid disorders and genetic disease. 
Respiratory diseases such as asthma, adult respiratory distress syndrome (ARDS), neonatal 
respiratory distress syndrome (RDS), chronic obstructive pulmonary disease (COPD), 
pulmonary tuberculosis (TB), cystic fibrosis, pulmonary arterial hypertension and human 
immunodeficiency virus (HIV)-related lung pathology, as well as various non-respiratory 
conditions are all prone to continued use of inhaled drugs. Thus, improvements to inhaled drug 
delivery systems as well as dual drug delivery tools are very desirable. Designing a successful 
system for drug delivery to the respiratory tract requires a comprehensive understanding of the 
disease condition, lung anatomy and physiology, physio-chemical properties of drug alone and 
the polymeric matrix combined production process of the drug (Mossaad 2014). 
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1.2 Structure and Function of the Respiratory Tract 
 
The primary function of the respiratory tract (RT) is gas exchange: facilitating the movement 
of oxygen into the blood from inspired air and removing carbon dioxide from the circulation 
through a very thin blood-gas barrier in the exchange area (see Figure 1.1). A secondary 
function appears to be the cleaning and humidifying of the incoming air to prevent damage 
to this vital organ. The RT is broadly divided into three regions: (1) the upper RT, also called 
the oropharyngeal region, consists of the mouth, pharynx and larynx. (2) The conducting 
airways, which include the trachea, bronchi and bronchioles. (3) The lower RT, also called 
the alveolar or pulmonary region, which extends from the respiratory bronchioles to the distal 
alveolar sacs and forms about 85% of the total lung volume.  
 
Figure 1.1: Structure of the respiratory system. A) The respiratory system is diagrammed with a transparent lung 
to emphasize the flow of air into and out of the system. B) Enlargement of boxed area from (A) shows transition 
from conducting airway to the respiratory airway, with emphasis on the anatomy of the alveoli. Red and blue 
represent oxygenated and deoxygenated blood, respectively (Barrett, Ganong 2010). 
 
 
The function of the upper RT is to heat and moisten, as well as remove particulate matter from 
the inspired air. The inspired air passes down the trachea and through the bronchioles, 
respiratory bronchioles, and alveolar ducts to the alveoli. The airways divide as many as 23 
times between the trachea and the alveolar sacs to form an asymmetric, continuous, 
dichotomously branching structure. The upper conducting airways form the first 16 divisions 
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(see Figure 1.2) that transport the air to and from the outside environment (Barrett, Ganong 
2010). 
 
Figure 1.2: The branching patterns of the airway during the transition from conducting to respiratory airway are 
drawn (not all divisions are drawn, and drawings are not to scale) (Barrett, Ganong 2010). 
 
1.3 Surfactant Replacement Therapy 
 
Surfactant therapy was established from the observation that the lungs of babies dying from 
RDS lack the surface-active material; and was further based on the assumption that it should 
be possible to compensate for this deficit by administering the absent material (or an equivalent 
substance) via the airways. Exogenous surfactant therapy has therefore been an essential part 
of the routine care of preterm neonates with RDS since the beginning of the 1990s (Robertson, 
Halliday 1998). However, this is not a new concept. The American pathologist, Peter 
Gruenwald, conveyed this theory in 1947, which was based on the pressure-volume recordings 
and histological observations on lungs of babies with RDS. He postulated that `the addition of 
surface active substances to the air or oxygen which is being spontaneously breathed in or 
introduced by a respirator might aid in relieving the initial atelectasis of newborn infants' 
(Gruenwald 1947). Fujiwara and colleagues (1980) undertook the pilot study for the clinical 
debut of surfactant therapy application, which showed the dramatic improvement of lung 
function in babies with RDS treated with a large dose of modified natural surfactant instilled 
directly into the airways. These findings created a historical moment as previous efforts to treat 
babies with RDS were unsuccessful (Fujiwara, Chida et al. 1980). The reason as to why 
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previous aerosolized artificial surfactant was ineffective has been attributed to the use of 
dipalmitoylphosphatidylcholine (DPPC) alone. DPPC is an essential component of pulmonary 
surfactant, but cannot be used as an effective substitute alone. It is now well known that 
hydrophobic proteins are required to enhance spreading of the surface-active material in the 
airspaces and are thus required in exogenous surfactants for appropriate efficiency (Robertson, 
Halliday 1998). Since then, many randomised controlled studies have demonstrated that 
surfactant therapy was not only well tolerated, but that it significantly reduced both neonatal 
mortality and pulmonary air leaks (Ainsworth, Milligan 2002). 
1.3.1 Pulmonary Surfactant Composition and Production 
 
Pulmonary surfactant is a lipoprotein complex produced by the Type II alveolar cells, stored in 
the lamellar bodies and then secreted into the alveolar space. It covers the alveolar epithelial 
surface and small bronchioles to form a lattice-like structure called ‘tubular myelin’ (Haagsman, 
Van Golde 1991, Wright, Dobbs 1991) that is believed to be the precursor to the surfactant 
monolayer (see Figure 1.3), and is the direct precursor to the surfactant film at the air–liquid 
interface. The mechanism in which these lamellar bodies are released is unclear (Clements, 
Oyarzun et al. 1981), although mechanical and humoral mechanisms have been implicated 
(Goerke, Clements 1986).  
 
Figure 1.3: Particles in the alveolar sub-phase. In this electron micrograph section of a rat lung, lamellar bodies 
(LB) are seen forming tubular myelin (TM) (bar at lower right=1.0 μm). The remaining vesicular structures may 
represent both used and rejected surfactant materials. Inset: detail of tubular myelin at lower left, showing small 
projections in the corners, thought to represent SP-A (bar=0.1 μm) (Goerke 1998). 
Stellenbosch University  https://scholar.sun.ac.za
5 
 
β-Adrenergic agents, and changes in ventilatory patterns are some physiological triggers for 
surfactant secretion from alveolar epithelia, in addition to several other biochemical mediators. 
As the film compresses it facilitates the reductions in surface tension and is also purified during 
the breathing cycle as certain protein components are compressed out of the film. As surfactant 
is actively being secreted, materials are constantly being exchanged from the film and are 
recycled into the type II epithelial cells (Figure 1.4A); this helps maintain a constant surfactant 
pool size within the alveolus. Thus, many recycled alveolar surfactant components are 
transported back to form newly formed lamellar bodies (Glasser, Mallampalli 2012). 
 
The schematic representation of the life cycle of pulmonary surfactant in the normal lung is 
displayed in Figure 1.4B. It was first discovered 57 years ago when Avery and Mead (1959) 
found that bronchoalveolar lavage (BAL) fluid of newborns with IRDS (then known as hyaline 
membrane disease) lowered surface tension less than that of healthy newborns when 
investigating the pathogenesis of respiratory failure of premature newborns (Avery, Mead 1959, 
Rosenberg, Seiliev et al. 2006).  
 
 
Figure 1.4: A) Several Alveoli. Type I pneumocytes are obvious by their large central nuclei while type II 
pneumocytes have a ‘flattened’ nuclei and a cytoplasm that spreads out to the side. An alveolar macrophage can 
also be noted within the alveolar space (McLeod 2010.) B) The Aveolus: Formation and metabolism of Surfactant. 
Lamellar bodies are formed by type II alveolar epithelial cells and secreted by exocytosis into the fluid lining the 
alveoli. The released lamellar body material is converted to tubular myelin and it is the source of the phospholipid 
surface film. Surfactant is taken up by endocytosis into alveolar macrophages and type II epithelial cells (Barrett, 
Ganong 2010, Hill 2016). 
 
Surfactant isolated from healthy mammals’ lung BAL fluid consists of 90% lipids and 8 - 10% 
proteins (Figure 1.5); however, the composition may vary and is dependent on factors such as 
age, species, specific lung compartment, disease state, diet and isolation method. Phospholipids 
A B 
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(80%) make up for the majority of the lipid content of which 8 - 10% is neutral. 
Phosphatidylcholine constitute for 80% of the phospholipids of which 40 - 80% of it is 
dipalmitoylphosphatidylcholine (DPPC) and 8 - 15% is phosphatidylglycerol (PG) (see Figure 
1.6). There may also be small quantities of phosphatidylethanolamine (PE), phosphatidylserine 
(PS), phosphatidylinositol (PI), and sphingomyelin (SM) (King, Clements 1972., Sanders 1982, 
Serrano, Pérez-Gil 2006). The presence of PI and the ratio of PI to PG is an indication of lung 
maturity. For instance, a low PG:PI ratio is a sign of lung immaturity (Ayden, 1999). There are 
4 surfactant-associated proteins: SP-A, SP-B, SP-C, and SP-D (see Figure 1.7). SP-C has the 
exception of being formed in the bronchiolar epithelial cell (Kalina, Mason et al. 1992) and not 
in the type II alveolar cells like its counterparts. The hydrophilic SP-A (35 kDa) and SP-D (43 
kDa) are referred to as collagen-containing C-type (calcium dependent) lectins called collectins, 
which contribute significantly to surfactant homeostasis and pulmonary immunity (Possmayer 
1988, Kishore, Greenhough et al. 2006). The smaller hydrophobic, carbohydrate containing 
proteins SP-B (8 kDa) and SP-C (4.2 kDa) make up less than 1% of the total protein weight 
and facilitate the adsorption and spreading of lipid to form the surfactant monolayer at the air-
liquid interface (Jobe, Wood 1993).  
 
Figure 1.5: Composition of human lung surfactant (Serrano, Pérez-Gil 2006). 
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The surfactant system, through specific lipid-lipid and lipid-protein interactions, displays how 
the membrane’s condition in several different forms governs biological functions. It sets it apart 
from understanding its structure alone, but rather understanding the structure-function and 
interactions present in highly differentiated cells (Pérez-Gil 2008).  
 
 
 
 
 
 
Figure 1.6: Structure of (Above) DPPC: 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine; (Below) PG: 1,2-diacyl-
sn-glycerol-3-phosphorylglycerol (Avanti Lipids Polar, Inc.). 
 
 
 
 
 
Figure 1.7: Structure of surfactant proteins (SP-A, SP-B, SP-C, and SP-D). (A) SP-A and SP-D are hydrophilic 
surfactant proteins and part of the collectin family. Common structural features are an amino N-terminal, a 
collagen like domain, a neck region, and a carbohydrate recognition domain (CRD). (B) SP-B and SP-C are 
hydrophobic surfactant proteins and play a role in biophysical surfactant functions. They are found in close 
association with surfactant phospholipids (Christmann, Buechner‐Maxwell et al. 2009). 
 
Formula: C40H80NO8P 
Molar Mass: 734.039 g/mol 
 
Formula: C38H75O10P 
Molar Mass: 722.969862 g/mol 
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1.3.2 Physiological Mechanisms of Action of Pulmonary Surfactant 
 
The main function of surfactant is in its biophysical behaviour to help maintain proper lung 
function; to act as an air–water surface tension lowering agent of a continuous liquid layer that 
is assumed to line the alveoli and adjacent terminal airways at all times and in this manner, 
surfactant reduces the work associated with breathing (Ayden 1999). During inspiration and 
expiration, the alveolar surface size and the area that surfactants covers can similarly alter repetitively. 
When the alveoli collapse at lower inspiratory pressures, the surfactant allows for their reopening and 
protects them from future collapse during expiration. The orientation of surfactant molecules is such that 
the polar heads group in the aqueous phase and the non-polar groups point towards the air. The orientation 
of the monolayers reduces surface energy/tension. The typical surface tension of water covering glycocalex 
of alveolar cells is 72 mN/m, surfactant adsorption decreases the surface tension to 23 mN/m or extremely 
low values to < 5 mN/m; that facilitates the work of breathing and assists with improved respiratory 
mechanics (Rosenberg, Seiliev et al. 2006). 
 
The first model that was introduced by von Neegaard in 1929 is still known as the “bubble 
model” and was further developed by Clements in 1962 (Hills 1991). However, there are other 
models that are in opposition that describe surfactant function within the alveoli such as: 
 
1. The “Totally dry” model by (Colacicco 1985) 
2. The “Shell” model/ “Geodesic-Dome” Model by (Morley 1987) 
3. The new, discontinuous model by (Hills, Burke et al. 1998, Hills 1999) 
 
These models are outside the scope of this report and will not be discussed further. However, 
they are discussed, in length by (Hills 1988).  
 
When the phospholipid and protein mixture are secreted, they are quickly adsorbed as a 
monomolecular film at the air-aqueous interface and is a mixture of saturated and unsaturated 
phospholipids. This film allows the adjustments of surface tension with area during dynamic 
expiration and inspiration and thus maintains alveolar stability. This increases lung compliance 
and resists possible alveolar atelectasis that results in clinically reduced work of breathing 
(Chimote, Banerjee 2005). The inability to execute these properties is defined as surfactant 
dysfunction. Thus in surfactant dysfunction, near zero minimum surface tension is not reached. 
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This results in alveolar collapse, which in turn requires increased breathing efforts to re-expand 
and stabilise the atelectatic alveoli (Banerjee 2002). 
 
1.3.3 Pulmonary Surfactant Dysfunction and Lung Disease 
 
When surfactant production or function is altered, many respiratory disorders may arise. Many 
pre-term infants born with surfactant deficiency develop respiratory distress syndrome (RDS) 
which is the prototypical lung condition characterised by inadequate surfactant production by 
the immature lungs. Lung inflammation is observed in many of these infants as respiratory 
failure and is compensated by active support such as mechanical ventilation or increased 
oxygen concentrations (Chakraborty, McGreal et al. 2010). Surfactant replacement is 
commonly used today in the clinical management of pre-term and/or new-born babies with 
RDS both as a prophylactic and rescue therapy, and there is accumulating evidence indicating 
that this treatment might also be effective in several other forms of lung disease including 
meconium aspiration syndrome, neonatal pneumonia, acute lung injury (ALI), and the `adult' 
form of acute respiratory distress syndrome (ARDS) (Robertson, Halliday 1998).The dynamic 
properties of lung surfactant permit the alveolar surface tension to change with inflation and 
deflation, thus keeping the smaller sized alveoli from complete collapse. The altered behaviour 
results in (see Figure 1.8) a reduction in the work of breathing. Loss of surfactant activity thus 
results in reduced lung compliance, atelectasis, and impaired gas exchange (Wright, Notter et 
al. 2001).  
 
Figure 1.8: Alveoli structure (A) with surfactant and (B) without surfactant (Johns Hopkins School of Medicine’s 
Interactive Respiratory Physiology) (Abbreviations: P, Pressure; P II cell, Type 2 pneumocyte). 
A 
B 
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There are a number of pathways by which lung surfactant activity can be compromised. The 
reductions in the content or composition of active large surfactant aggregates have been 
reported in BAL, oedema fluid, or tracheal aspirates from patients with ALI/ARDS or other 
diseases involving lung injury (Petty, Reiss et al. 1977, Hallman, Spragg et al. 1982, Seeger, 
Pison et al. 1990). The one important mechanism of surfactant dysfunction in ALI/ARDS is 
the physicochemical interactions with substances in the alveoli as a result of permeability 
oedema or inflammation (see Figure 1.9). There have been many studies documenting lung 
injury and impairment of surfactant due to inhibitors such as plasma and blood proteins, 
reactive oxidants, proteases and other lytic enzymes as well as phospholipases (Raghavendran, 
Willson et al. 2011). It is however important to document that the surface activity deficits from 
all these mechanisms can be alleviated in vitro by exogenous surfactant administration, even if 
these inhibitor substances remain present (Wang, Holm et al. 2005), thus supporting surfactant 
supplementation strategies. 
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Figure 1.9: Role of surfactant in non-neonatal acute lung injury. Increased pulmonary endothelial permeability, 
epithelial injury, and apoptosis lead to an influx of protein-rich fluid that inactivates surfactant. Similarly, 
cytokines, neutrophils, reactive oxygen species (ROS), thrombin, and mechanical stretch contribute to an intense 
pulmonary inflammatory response, with accumulation of both pro-inflammatory and anti-inflammatory mediators 
that may inactivate surfactant and decrease surfactant synthesis. Reduction in the production and turnover of 
surfactant leads to decreased lung compliance, resting lung volume, and functional residual capacity. NETS = 
neutrophil extracellular traps; TNF-α = tumor necrosis factor alpha. Courtesy Dr Anil Sapru (Willson 2015). 
 
Given the importance of surfactant associated proteins in the function and metabolism of 
surfactant, inherited deficiencies of specific proteins could potentially cause respiratory 
diseases (Nogee, deMello et al. 1993). These authors reported a case of congenital pulmonary 
alveolar proteinosis where the absence of SP-B and its mRNA led to the dysfunction of the 
surfactant’s spreading properties; however, the mechanism is still unclear. Another mutation 
that leads to abnormalities in surfactant composition and function is the spontaneous deletion 
on one allele of the SP-C gene that is associated with sporadic interstitial lung disease. This 
results in the aggregation and misfolding of the SP-C and subsequent cell injury and 
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inflammation (Hamvas, Nogee et al. 2004). This pulmonary inflammatory response may have 
further implication on surfactant inactivation as mentioned previously.  
Also, infectious diseases may too, in turn, alter the activity of these proteins, or phospholipids, 
that may result in surfactant dysfunction. Some research groups have also investigated whether 
the host inflammatory response contributes to respiratory impairment by disrupting the 
pulmonary surfactant system. One such group’s findings demonstrated that the surfactant 
pathology associated with Pneumocystis pneumonia (PCP) is related to the inflammatory 
process rather than being a direct effect of P. carinii. Moreover, they found that the CD8+ 
lymphocytes were involved in the mechanism leading to surfactant dysfunction (Wright, Notter 
et al. 2001). It has also been demonstrated that SP-A suppresses the T-cell dependent lung 
inflammatory response that often occurs in patients (and mice) following allogeneic bone 
marrow transplant reiterating its secondary immunomodulatory function (Wright, Borron et al. 
2001). Another significant pulmonary infection to consider in the role of surfactant dysfunction 
is pulmonary tuberculosis. The M. tuberculosis bacteria tend to reside within the alveolar space 
and are thus in close proximity with the surrounding surfactant. Mycolic acid, which is 
moderately surface active, is able to detach from the mycobacterium’s cell wall and could 
possibly interact with the pulmonary surfactant resulting in lung surfactant dysfunction 
(Chimote, Banerjee 2005). 
 
Given the known contributions of surfactant dysfunction in ILD/RDS and other infectious 
diseases, it seems likely that surfactant therapy in combination with other agents will ultimately 
be applicable for at least some adult as well as paediatric patients. A combination therapy 
approach is considered the most relevant for adults with ALI/ARDS as previous responses to 
exogenous surfactant delivery have, to date, been unsatisfactory. Thus, it stands to reason that 
the use of multiple therapeutic agents (biological targets and pharmacologic agents) or 
interventions based on a mechanistic rationale for synergy may significantly enhance outcomes 
in patients with complex inflammatory lung injury pathology (Raghavendran, Willson et al. 
2011). 
1.3.4 Natural extract versus Synthetic Surfactant 
 
Exogenous surfactants may be of animal or synthetic origin and both types have been 
extensively studied in animal models and in clinical trials to determine the optimum 
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timing, appropriate dosage, and frequency, route and method of administration (Ainsworth, 
Milligan 2002).  
 
Bengt Robertson and Tore Curstedt developed a porcine surfactant, Curosurf® (aptly 
named for their surnames), which was effective in immature animals and was used in a 
pilot clinical trial that started in 1983. Further trials conducted in pre-term infants with 
RDS decreased neonatal mortality rates and showed that early treatment was more 
effective than later administration (Curstedt, Halliday et al. 2015). The surfactant could be 
manufactured in a reproducible way in large quantities; however, the manufacturing 
process was very time consuming and for the production of a batch for the treatment of 
80–100 preterm infants’ lungs, approximately 50 adult pigs were needed (Robertson, 
Curstedt et al. 1990). Although effective in the treatment of preterm infants with RDS, 
modified natural surfactants have proven to be expensive and the supplies  are limited. 
There have also been concerns about the potential risk of immunogenic and infectious 
complications using these preparations and concerns still remain for the administration of 
animal-derived proteins in more immunocompromised populations, such as children or 
adults with acute lung injury (Lacaze-Masmonteil 2008). Nevertheless, it is worthy to 
mention that no adverse effects of this nature have been described in any of the infants 
previously treated (Kattwinkel 2005, Curstedt, Halliday et al. 2015). On the other hand, 
synthetic surfactants have the potential to completely eliminate the already very low and 
hypothetical risks of transmission of viral or unconventional infectious agents (Lacaze-
Masmonteil 2008).  
 
The necessity for synthetic surfactant preparations was prompted by the need to expand 
the indications for surfactant treatment that can be more easily produced, in large 
quantities, at less batch-batch variation, and at a reasonable cost. As mentioned before, 
there is a wide variety of commercially available, animal-derived surfactant formulations and 
some, though limited, synthetic surfactants (see Table 1.1), and both are beneficial as therapy 
for neonatal RDS. Animal-derived surfactants (Beractant®) and calfactant (Infasurf®) are 
modified or purified from bovine or porcine lungs and are still preferred over first generation, 
protein-free synthetic surfactants (e.g, colfosceril palmitate) (Polin, Carlo 2014).  
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Table 1.1: Composition and Dosage of Surfactants (Polin, Carlo 2014). 
Surfactant Main 
Phospholipids 
Proteins Phospholipid 
Concentration 
Suggested 
Dose 
Phospholipid 
per Dose 
Animal-derived      
Poractant (Curosurf®) 
minced porcine lung 
extract 
DPPC and PG (0.6%) SP-B 
and (1%) SP-C 
80 mg/mL 2.5 mL/kg 100-200 mg/kg 
Liposurf® (Bovine 
lipid extract surfactant 
suspension) 
DPPC and PG 176 – 500 μg of 
SP-B and SP-C 
per mL 
27 mg/mL 5 mL/kg 135 mg/kg 
Beractant (Survanta®) 
minced bovine lung 
extract 
DPPC and PG (<0.1%) SP-B 
and (1%) SP-C 
25 mg/mL 4 mL/kg 100 mg/kg 
      
Synthetic      
Colfosceril palmitate 
(Exosurf®) 
DPPC (100%) None 13.5 mg/mL 5 mL/kg 67.5 mg/kg 
Synsurf® DPPC and PG P-Lys and  
P-Glu 
60 mg/ml 1.7 mL/kg 100mg/kg 
Lucinactant 
(Surfaxin®) 
DPPC and 
POPG 
KL4 peptide as 
SP-B 
30 mg/mL 5.8 mL/kg 175 mg/kg 
 
Each different component of surfactant has an important function that collectively and 
independently influences both its primary dynamic surface behaviour (reduction in surface 
tension) and secondary role in lung defence. The continuous exploration in this field of 
study has led to the greater understanding of these individual components, particularly the 
surfactant-associated proteins, which in turn made it possible for the development of newer 
synthetic surfactants; however, it is not without difficulty (Ainsworth, Milligan 2002, 
Curstedt, Halliday et al. 2015). The structural complexity and instability of SP-B and SP-
C was overcome to a certain extent by the synthesis of more stable and rather simple 
analogues of SP-B and SP-C (Almlén, Stichtenoth et al. 2008, Almlén, Walther et al. 2010, 
Curstedt, Halliday et al. 2015). The relatively incomplete knowledge of some 
phospholipids’ function in surfactant, in combination with the limited commercial 
availability of many synthetic phospholipids, has led to the use of very simple 
phospholipid mixtures in earlier synthetic surfactant preparations (Curstedt, Halliday et 
al. 2015). Before protein analogues were introduced or deemed necessary for surfactant 
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success, the first protein-free synthetic surfactant colfosceril palmitate, also known as 
Exosurf®, was tested around 1989 for the prophylaxis and treatment of infants at risk for 
RDS. Since then, the drug was tested in many clinical trials and found to be efficacious, 
however, it was discontinued firstly, in the United States, and later in the UK (2003). 
Exosurf® trials have been underpowered in studies where its efficacy was examined 
against newer surfactants that were making their debut (Kattwinkel 2005). Another protein–
free synthetic surfactant, Pumactant, was voluntarily withdrawn from the market in 2000 
by the licence holder following the results of a randomized clinical trial which 
unexpectedly showed higher mortality rates in neonates who were administered Pumactant 
(Department of Health, United Kingdom 30 August 2000). These findings reiterate the 
importance of protein analogues within phospholipid surfactant mixtures.  
 
SP-B is essential for lamellar body formation as well as for DPPC configuration at the air-
fluid interface (at body temperature). Therefore, the search for a synthetic surfactant 
preparation that contains a functional synthetic apoprotein that is equivalent or superior to 
the animal-derived surfactants has continued. Although the molecular structure of SP-B 
has been synthesised in the laboratory, the molecule however does not configure 
appropriately (Kattwinkel 2005). Unfortunately, no successful trials with a synthetic SP-
B-containing preparation have been published. An analogue of SP-C has been produced 
and is able to promote film adsorption in vitro and has been shown to treat surfactant 
deficiency in animal models (Davis, Jobe et al. 1998). There has been a trial of this analogue 
in adult ARDS but it proved unsuccessful (Spragg, Lewis et al. 2004). Again, there have 
thus far been no published neonatal trials with this analogue. 
 
Recently, a new-generation synthetic surfactant containing both phospholipids and 
proteins (SP-B and SP-C analogues) has been developed. After preclinical testing in 
preterm lambs (Sato, Ikegami 2012, Seehase, Collins et al. 2012) and newborn pigs (Salvesen, 
Curstedt et al. 2014), CHF5633® (developed Chiesi Farmaceutici, Tore Curstedt and Jan 
Johansson) has undergone a preliminary first study in pre-term infants. CHF5633® was 
found to be well tolerated and showed a promising clinical efficacy profile. The 
encouraging data provides a basis for ongoing randomised controlled trials (Sweet, Turner 
et al. 2017). This study stands testament to the fact that new surfactant preparations could 
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revolutionise the treatment of preterm infants worldwide as it could be manufactured 
consistently and safely in almost unlimited quantities. 
 
Advantages of one type of surfactant over another type are usually categorised by the 
biophysical properties, animal studies and randomised trials in neonatal populations; 
however, it has only been a recent development to include possible immunological 
categories as well (Chroneos, Sever-Chroneos et al. 2010, Wright 2005). The choice of 
surfactant may also be based upon the neonatologist’s opinion regarding the necessity for 
a rapid response or the timing of administration (Halliday, Speer 1995). At present, 
animal-derived exogenous surfactants are preferred to other surfactants as they have 
relatively few adverse effects associated with the large and rapid changes in oxygenation  
during administration; however, with newer protein containing synthetic surfactants 
emerging this may soon change. Synthetic surfactants have slower response rates and may 
therefore be favoured for prophylaxis (preventing/worsening RDS rather than treatment of 
established RDS) whereas natural surfactants may be more suitable for very ill babies at 
risk of barotrauma and pulmonary air leaks due to their rapid response (Halliday, Speer 
1995, Polin, Carlo 2014).  
 
Another synthetic surfactant to be FDA approved, lucinactant (Surfaxin® Discovery 
Laboratories), contains a 21-amino acid peptide (leucine and lysine repeating units, KL4 
peptide) that mimics SP-B activity and has recently been accepted for the prevention and 
treatment of RDS in preterm infants (Sinha, Lacaze-Masmonteil et al. 2005, Moya, Sinha et al. 
2007). When compared with animal-derived surfactant (beractant or poractant), lucinactant 
was shown to be an equivalent alternative. Neonatal morbidities (intraventricular hemorrhage, 
periventricular leukomalacia, pulmonary hemorrhage, sepsis, patent ductus arteriosus, 
retinopathy of prematurity, necrotizing enterocolitis, and bronchopulmonary dysplasia) were 
not significantly different between preterm infants treated with animal-derived surfactants and 
those treated with synthetic surfactants (Polin, Carlo 2014). This prophylactic study also 
compared the efficacy of lucinactant (Surfaxin®) with colfosceril palmitate (Exosurf®). They 
concluded that lucinactant is a more effective surfactant preparation than colfosceril palmitate 
for the prevention of RDS as it reduces the incidence of bronchopulmonary dysplasia (BPD) 
rates. Therefore, lucinactant was the first of a new class of surfactants containing a functional 
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peptide of SP-B that proved itself an effective therapeutic option for preterm infants at risk for 
RDS (Moya, Gadzinowski et al. 2005).  
 
A previous multicenter randomized controlled trial conducted by Hudak and colleagues (1997) 
compared the efficacy and safety of the protein/peptide free synthetic surfactant colfosceril 
palmitate (Exosurf®) and a surfactant extract of calf lung lavage (Infasurf®) in the prevention 
of neonatal respiratory distress syndrome in premature infants. The prophylactic surfactant 
administration resulted in the animal surfactant-treated infants displaying significantly less air 
leaks compared to those of the Exosurf® group; however, intraventricular hemorrhage 
occurred more frequently in the Infasurf® surfactant-treated infants. No decrease in the risk of 
mortality associated with the prophylactic use of animal-derived surfactant was reported also 
(Hudak, Martin et al. 1997). 
 
Comparisons of synthetic and animal-derived surfactants have largely been used as rescue 
strategies in the past where surfactant is given to neonates with established respiratory distress 
syndrome; the exception to date are the two prophylaxis trials mentioned above. Ainsworth 
and colleagues (2000) conducted a randomized controlled trial to compare a synthetic 
surfactant (Pumactant®) with a natural porcine surfactant (poractant alfa, Curosurf®) for the 
treatment of respiratory distress syndrome in neonates. However, as mentioned previously, the 
trial was stopped on the recommendation of the data and safety monitoring committee because 
of concern regarding increased mortality in the group receiving synthetic surfactant 
(Ainsworth, Beresford et al. 2000, Ardell, Pfister et al. 2015).  
 
Early rescue is defined as surfactant treatment within 1 to 2 hours of birth, and late rescue is 
defined as surfactant treatment 2 or more hours after birth (Polin, Carlo 2014). A recent meta-
analysis of early (within 2 hours) versus delayed surfactant treatment concluded that the risks 
of mortality, air leak, chronic lung disease, and chronic lung disease or death were significantly 
decreased in the early administration group (Polin, Carlo 2014). Although there are no 
statistically significant benefits to prophylactic use of surfactants when compared with 
prophylactic continuous positive airway pressure (CPAP), several studies have investigated 
whether administration of surfactant early in the course of respiratory insufficiency improves 
clinical outcomes (Polin, Carlo 2014). The studies found that using CPAP immediately after 
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birth with subsequent selective surfactant administration should be considered as an alternative 
to routine intubation with prophylactic or early surfactant administration in preterm infants. 
 
A synthetic peptide-containing surfactant (Synsurf®) consisting of phospholipids and poly-L-
lysine electrostatically bonded to poly-L-glutamic acid has been developed based on the KL4-
surfactant principle by van Zyl et al. (2013a). The polymers were added to the phospholipids, 
in order to mimic the hydrophobic and hydrophilic nature of SP-B in the mixture (Van Zyl, 
Smith et al. 2013a). Their first pre-clinical study demonstrated that Synsurf®, when compared 
with Exosurf®, improves oxygenation by lowering pulmonary shunt in New Zealand white 
rabbits with acute lung injury and surfactant-deficient lung disease. In a following randomized 
controlled trial, the two surfactants, Synsurf® and Curosurf®, were tested in a respiratory 
distress preterm lamb model. This prophylactic treatment demonstrated that a novel synthetic 
peptide-containing surfactant (Synsurf®) resulted in a more sustained, improved oxygenation 
response compared to that of Curosurf®- or saline-treated premature lambs when treated before 
first breath. The authors reasoned that the polypeptide poly-L-lysine, which is widely used in 
membrane research due to its interaction with acidic lipids, was worth studying as a KL4 
alternative (van Zyl, Smith 2013b). Future feasibility study for Synsurf® treatment of pre-term 
infants at risk for RDS are still being considered; but preliminary animal studies have provided 
promising data to support future human investigations.  
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1.4 Surfactant: The Innate and Adaptive Immune System 
1.4.1 Lungs and Inflammation 
 
The lungs present an immunological challenge for the host as they are most frequently targeted 
by pathogens. The respiratory epithelium serves as the surface for gaseous exchange along with 
its ability to fight inhaled pathogens, pollutants and particles. The lungs are constantly 
challenged and therefore have several different defence mechanisms in place such as filtration 
of air in the naso-oropharynx and conducting airways, sneezing and coughing. The epithelium 
represents a physical barrier that produces mucus, which, along with, mucociliary clearance 
combats any possible onslaught (Wright 2005). 
A variety of cells participate in the pulmonary immune response, and the relative involvement 
of different cells varies with different diseases and the degree of inflammation. The innate 
immunity is the first line of defence and it recruits a number of leukocytes including basophils, 
eosinophils, natural killer (NK) cells, mast cells along with the phagocytic cells macrophages, 
neutrophils and dentritic cells (DCs). The immune cells recognise the pathogen by relying on 
a large family of pattern recognition receptors (PRRs) termed pathogen-associated molecular 
patterns (PAMPs). These immune cells can either engage in phagocytosis to “engulf” 
pathogens or release inflammatory mediators such as histamine and leukotrines (eicosanoid 
inflammatory mediators) (Mogensen 2009). 
 
The adaptive immune system is also known as the acquired immune system and it is composed 
of highly specialised, systemic cells. These cells, when they encounter a pathogen, create an 
immunological memory with a specific response, which will be enhanced to subsequent 
encounters with that pathogen. The adaptive immune response involves DCs and T and B 
lymphocytes (and to a lesser extent macrophages) which are known as professional antigen 
presenting cells (Mogensen 2009). 
 
1.4.2 Inflammation and Cytokines 
 
Inflammation is a self-protective mechanism initiated by the body’s innate immune system 
against tissue injury or infection; but may elicit an adaptive trait by recruiting cells associated 
with the system to act in collaboration. It underlines a wide variety of physiological and 
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pathological processes. The latter aspect restricts the tissue damage at an affected site and is 
characterised by the secretion of numerous inflammatory mediators, which trigger the 
recruitment of leukocytes and other proteins. These processes are well appreciated, whilst the 
physiological functions are yet to be determined. Much progress has been made in 
understanding the cellular and molecular mechanisms found in the acute inflammatory 
response to infection and, to a lesser extent, tissue injury. In addition, the events leading up to 
localised chronic inflammation, particularly that which is associated with chronic infections 
and autoimmune diseases, are only partially known. Systemic chronic inflammation’s causes 
and mechanisms are much less well understood, but do not seem to be caused by the same 
activators as those associated with local lung infection and injury. It is rather accompanied by 
malfunction of tissue. That said; it is the homeostatic imbalance of one of several physiological 
systems that are not directly related to the function of host defence or tissue repair (Medzhitov 
2008). The fundamental function of the inflammatory process is to resolve the infection and 
repair the damaged tissue in order to return the system back to a state of homeostasis. The 
effectiveness of this function relies on the system’s ability to produce a rapid response, whilst 
ideally limiting the damage to a specific region. However, chronic inflammation, as seen in 
COPD, causes more damage to the system than a microbe trigger (Barton 2008). 
 
The innate immune response is the first line of defence against an invading pathogen or 
infection and is activated within a few hours of exposure. Lipopolysaccharides (LPS) and 
peptidoglycans from bacterial cell walls are examples of PAMPs that trigger recognition on 
the PRR in immune cells (Horton 2010). Alongside neutrophils and DCs, macrophages, which 
link the innate and adaptive immune systems, possess a type of germline-encoded 
receptor/PRR called Toll-like receptors (TLRs) on their surface and within their cytoplasm. 
Once the TLRs detect PAMPs, the innate immune system is initiated and the release of pro-
inflammatory mediators such as cytokines, chemokines and lipid mediators into the circulation 
is initiated. It does so in distinctive dynamic pattern and results in the activation, recruitment 
and/or migration of cells to the site of infection (see Figure 1.10) (Akira, Takeda et al. 2001, 
Russell 2014). 
 
The IL-1 receptor (IL-1R) family members consist of very wide related receptors, including 
the TLRs, and are characterised by very different extracellular immunoglobulin-like domains 
and large intracellular Toll/IL-1R (TIR) domains (Slack, Schooley et al. 2000). When the TLRs 
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are activated, adapter proteins and kinases, such as MyD88 (Wesche, Henzel et al. 1997) and 
IRAK (Akira, Takeda 2004), are recruited. 
 
 
Figure 1.10: The LPS-mediated cellular production of inflammatory cytokines within the macrophage. IL-1β and 
TNF- α are examples of cytokines that can stimulate their own synthesis. Abbreviations: LPS, 
lipopolysaccharide; ROS, reactive oxygen species; TLR4, toll-like receptor 4; NF-κB, nuclear factor-κB; IL-1β, 
interleukin 1 beta; iNOS, inducible nitric oxide synthase; TNF-α, tumor necrosis factor alpha 
 
The transcription factors AP-1, CREB, NF-B and IRF3 are activated through direct or indirect 
mechanisms after which they are translocated to the nucleus. There, they induce gene 
transcription of pro-inflammatory factors. The wide variety of target genes regulated by NF-
κB includes those encoding cytokines (e.g., IL-1, IL-2, IL-6, IL-12, TNF-α, LTα, LTβ, and 
GM-CSF), chemokines (e.g., KC/GRO, IL-8, MIP-1α, MCP1, CCL5/RANTES, and eotaxin) 
(Ghosh, Karin 2002). Interestingly, IL-1 and TNF- are exploited in a feed forward loop to 
initiate and intensify the inflammatory response by re-binding to the IL-1Rs. The inflammatory 
response is driven and maintained by highly integrated gene transcription control within the 
nucleus of the cell; as well as with multiple steps of post-transcriptional modifiers that 
modulate mRNA production, transport, translation and posttranscriptional regulation. The rates 
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of mRNA transport, decay, and translation crucially influences the timing and magnitude of 
the cellular immune responses (Ishmael, Fang et al. 2007). 
 
Most studies on inflammation have focused on preventing the start of inflammation rather than 
halting progression of the response. However, as we explore further into finding improved 
treatments for inflammatory disorders, it is imperative to have a better understanding of the 
inflammatory mechanisms and the resulting consequences for possible future therapies 
(Nguyen, Rajaram et al. 2012). 
 
1.4.3 Surfactant Collectins and Immunity 
 
Pulmonary surfactant serves two functions in the lung. Firstly, it is a surface acting agent, 
initially identified as a lipoprotein complex that lowers surface tension at the air-liquid interface 
of the alveolar surface. Secondly, the hydrophilic surfactant proteins SP-A and SP-D (also 
known as collectins) are important components of the innate immune response in the lung and 
therefore assist in pulmonary host defence. Furthermore; they may also modulate the adaptive 
immune response. The inflammatory response in the alveolar microenvironment is tightly 
regulated to avoid damage to the gas-exchanging delicate structures through the concerted 
efforts of the innate and adaptive immune system. 
 
The phospholipid and protein combination has unique spreading qualities (90% phospholipids 
and 10% proteins) courtesy of the hydrophobic surfactant proteins B and C (SP-B, SP-C). This 
promotes lung expansion during inspiration and prevents lung collapse during expiration. They 
have an essential function in the spreading, adsorption and stability of surfactant lipids 
(Haagsman, Hogenkamp et al. 2008). Surfactant composition and pool size is controlled by 
secretion, re-uptake, and recycling by alveolar type II epithelial cells and both alveolar type II 
epithelial cells and macrophages are responsible for the degradation thereof (Chroneos, Sever-
Chroneos et al. 2010).  
Earlier studies have provided support for the concept that surfactant might have a role in linking 
innate and adaptive immunity in the lung by modulating functions of both DCs and T cells. 
DCs, the most potent antigen-presenting cells in the body, are localised at the host–environment 
interface, in regions such as the skin and the lung (Havenith, Breedijk et al. 1992). In the lung, 
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DCs are found in the airway epithelium, the lung parenchyma and the alveolar air-space (Sertl 
1986). 
On the basis of the observation that lymphocytes, isolated by lung lavage, are hyporesponsive 
compared with circulating peripheral lymphocytes; Ansfield and co-workers (1979) proposed 
and showed that surfactant and, in particular, surfactant lipids inhibit lymphocyte function. 
Subsequent studies by Borron and colleagues (1998) showed that SP-A and SP-D inhibit 
proliferation of T cells that have been stimulated with plant lectins, CD3-specific antibodies or 
phorbol esters, by a process that is thought to be mediated (at least, in part) by inhibition of IL-
2 production. In addition, both the collagen-like region and the CRD101 of SP-A have been 
implicated in the inhibition of lymphocyte function, probably owing to inhibition of calcium 
signalling (Borron, McCormack et al. 1998, Ansfield, Kaltreider et al. 1979). 
Although a direct role for SP-A and SP-D in modulating DCs and T-cell functions has been 
shown in vivo, SP-D-null mice have an interesting phenotype with respect to their lymphocytes. 
Fisher and colleagues reported that SP-D-null mice have peribronchial and perivascular 
accumulations of lymphocytes in airways and vessels but not in the interstitium. These 
lymphocytes were activated, as seen by increases in the proportion of both CD4+ and CD8+ T 
cells that expressed both CD25 and CD69 (Shepherd 2002). 
Shepherd (2002) stated in an invited commentary that these studies indicate that SP-D and SP-
A might provide an important link between innate and adaptive immunity, by modulation of 
DCs and T-cell functions. In such a situation, SP-D in the alveolar space would enhance the 
uptake of pathogens by immature DCs, which are recruited into the alveolar air-space during 
infection or inflammation. For example, although previous studies have shown that SP-D can 
bind to Escherichia coli (E. coli) and enhance its uptake by macrophages (see Figure 1.11), 
this is the first report showing that SP-D enhances E. coli entry into DCs (Brinker, Martin et 
al. 2001). SP-A would function to inhibit DC maturation, and both SP-A and SP-D would 
suppress T-cell activation in the alveolar space, which if it occurred, could result in an 
inflammatory cascade that could damage the lung and impair gas exchange. Additional studies 
will be required to elucidate the role of surfactant in regulating adaptive immune responses in 
vivo. 
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Figure 1.11: Both SP-A and SP-D opsonise pathogens and enhance their phagocytosis by innate immune cells 
such as alveolar macrophages and neutrophils (Wright 2003). 
 
1.4.4 Surfactant: Effect on Alveolar Macrophages 
 
Harvesting alveolar macrophages (AMs) by bronchoalveolar lavage was first described in 1960 
and has since been extensively investigated (Gee, Fick 1980). These cells are critical for host 
defence as they are the major cell type in recognising infection or injury and innate immunity 
and comprise 85% of the recovered cells in human lung lavage fluid. They phagocytose 
particulate matter and invading microorganisms, release cytotoxic reactive oxygen species 
(ROS) and proteolytic enzymes, and produce nitric oxide (NO) for microbial killing and 
signalling functions (Fels, Cohn 1986). As previously stated, AMs bring about the pulmonary 
inflammatory response via production of cytokines and chemokines as they are responsive to 
both specific and nonspecific stimuli; thereby being capable of forming part of both the innate 
and adaptive immunity. Furthermore, they regulate antigen presentation and opsonisation 
(Wright 2005). AMs also remove intra-alveolar debris whilst regulating the metabolism and 
recycling of endogenous surfactant (Kerecman, Mustafa et al. 2008). 
 
As mentioned previously, the two main functions of surfactant are to improve pulmonary 
mechanics and oxygenation. It (and/or its components) also assists to modulate innate 
pulmonary immunity and the mechanism of this process lies in the alteration of immune cell 
function through initiating the inflammatory cascade (Suresh, Soll 2005). Natural surfactant 
significantly decreased macrophage-mediated neutrophil chemotaxis. Finck and colleagues 
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(1998) suggested that at low concentrations, surfactant inhibits chemokine release and may 
reduce pulmonary neutrophil sequestration in vivo. It is also well known that alveolar 
macrophages can be induced to produce nitric oxide (NO) via inducible nitric oxide synthase 
(iNOS) as Lavnikova and collegues (1993) demonstrated with rat alveolar macrophages which 
produced NO in response to inflammatory stimuli or cytokines, e.g., lipopolysaccharide (LPS) 
or interferon-γ (IFN-γ) (Lavnikova, Drapier et al. 1993, Finck, Hodell et al. 1998). 
Furthermore, another study concluded that individual surfactant phospholipids differently 
modulate the priming of AMs for oxidative responses (Hayakawa, Giridhar et al. 1992). 
 
The natural surfactant’s hydrophilic proteins (SP-A and SP-D) have been shown to mediate 
host defence properties and SP-A specifically decreases TNF-α production, phagocytosis of 
pathogens and release of ROS (Chroneos, Sever-Chroneos et al. 2010). However, some studies 
have indicated that exogenous surfactant preparations without measurable hydrophilic proteins 
also inhibits LPS-stimulated IL-1β and TNF-α secretion and decreases cytokine RNA 
expression in AMs (Thomassen, Antal et al. 1994). The mechanism by which exogenous 
surfactants and their components regulate this anti-inflammatory effect is not fully known. 
However, previous studies by Thomassen and colleagues may offer insight as they 
demonstrated inhibition of endotoxin-stimulated cytokine secretion from human alveolar 
macrophages in vitro by the synthetic surfactant Exosurf®. They concluded that the 
suppression was not stimulus specific but Exosurf® reduced both cell associated and secreted 
TNF-α and IL-1β. This indicates that Exosurf® is not simply blocking cytokine release but, 
with the observations that with decreased mRNA levels at different time points, it supports the 
fact that Exosurf® could pre-translationally mediate AM cytokine production (Thomassen, 
Antal et al. 1994).  
There have been some studies that have shown, under different circumstances, that SP-A and 
SP-D enhance pathogen-dependent activation of pro-inflammatory responses of alveolar 
macrophages during phagocytosis of SP-A or SP-D-opsonized microbes in vitro. Weikert and 
colleagues (2000) demonstrated this with a study that included bacillus Calmette-Guerin 
(BCG) organisms grown in the absence of SP-A; where growth increased over a 5-day period 
whereas inclusion of SP-A dramatically inhibited BCG growth. Inhibition of nitric oxide 
production blocked BCG killing in the presence and absence of SP-A. It was concluded that 
the ingestion of SP-A-BCG complexes by rat macrophages leads to production of inflammatory 
mediators and increased mycobacterial killing (Weikert, Lopez et al. 2000). Barr and 
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colleagues (2000) studied the effect of SP-A- mediated uptake of respiratory syncytial virus 
(RSV) on production of TNF-α and interleukin IL-10 by peripheral blood monocytes (PBMC) 
and alveolar macrophages. Their findings suggested that SP-A is an important opsonin for RSV 
and that SP-A-mediated uptake of RSV may alter some of the unusual cytokine responses that 
are postulated to be involved in incomplete immunity to recurrent infection (Barr, Pedigo et al. 
2000). Both of these studies are examples of a pro-active clearance mechanism that also 
operates in vivo during initial clearance of experimental pulmonary infections (Chroneos, 
Sever-Chroneos et al. 2010).  
 
In contrast, other studies have shown that, in contrast, SP-A and SP-D suppress secretion of 
pro-inflammatory cytokines and oxidant intermediates when macrophages are challenged with 
components (e.g. LPS). The role of surfactant-associated protein (SP) A in the mediation of 
pulmonary responses to bacterial LPS was assessed in vivo with SP-A gene-targeted [SP-
deficient; SP-A(-/-)] and wild-type [SP-A(+/+)] mice in a study performed by Borron et al. 
(2000). The SP-A(-/-) mice produced significantly more TNF-alpha and nitric oxide than SP-
A(+/+) mice after LPS treatment. Intratracheal administration of human SP-A to SP-A(-/-) 
mice restored regulation of TNF-alpha, macrophage inflammatory protein-2, and nitric oxide 
production to that of SP-A(+/+) mice. This study displays the protective function of SP-A in 
both in vivo animal models and in vitro macrophage components as endogenous and/or 
exogenous SP-A inhibits pulmonary LPS-induced cytokine and nitric oxide production (Borron, 
McIntosh et al. 2000). It has also been reported that SP-A enhances the secretion of anti-
inflammatory IL-10 and induces the secretion of TGF-β when in the presence of mycobacterial 
cell wall antigen or apoptotic cells (Reidy, Wright 2003).  
 
Therefore, it is necessary to investigate the intracellular events in macrophages treated with 
exogenous surfactant and assess the possible immunoactive and anti-oxidant properties of said 
exogenous surfactants in endotoxin-activated and non-activated macrophages. These findings 
may elucidate the coordination and synchronisation of surfactant metabolism with immune 
responses within the lung. 
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1.4.5 Potential Immunogenicity and Immunomodulatory activity of Surfactants 
 
To demonstrate the efficacy and safety of the porcine pulmonary surfactant preparation 
(Butantan® surfactant) in premature infants, Precioso and colleagues saw it necessary to study 
its immunogenicity in an adult rabbit model first. This comes directly from the need to study 
any possible immunogenicity the introduction of the porcine surfactant proteins may elicit in 
the airway of premature infants. This includes possible antigenic stimuli (linking the innate and 
adaptive immunity) with a resultant immunological response against those proteins. Their 
results demonstrated relevance from a clinical as well as an economical point of view 
concerning the efficacy and safety of Butantan surfactant since it may be a suitable alternative 
replacement therapy to Curosurf® or Survanta® (Precioso, Sakae et al. 2006).  
Various research groups have chemically prepared peptides with sequences based on SP-B 
such as a KL4- surfactant, namely Surfaxin®, which was the first synthetic peptide-containing 
surfactant approved by the FDA (Cochrane, Revak et al. 1996). This surfactant was thought to 
become an alternative to Curosurf® used as the standard of care in managing RDS; however, 
Surfaxin® was discontinued in 2015. Based on its design, van Zyl and colleagues developed a 
polymer-containing surfactant (Synsurf®) consisting of the phospholipids 
dipalmitoylphosphatidylcholine (DPPC), phosphatidyl glycerol (PG) and poly-L-lysine 
electrostatically bonded to poly-L-glutamic acid. The polymers were added to the 
phospholipids in order to mimic the hydrophobic and hydrophilic nature of SP-B or SP-C in 
the mixture (Van Zyl, Smith et al. 2013a).  
Surfactant preparations which have been investigated for therapy differ in composition of their 
phospholipids, with or without proteins, natural as well as synthetically manufactured 
surfactants containing peptide constructs (Strayer, Merritt et al. 1989). In this study, we deemed 
it necessary to establish whether Synsurf® elicits immunomodulatory and immunogenicity 
characteristics in comparison to other natural surfactants currently in use today. A study 
conducted by Whitsett and co-workers investigated whether antibodies generated against 
bovine surfactant proteins, SP-B or SP-C, are detected in serum from infants treated with 
Survanta®. It was discovered discovered that polyclonal antisera generated in rabbits against 
the small molecular weight proteins were uniformly reactive with the bovine surfactant test 
antigens. However, antibodies reacting with the surfactant proteins were never detected by 
immunoblot analysis with the sera of infants (Whitsett, Hull et al. 1991). 
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The possibility exists that this study correlates with the findings from a previous study done by 
Strayer et al. (1991) who sought to determine the immunogenicity and the degree of 
immunologic cross-reactivity of animal pulmonary surfactants because of the expanded use of 
surfactants to treat neonatal RDS as well as adult RDS. They once again stressed the importance 
of examining the potential immunologically mediated side effects such as antibody- or immune 
complex-mediated tissue injury. It is thus critical to recognise the spectrum of injury that is 
associated with neonatal and adult RDS and its treatment. Therefore, treatment and therapy of 
RDS should take into consideration the possibility that cross-reactive immunogenic substances 
may be introduced in patients with RDS. Also, the possibility that effective treatment of RDS 
may decrease the immune system's exposure to immunogenic endogenous surfactants. This 
may then mitigate potential future damage due to surfactant immunogenicity (Strayer, Hallman 
et al. 1991). 
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1.5 Mycobacterium Tuberculosis and Surfactant therapy 
1.5.1 Brief history of Tuberculosis 
 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis. 
It typically affects the lungs (pulmonary TB) but can affect other sites as well (extrapulmonary 
TB).By making use of modern day DNA extraction and purification methods, molecular 
evidence for TB was found in an ancient Egyptian mummy from the New Kingdom which 
dated back to about 1550 — 1080 BC (Nerlich, Haas et al. 1997). The skeletal remains of 
Egyptian mummies offered supporting evidence showing that prehistoric humans (4000 BC) 
had TB, and the tubercular decay in the spines of Egyptian mummies was reported (3000-2400 
BC)(Zink, Sola et al. 2003). The German physician Robert Koch was the first to identify and 
describe the M. tuberculosis bacilli in 1882; however, tuberculosis was generally referred to as 
“consumption” in the poor urban population of Britain and Europe in the early 19
th
 century 
(Koch 1882). The only treatment available at that time was to stimulate the body’s own immune 
system. Doctors expressed focus on a healthy diet, fresh air, hygiene and the administration of 
expectorants and purgatives. This led to the opening of the first sanatorium in 1854 in Germany 
(Rivero 2008). 
1.5.2 Epidemiology of Tuberculosis 
 
Worldwide, it was estimated that 9.6 million people were infected with TB in 2014: 5.4 million 
men, 3.2 million women and 1.0 million children. Globally, 12% of the 9.6 million new TB 
cases in 2014 were HIV-positive; almost 75% of these cases were in the African Region. These 
cases led to the deaths of 1.5 million people (1.1 million HIV-negative and 0.4 million HIV-
positive) and totalled to 890 000 men, 480 000 women and 140 000 children (World Health 
Organization 2015). There have been 22 high burden countries (HBC’s) identified by the WHO 
that contribute to 81% of the global TB occurrence. South Africa has been reported to be the 
sixth highest regarding incidence and the eighth highest regarding estimated prevalence (World 
Health Organization 2015). Even though the global TB rates have slowly declined (an average 
of 1.5% per year since 2000); when taking into account the adjustment of population size, from 
2012 to 2014, South Africa held its position as having the highest incidence and prevalence of 
TB among the HBC’s (World Health Organization 2012, World Health Organization 2015). 
South Africa also experienced the largest number of HIV-associated TB cases and the second 
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largest number of diagnosed multidrug resistant (MDR) TB cases following India. TB remains 
a global health threat and South Africa has one of the highest rates of TB prevalence (56-66%) 
driven by HIV (Churchyard, Fielding et al. 2014). 
 
 
Figure 1.12: Estimated TB incident rates in 2014 (World Health Organization 2015). 
 
 
Figure 1.13: Trends in tuberculosis case notification rates and HIV prevalence in South Africa (Churchyard, 
Fielding et al. 2014). 
 
A person obtains the M. tuberculosis (M.tb) infection by the inhalation of infected aerosols 
droplets (2–5 mm in diameter containing as few as 1–3 bacilli) (Koul, Arnoult et al. 2011), 
Stellenbosch University  https://scholar.sun.ac.za
31 
 
which are produced by people with the active pulmonary disease (Wallis, Pai et al. 2010). 
When one encounters M.tb bacilli (Figure 1.14), three possible outcomes can occur: 1) Clinical 
symptoms may develop in a few members of the population who develop primary active TB, 
2) Latent infection occurs when the majority of infected persons show no disease symptoms 
but may develop an effective acquired response, 3) it is possible for a portion of latently 
infected persons to reactivate and develop post-primary active TB (Gideon, Flynn 2011). 
 
 
Figure 1.14: Stages of M. tuberculosis infection (Koul, Arnoult et al. 2011). 
 
1.5.3 Multi-drug Resistant and Extensively-drug Resistant TB 
 
Multi-drug resistant tuberculosis (MDR-TB) is defined by the WHO as M. tuberculosis strains 
resistant to rifampicin and isoniazid; whereas, extensively resistant tuberculosis (XDR-TB) is 
defined as MDR-TB that is also resistant to a minimum of three of the six classes of second 
line drugs (aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine and 
para-aminosalicylic acid (PAS)). Drug resistance determination is difficult to establish due to 
the challenges associated with drug-susceptibility testing (DST) such as diagnosis treatment. 
Therefore, the WHO’s XDR-TB Task Force governed in Geneva, Switzerland (October 2006), 
and modified the definition of XDR-TB. It is now re-defined to XDR-TB as having ‘resistance 
to at least rifampicin and isoniazid (i.e. the definition of MDR-TB), in addition to any 
fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB 
treatment: capreomycin, kanamycin and amikacin’ (Migliori, Besozzi et al. 2007).  
Estimates of 3.3% of the worldwide new cases and 20% of previously treated cases have MDR-
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TB, only about a quarter of these (123 000) were detected and reported. In 2014, there were an 
estimated 480 000 (360 000–600 000) new cases of global MDR-TB (although there were only 
300 000 reported cases, 53% were among new cases and 47% were among previously treated 
cases) of which 50% of these were in India, China and the Russian Federation. Three-quarters 
of the 123 000 patients with rifampicin-resistant tuberculosis (RR-TB)/MDR -TB lived in the 
European Region, India, South Africa or China; equivalent to 41% of the total global MDR-
TB burden reported in 2014. Approximately 190 000 (120 000–260 000) deaths resulted from 
MDR-TB. TB patients co-infected with HIV were estimated at 77% of known TB patients (392 
000 people). Of the represented MDR-TB data, XDR-TB amounted to 9.7% portion (World 
Health Organization 2015). The number of reported MDR-TB and XDR-TB cases in SA 
increased between 2010 and 2012, with 15 419 and 1 596 cases, respectively, diagnosed in 
2012. In 2014, there were 8 640 reported new cases worldwide as well as 32 160 cases of 
previously diagnosed cases who relapsed to re-treatment (World Health Organization 2012, 
World Health Organization 2015). 
A physician in India identified and reported an alleged incurable form of TB in 2012 which 
resulted in the first cases of (what was referred to as) totally drug-resistant tuberculosis, TDR-
TB (Migliori, Besozzi et al. 2007). More recently, cases have also been reported in Iran, India 
and South Africa. TDR-TB has been loosely defined as displaying in vitro resistance to all 
first- and second-line drugs tested (rifampicin, isoniazid, streptomycin, ethambutol, 
pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, 
ciprofloxacin, capreomycin and kanamycin) (Parida, Axelsson‐Robertson et al. 2015). This led 
to the WHO consultative meeting on TDR-TB and in conclusion the committee members did 
not officially endorse the ‘TDR-TB’ terminology (Udwadia, Amale et al. 2012). As it still 
remains to be fully defined, many argue that it is another form of XDR-TB and some rather 
refer to it as XDR-TB as DST data is 1) limited, 2) not yet established for TDR-TB, or 3) as 
correlations of DST results and clinical response to treatment have not yet been established. 
Bedaquiline, delamanid and linezolid are three new drugs that were recently approved by the 
US Food and Drug Administration (FDA) and the European Medicines Agency. The 
effectiveness of these drugs against these TDR-TB strains has yet to be considered and they 
may offer therapeutic solutions for TDR-TB, challenging TDR terminology (Parida, Axelsson‐
Robertson et al. 2015).  
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1.5.4 The Evolution of Current TB Chemotherapy 
 
The effective treatment of TB started in 1946 when Streptomycin (SM) was discovered two 
years prior (Figure 1.15). The Tuberculosis Research Unit of the British Medical Research 
Council (BMRC) undertook the first clinical trial. However, the frequent emergence of SM 
resistance led to a second BMRC clinical trial. The combined treatment with SM and para-
aminosalicylic acid (PAS) greatly reduced the incidence of SM resistance (Mitchison, Davies 
2012). This was then followed by the introduction of isoniazid (INH) in the 1950s, which 
established the basis of anti-TB chemotherapy until the 1960s. Some regimens explored the 
possibility of using INH alone. Shortly after this effort, the BMRC headed a national survey in 
the United Kingdom that led to the discovery that resistant strains were almost always resistant 
to one of the three available drugs (Fox, Wiener et al. 1957). A combination of SM, INH and 
PAS formed the first combination TB chemotherapy regimen that was administered over a 
period of 24 months so that at least two would combat almost any possible resistant strain. 
Ethambutol (ETH) was substituted for PAS in the early 1960s and treatment duration was 
shortened by 6 months (Schmitz, Kleine-Allekotte 1960). More than 95% of patients were 
cured when Rifampicin (RIF) was included in the regime after its discovery in 1965 and the 
treatment duration was further reduced to 9-12 months. Lastly, Pyrazinamide (PZA) was 
introduced in the 1980s and shortly thereafter, facilitated the newly WHO launched modern-
day short-course treatment; also known as the directly observed treatment, short-course 
(DOTS) strategy (Nuermberger, Spigelman et al. 2010). DOTS allow patients to consume each 
dose of anti-TB drugs under supervision to the treatment strategy. It is strongly recommended 
as this approach maximizes the probability of therapy completion limiting the emergence of 
possible drug-resistance (Blumberg, Burman et al. 2003).  
According to the South African tuberculosis control program, the current standard first line 
treatment regimen of 2014 consists out of an initial (or intensive) phase and a continuation 
phase (See Table 1.2). Although treatment of drug-susceptible TB under ideal conditions by 
DOTS may be successful in 95% of cases, cure rates in the field are often significantly lower 
(World Health Organization 2012, World Health Organization 2015). 
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Table 1.2: Treatment regimen for known drug sensitive TB in adults. R – Rifampicin H – Isoniazid Z or PZA– 
Pyrazinamide E or ETH – Ethambutol (Republic of South Africa: National Department of Health 2014). 
Pre- Treatment 
body weight (kg) 
Intensive phase: 2 
months 
Continuation phase: 4 months 
RHZE 
(150/75/400/275) mg 
RH  
(150/75) mg 
RH  
(300/150) mg 
30–37 kg 
 
2 tablets 2 tablets  
38–54 kg 
 
3 tablets 3 tablets  
55–70 kg 4 tablets  2 tablets 
≥71kg 5 tablets  2 tablets 
 
The basic principles of treatment and recommended standard anti-TB regimens for adults are 
also indicated for children. Doses for children are usually extrapolated from adult 
pharmacokinetic studies, and recent data point to the inadequacy of currently recommended 
doses of RIF, INH, and ETH. Children eliminate INH faster and require a higher body weight 
dose (mg/kg) to achieve serum concentrations comparable to those in adults (McIlleron, 
Willemse et al. 2009). 
 
Figure 1.15: Timeline in TB and antitubercular drug development, DOTS, directly observed therapy, MDR 
multidrug resistant, M.tb, Mycobacterium, tuberculosis, TB, tuberculosis, XDR, extensively drug resistant (Lalloo, 
Ambaram 2010). 
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When treating MDR-TB, consideration of specific resistance gives way to two treatment 
possibilities. Firstly, a combined treatment plan of aminoglycoside, a fluoroquinolone, PZA, 
and ethionamide or prothionamide can be used for MDR-TB with resistance to both INH and 
RIF. However, the second option of an aminoglycoside, fluoroquinolone, PAS, cycloserine, 
and ethionamide or prothionamide is required for disease with resistance to INH, RIF, ETH 
and PZA (Nuermberger, Spigelman et al. 2010). Managing MDR-TB is challenging because it 
requires a prolonged treatment regimen of 24 months that includes second-line drugs, which 
are more toxic and expensive than first-line drugs. The WHO guidelines for programmatic 
management of MDR-TB for 2015 has gone unchanged since 2006. For an optimal regimen it 
should include a fluoroquinolone (ofloxacin, moxifloxacin, ciprofloxacin), an injectable agent 
(capreomycin, kanamycin, or amikacin), and at least 2 of the following drugs: cycloserine, PAS, 
and first-line agents other than INH and RIF such as PZA and ETH (World Health Organization 
2015). 
1.5.5 Prospects and Challenges for Future TB Chemotherapy 
 
Due to the satisfactory cure rates regarding first line drugs in the developing world, research 
into new anti-tubercular drugs continued to plateau until the late 1990s. The HIV epidemic 
along with drug-resistant TB drove renewed interest into developing several candidate 
molecules. This resulted in the synergistic research of newer drugs as well as more effective 
regimens. The DOTS strategy has revealed that it is difficult to maintain in many national TB 
control programmes over an extended period of time. Failure to ensure patient compliance is 
one of the most common reasons for this due to the treatment associated adverse-effects. First 
line drugs (see Table 1.3) are known to cause nausea, vomiting and drug induced hepatitis. 
Non-compliance to the recommended chemotherapeutic regimen not only lowers cure rates, 
but leads to the development of drug-resistant TB, inclusive of the formidable scenarios of 
MDR-TB and XDR-TB (Zignol, Hosseini et al. 2006, Van Rensburg 2012). The known 
concern of current TB drugs interactions with the antiretroviral drugs taken by HIV positive 
people, means that there is an urgent need for new TB drugs. However, new TB drugs should 
desirably offer: 1) shorter and simpler, but still affordable, multi drug regimens for drug 
sensitive TB; 2) shorter, more effective, less toxic, and less expensive regimes for drug resistant 
TB; 3) short, simple, easily tolerable and safe regimes for latent TB; 4) as well as drugs with 
few drug-drug interactions, so they can be safely provided to patients co-infected with HIV. 
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Table 1.3: Classification of anti TB drugs (World Health Organization 2015). 
First - line Second - line Third - line 
Rifampicin  
Isoniazid  
Ethambutol  
Pyrazinamide 
Aminoglycosides 
Amikacin 
Neomycin 
Polypeptides 
Capreomycin  
Viomycin  
Emviomycin  
Flouroquinolones  
Ofloxacin  
Levofloxacin 
 Ciprofloxacin 
 Moxifloxacin 
 Thioamides 
 Ethionamide 
 Prothionamide 
 Para-aminosalicylic acid 
Rifabutin 
Macrolides 
Clarithromycin 
Linezolid 
Thiacetazone 
Thioridazine 
Arginine 
VitaminD 
Perchlorperazine 
 
Another pressing concern that needs attention is the availability of paediatric formulations with 
specific consideration to both individual and fixed drug combinations that offer good 
bioavailability. There are liquid formulations that are easy to administer to young children, but 
these bulky and more expensive formulations come with unacceptable toxicity levels. For 
example, INH syrup causes diarrhoea due to the sorbitol base (Kanabus 2016). 
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Table 1.4: TB drugs used to treat drug resistant TB according to group (Kanabus 2016). 
 
Few trials have been carried out on the drugs in Group 5 (see Table 1.4) to see how effective 
they actually are in the treatment of drug resistant TB. For example, the drug linezolid is an 
antibiotic usually used to treat severe bacterial infections. The first trial of this drug was led by 
the National Institute of Allergy and Infectious Diseases to investigate the use of it in treating 
XDR-TB. It was a small trial but it did show that the drug was effective when added to patients’ 
current treatments, although most of the patients experienced adverse effects (nausea, 
vomiting, and epigastric pain) (Steenhuysen 2012). Besides linezolid being able to offer a 
100% bioavailability and appears to be well tolerated; it has the ability to enter macrophages 
and thus also has intracellular activity. This is an important feature of this drug when used 
against mycobacteria that cause chronic infections and require long-term therapy (Wallace, 
Brown-Elliott et al. 2001).  
 
One prospect that has shown some promise in the advancement of TB chemotherapy is the 
repurposing of current chemotherapeutic agents; as is the case with linezolid. Drug resistance 
mainly involves genetic evolution of the pathogen to overcome the toxic effects of the drug 
and is exacerbated by inappropriate prescription and/or patient non-compliance. Thus, even 
though research into novel agents and new drugs is important, it is likely that resistance towards 
these agents will develop in the organism. Thereby, making it more important to work towards 
Group 1 
 
First Line 
Oral Agents 
Group 2 
 
Injectable 
Agents 
Group 3 
 
Fluoroquinolones 
Group 4 
 
Oral 
Bacteriostatic 
Second Line 
Agents 
Group 5 
 
Agents with an unclear 
role in the treatment of 
drug resistant TB 
pyrazinamide  
 
kanamycin  
 
levofloxacin  
 
para–
aminosalicylic 
acid  
clofazimine  
ethambutol amikacin moxifloxacin cycloserine linezolid 
rifabutin capreomycin ofloxacin terizidone amoxicillin/clavulanate 
 streptomycin  thionamide thioacetazone 
   protionamide imipenem/cilastatin 
    clarithromycin  
Stellenbosch University  https://scholar.sun.ac.za
38 
 
increasing the treatment options that are currently available that target diverse metabolic 
pathways in the bacilli (Maitra, Bates et al. 2015). However, a concern that one would need to 
take into consideration when including new derivatives in different drug combinations, is the 
possibility of cross-resistance (Casenghi, Schoen-Angerer 2006). Another example is a recent 
study done at Stellenbosch University, called NC001. It involved a new drug combination of 
an experimental medicine called PA-824 (nitroimidazole derivative) alongside bedaquiline, 
moxifloxacin and pyrazinamide. This cocktail, dubbed PaMZ, proved to be safe and presented 
the potential to reduce the time needed to treat drug resistant forms of the disease (Van 
Rensburg 2012). 
 
The pulmonary collectins, SP-A and SP-D, as previously mentioned, have been reported to 
bind LPS, opsonize microorganisms, and enhance the clearance of lung pathogens. They 
enhance the in vitro phagocytosis and environmental killing of a variety of pulmonary 
pathogens by binding to mycobacterial organisms (Wright 2005, Samten, Townsend et al. 
2008). Research has shown that most neonates who suffer from surfactant dysfunction are 
highly susceptible to GBS (group B streptococcal) infection and respiratory failure. Data from 
animal experiments have indicated that exogenous surfactant improved lung function and 
diminished bacterial growth in immature rabbits with experimentally induced neonatal GBS 
pneumonia (Herting, Sun et al. 1997). Therefore, apart from the biophysical properties of 
surfactant function within the lung, surfactant also plays an important role in the antibacterial 
defence system of the lung. Thus, the possible use of surfactant as a carrier for antibiotics or 
specific immunoglobulins is currently an excellent niche for respiratory drug delivery research. 
 
Previous work by Pasula and colleagues (1997) suggest that the attachment of M.tb organisms 
to AMs can be mediated by SP-A. They further stipulated that it is most likely mediated by a 
carbohydrate-recognition domain on M.tb and the SP-A binding appeared to be specific and 
saturable. Therefore, this data is consistent with the hypothesis that SP-A functions as a “bridge” 
between the M.tb and AMs, facilitating an important first step in the development of infection 
(Pasula, Downing et al. 1997). Another study by Weikert and colleagues demonstrated how 
SP-A not only binds to BCG but enhances its uptake by rat AM. Once inside the macrophage, 
survival of the mycobacteria is dependent on its escaping the bactericidal mechanisms of the 
host. Rodent macrophages kill ingested mycobacteria through the induction of iNOS and 
subsequent production of NO. Interference of these systems via iNOS inhibitors have proven 
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the proliferation of M.tb and resulted in disease (Weikert, Lopez et al. 2000). Thus, when 
considering linezolid’s characteristic trait of having intra-macrophage activity, it appears to be 
a worthy drug for further investigation alongside surfactant therapy due to its desirable 
properties as a new drug for therapy.  
 
Currently, a common belief to approach the investigation of drug treatment efficacy for 
tuberculosis lies in exploring novel systems for drug delivery (Mckinney 2000). Local delivery 
to the lungs by inhalation has emerged as one of the most attractive administration routes to 
target pulmonary TB infection. Inhaled therapy or the direct administration of antibiotics into 
a tracheobronchial tree using nebulization or intratracheal instillations, delivers the drug to the 
diseased organ with a reduction in adverse effects associated with systemic toxicity whilst 
providing high concentration of drug in a focus of infection (Pandey, Khuller 2005, Parikh, 
Dalwadi et al. 2014). Administering drugs by the pulmonary route to the lungs allows higher 
drug concentrations within these lesions. Supplementing conventional therapy with inhaled 
anti-TB therapy may allow therapeutic concentrations of drug to penetrate locally into lung 
lesions and treat the resident mycobacteria (Muttil, Wang et al. 2009). The use of exogenous 
pulmonary surfactant as a vehicle for antibacterial agents has proven its theoretical feasibility 
to enhance the efficiency of local antimicrobial therapy but this method is still not practised in 
clinical settings (Kharasch, Sweeney et al. 1991, van't Veen, Mouton et al. 1995).  
 
One such an innovative approach was investigated during the course of this thesis where the 
feasibility of using various surfactants in drug delivery in vitro was investigated.  
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1.6 Pulmonary Drug Delivery: Aerosol Characteristics and Inhalation 
Devices 
 
Inhalation therapy has been used for thousands of years as a method for delivering medicine, 
albeit in a different form and use. Many of the principles used then are still embodied in modern 
devices still available today (Sanders 2007). Currently with the increase in our understanding 
of the physiology of the lung and related diseases, pulmonary drug delivery (PDD) is fast 
becoming an alternative choice to treat local and systemic diseases. The lungs remain an 
attractive target for drug delivery due to the non-invasive administration as it avoids first-pass 
metabolism, a more rapid onset of therapeutic action, direct delivery to the site of treatment of 
respiratory diseases as well as the availability of a huge surface area for local drug action and 
systemic absorption of drug. Furthermore, while intravenous or oral administration results in 
high systemic drug concentrations for a short period of time, typically, a relatively low amount 
actually reaches the lung. A low lung-to-plasma ratio can potentially lead to treatment failure 
and may increase systemic side effects (Peng, Lin et al. 2016). Focused pulmonary delivery of 
drugs exposes lung tissue to drug concentration levels significantly higher compared to other 
routes of administration by reducing systemic toxicity (Meenach, Anderson et al. 2014). The 
therapeutic applications of pulmonary drugs have extended their borders beyond conventional 
indications (asthma, COPDs, and cystic fibrosis) to include other inhalable compounds such as 
antimicrobials and protein therapeutics. Since the physio-chemical properties, dose regimen 
and patient interface may vary from previous therapies; new formulation techniques and device 
designs become necessities to explore (see Figure 1.16). There has been an emergence of 
innovative technologies in aerosol based therapeutics as a result of the recent therapeutic 
indications that has arisen; which, in turn have sparked studies to ensure optimal aerosolisation 
performance, therapeutic efficacy and patient adherence (Zhou, Tang et al. 2014).  
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Figure 1.16: Inhalation device design relationships (Zhou, Tang et al. 2014) 
Preparations for inhalation are liquid or solid preparations intended for administration as 
vapours or aerosols to the lung in order to obtain a local or systemic effect. They contain one 
or more active substances that may be dissolved or dispersed in a suitable vehicle (British 
Pharmacopoeia 2000). Depending on the type of preparation, they may contain propellants, co-
solvents, diluents, antimicrobial preservatives, solubilising and stabilising agents, etc. These 
excipients are substances formulated alongside the active ingredient and do not adversely affect 
the functions of the mucosa of the respiratory tract or its cilia but rather act as a therapeutic 
enhancement facilitating drug absorption, reducing viscosity (Chang 2013), enhancing 
solubility (Heinemann, Klappoth et al. 2000), or have the purpose of long-term stabilisation 
(Respaud, Marchand et al. 2014). The selection of appropriate excipients much depends upon 
the route of administration as well as the dosage form, and the active ingredient itself. 
Preparations intended to be administered as aerosols (dispersions of solid or liquid particles in 
a gas) are administered by one of the following devices: nebuliser, breath actuated or 
pressurised metered-dose inhaler (MDI/ pMDI), or dry-powder inhaler (DPI) (British 
Pharmacopoeia 2000). 
 
1.6.1 Ideal Aerosols 
 
An aerosol is defined as a relatively stable colloidal suspension of solid or liquid particles in a 
gas (usually air). There are three major categories of devices currently in clinical use to generate 
the aerosol particles: nebulizers, MDIs, and DPIs (Mansour, Rhee et al. 2009). The efficacy of 
the inhaled aerosol depends upon a few factors regarding the particles that comprise the aerosol. 
The aerosol must be able to reach the desired site of action in the respiratory tract (i.e. 
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pulmonary region). Drugs administered directly to the lungs in patients with pulmonary 
diseases may accumulate in central rather than peripheral airways. This may be due to the 
physiologic properties of fluid dispersion in respiratory pathways and the alterations specific 
to inflammatory alterations of the airways such as bronchial hyper secretion, 
bronchoconstriction, and bronchial oedema (Labiris, Dolovich 2003a). For a device or 
formulation to be practical and effective, therapeutic concentrations of the aerosol particles 
must first be capable of releasing the drug at the site of action, within a small number of breaths, 
before clearance mechanisms carry the compound away from the deposition site (Nahar, Gupta 
et al. 2013).  
 
Figure 1.17: The number and dimensions of the airways of the adult lung and structure of the airway wall with 
the generations as explained by Weibel’s tracheo-bronchial tree (Nahar, Gupta et al. 2013). 
 
1.6.2 Nebulisers, Dry Powders and Pressurised Metered-Dose Inhalers 
 
The deposition of therapeutic aerosols occurs by inertial impaction within the oropharynx and 
large conducting airways whereas the deposition in the small conducting airways and alveoli 
is due to gravitational sedimentation; however, both are determined by mode of inhalation, 
particle or droplet size, and the degree of airway obstruction (Lippmann 2011). 
 
There are many devices currently used to deliver aerosolised therapeutic agents. One of the 
more popular used methods of aerosol drug delivery is the MDI (breath actuation), or pMDI, 
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due to its reliability and cost effectiveness. Its use is however limited to treating upper airway 
conditions as deeper lung drug-deposition is challenged with peptide formulations due to 
inefficient fine particle range and limited delivered dose. Nebulisers employ an aqueous based 
drug solution through an air jet or an ultrasonic device. This mechanism differed from MDIs 
as it typically delivers doses over multiple breaths. There have been advances in nebuliser 
technology that have overcome the conventional limitations of the bulky and costly units; and 
they still remain an attractive form of independent aerosol inhalation methods that are 
reasonably easy. If further improvements are made, the nebulising system may very well 
become an alternative mainstream portable inhaler system rather than a specialty device 
(Daniher, Zhu 2008).  
 
The pMDIs have, for many years, since being first introduced in the 1950s, led the application 
form of inhalation therapy as they have many favourable features, such as easy handling, high 
reliability and accurate metering performance. They currently account for more than 90% of 
all inhaled asthma therapy (Malcolmson, Embleton 1998). PMDI preparations for inhalation 
contain the solutions, suspensions or emulsions (alongside propellants or mixtures of liquefied 
propellants which may act as solvents) supplied in specialised containers equipped with a 
metering valve and which are held under pressure and enable efficient and consistent dose 
delivery to the patient (Stein, Sheth et al. 2014). Suitable co-solvents, solubilisers and 
stabilisers may be added in the excipient if the delivered drug is insoluble or quickly degradable 
(British Pharmacopoeia 2000). The propellant, which comprises the bulk of the pMDI 
formulation, is the driving force that atomizes the droplets containing the drug (and excipients); 
it should be the driving force for ideal lung deposition. The phase-out program of 
chlorofluorocarbon inhalers (Montreal Protocol on Substances that Deplete the Ozone Layer) 
allowed for the introduction of more environmentally friendly hydrofluoroalkane propellant 
based inhalers which paved the way for many improvements to the methods of formulating 
pMDI drug delivery (U.S. Food and Drug Administration 2015). More attention was indicated 
to understanding formulation variables, product performance and patient interface, whilst 
considering the physico-chemical properties of the various excipients and active 
compounds(Myrdal, Sheth et al. 2013).  
 
The device hardware (see Figure 1.18) includes a canister that is appropriately sized to contain 
sufficient formulation for the required number of doses. A metering valve is included that is 
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capable of delivering a consistent amount of drug with each dose delivered (Stein, Sheth et al. 
2014).  
 
 
Figure 1.18: Schematic of a pMDI press-and-breathe actuator. Drawing courtesy of 3M Healthcare Ltd (Stein, 
Sheth et al. 2014). 
 
The pMDI still, 50 years after its invention, remains a mainstay of asthma and COPD therapy 
worldwide. They are compact and convenient pulmonary drug delivery system that has the 
advantage of being easily grasped by patients and their multi-dose nature makes them more 
affordable than competing inhalation delivery systems. The developments of pMDI actuators 
have been a part of the devise technology improvement that continues to enhance drug delivery 
efficiency. This stands to prove that innovations that enhance the functionality of pMDIs will 
be balanced between the advantages of the system and their low cost. This is a crucial 
component to take into consideration as the expansion of health care in developing countries 
as well as the increased focus on the costs involved, will ensure that pMDIs remain a cost-
effective and crucial pulmonary drug delivery system for treating various lung diseases or 
conditions (Stein, Sheth et al. 2014). 
 
DPIs have experienced a big increase in development in the last 10 years due to the renowned 
limitations in other types of inhalation devices. Development of DPIs for the therapy of well-
known diseases such as asthma and COPD has led to the increasing realisation of its potential 
role in other possible therapies that include inhaled antibiotics or peptides and proteins 
(Newman 2004). Therefore, the investigation of these devices may lead to the optimization of 
drug delivery. It offers many advantages that include minimal patient hand-lung coordination, 
portability, and improved stability over liquid aerosols. Due to the absence of a propellant, they 
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allow for the delivery of compounds that are not water-soluble and that are difficult to deliver 
as inhaled aqueous solutions via pMDIs or nebulization (Meenach, Anderson et al. 2014). 
However, improvements in drug formulations need to be taken into consideration. 
Formulations that, within the inhaled air stream, offer easier dispersion by relatively simple 
inhaler devices. One can then predict that DPIs could become the device category of choice for 
a wide range of inhaled therapies, involving both local and systemic drug delivery (Newman 
2004). DPIs can be manufactured via spray-drying methods that employ a high throughput 
engineering method of solid-state particles that allows for microencapsulation of active 
compounds. This method of particle engineering allows for dry powder formulation designs to 
benefit regarding improved stability, improved powder dispersibility, controlled release, and/or 
increased drug permeability. The possibility of sustained release from a therapeutic aerosol 
may lengthen the drug lodging time within the airways or the alveolar region. This could 
increase patient compliance and reduce dosing frequency (Meenach, Anderson et al. 2014). 
 
1.6.3 Aerosolised Surfactant as a Pulmonary Drug Delivery Vehicle 
 
When considering surfactant administration, it differs based on manufacturers guidelines for 
individual surfactants. The dose, frequency of administration, and treatment procedures have 
been modelled after research protocols. Furthermore, it was found that repeated doses of 
surfactants given at intervals for predetermined indications have decreased mortality and 
morbidity compared with placebo or single surfactant doses (Soll, Ozek 2009). However, given 
the long half-life for surfactant in preterm infants with RDS, re-dosing usually occurs every 12 
hours unless the surfactant is inactivated by an infectious process, meconium, or blood (Cogo, 
Facco et al. 2011). Surfactant administration procedures most commonly involve the 
endotracheal route, either as bolus, in smaller aliquots or via an adaptor port, and are therefore 
invasive and may be complicated by transient airway obstruction, oxygen desaturation, 
bradycardia, and various other physiological impediments (Polin, Carlo 2014, Kendig, Ryan et 
al. 1998). Many animal models of surfactant administration and small clinical trials of human 
preterm infants have demonstrated significant differences in clinical outcomes between 
methods (Zola, Gunkel et al. 1993, Ueda, Ikegami et al. 1994, Valls‐i‐Soler, López‐Heredia et 
al. 1997). Most of the data collected are conflicting and limited; thus indicating that the optimal 
method of surfactant administration in preterm infants has yet to be clearly proven. Moreover, 
the recommended optimal number of doses of surfactant and which body position is best when 
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surfactant is administered are still two crucial aspects of surfactant therapy which have 
insufficient evidence (Polin, Carlo 2014). 
 
There are a number of alternative methods to intratracheal administration of surfactant that 
have been evaluated in clinical trials (Kribs 2011, Abdel‐Latif, Osborn 2011, Abdel‐Latif, 
Osborn 2012). The increasing interest and use of non-invasive ventilator support for neonatal 
RDS and lung injury has motivated clinicians and researchers to look for alternative methods 
of administering exogenous surfactant. Aerosolised surfactants have been the most attractive 
route and have received much attention as they may prevent the need for endotracheal 
intubation. They have already been proven to be efficient and safe in animal models of 
respiratory distress syndrome by improving both ventilation and lung mechanics, even with 
minimal lungs deposition (Lewis, Ikegami et al. 1991, Li, Chen et al. 1994, Ellyett, Broadbent 
et al. 1996, Walther, Hernández-Juviel et al. 2014). However, the therapeutic effects of 
aerosolised surfactant in human clinical trials have not been convincing as most ultrasonic or 
jet nebulisers require the patient to have mechanical ventilation to deliver aerosolised 
surfactants and the improper use of these ventilators may cause or enhance lung injury (Pavone, 
Albert et al. 2007). It has been found that delivering an aerosolised surfactant by CPAP has 
beneficial effects in the treatment of NRDS without the need for mechanical ventilation. These 
results suggest that aerosolised surfactants inhaled by spontaneous breathing may be an 
attractive alternative method of surfactant-based therapies (Sun, Yang et al. 2009). 
 
In addition, four small clinical studies have been performed to date. The safety and feasibility 
of these studies were confirmed; however, the effectiveness of this form of treatment requires 
further study as some groups excluded controls or the intervention was deemed as “too late”. 
Nebulised Alveofact® showed improvement in oxygenation and alveolar ventilation in preterm 
infants whereas aerosolised Curosurf® showed no superiority over nasal CPAP alone. These 
outcomes highlight the need to include optimising the dose of aerosolised surfactant, choosing 
particle size, developing the best delivery system, and using a surfactant formulation that 
maintains its integrity and activity once aerosolised (Mazela, Merritt et al. 2007).  
 
Arroe et al. conducted a pilot study to estimate whether inhalation of an aerosolised synthetic 
surfactant (Exosurf®) delivered via nasal CPAP in preterm newborns with moderate RDS 
would improve systemic oxygenation. No adverse effects were noted but no improvement of 
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clinical substance were seen either (Arroe, Pedersen-Bjergaard et al. 1998). One may speculate 
that the absence of surfactant proteins contributes to the ineffective aerosolisation as Exosurf® 
was previously proven to be inefficacious compared to natural surfactants and therefore 
discontinued (Kattwinkel 2005). However, neither did the aerosolised animal derived 
surfactant (Curosurf®) display beneficial effects within a nebulised surfactant model for 
neonatal RDS, which are contrary to the experiments done by Berggren et al. (2000). Their 
findings are indicative to differences in administration techniques and further work is most 
undoubtedly needed for the optimisation of aerosolised surfactant delivery to the neonatal lung 
in clinical practice (Berggren, Liljedahl et al. 2000).  
 
An example of an optimisation study is the investigation of an aerosolised form of lucinactant, 
Surfaxin® performed by Johnsen and colleagues (2006), or in this case Aerosurf®, has shown 
the feasibility and safety of delivering a peptide-containing synthetic surfactant to newborns 
with early signs of RDS. This study used a clinically approved device, the Aeroneb Pro 
(Artemis Medical Ltd, Dartford, Kent, UK) with a specially designed CPAP adaptor, to show 
the efficacy of such a model (Mazela, Merritt et al. 2007). Moreover, additional detailed 
analyses showed that the aerosolised lucinactant retained its biochemical activity (Johnson, 
Mazela et al. 2006, Finer, Merritt et al. 2010). 
 
The use of exogenous pulmonary surfactants as a carrier for drugs (e.g. antibiotics) is a recent 
concept that has been under investigation as a synergistic approach to pulmonary drug delivery. 
When considering inhalation administration of drugs or surfactant, the site of maximum 
deposition within the lung is dependent on the size of the particle, with small particles having 
maximum penetration but poor deposition and large particles having poor penetration but large 
deposition. There is always the risk of non-uniform distribution of surfactant administration 
that may also result in regional atelectasis which hopefully aerosolised surfactant may 
overcome (Ellyett, Broadbent et al. 1996). However, the potency of some drugs may change 
with aerosolisation, and therefore may require dose adjustment just as surfactant phospholipid 
dosage and tidal volume are taken into consideration for inhalation therapy (Willson 2015). 
Most studies have covered the concept of liposomal drug-surfactant preparations and have 
proven foundational to optimise other modes of delivery (e.g. nebulisation, DPI, pMDI) (Justo, 
Moraes 2003, Chimote, Banerjee 2009). Provided that the encapsulated drug-surfactant 
suspension functions as an excellent surfactant with rapid adsorption, it is hypothesised that it 
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will improve the distribution of the drugs at the alveolar levels; resulting in atelectatic alveoli 
expansion. This will allow the chemotherapeutic agents to reach the previously collapsed 
alveoli, which are likely to be highly infected (Chimote, Banerjee 2009). Moreover, 
interactions between pulmonary surfactant and antimicrobial agents have been reported. It is 
therefore crucial to evaluate these interactions before using surfactant-antibiotic mixtures in 
clinical trials (van't Veen, Mouton et al. 1995).  
 
Although pulmonary drug delivery has been established and proven effective for conditions 
such as asthma and cystic fibrosis, the concept of antibiotic pulmonary delivery (in 
combination with exogenous surfactant preparations) is a fairly recent area of study with the 
long-term goal of preparing inhalable particles for TB therapy. Deep- lung delivery has always 
been an obstacle, beyond the atelectatic regions, as it has been observed that particles reaching 
the lungs are phagocytosed rapidly by alveolar macrophages (AM) (Evora, Soriano et al. 1998, 
Sharma, Saxena et al. 2001). Although phagocytosis and sequestration of inhaled micro-
particles may cause complications for drug delivery to other cells comprising lung tissue, it is 
however, an advantage for chemotherapy of TB as the phagocytosed micro-particles can 
potentially deliver larger amounts of drug to the AM cytosol where the TB bacilli sometimes 
reside (Sharma, Saxena et al. 2001). 
 
These new approaches of aerosolised exogenous surfactants for the use of inhalable drug 
therapy that have reached pre-clinical stage are enumerated. The potential of drug delivery 
systems to improve and optimise currently available antibiotic therapies (among others) in the 
context of lung infections supports the need to gain insight into the complex context that 
surrounds the infection. One also has to gain understanding about the interactions of different 
fields, such as microbiology, physiopathology, immunology, 
pharmacokinetics/pharmacodynamics, pharmacology and nanotechnology which in turn opens 
wider scopes of further research into pulmonary drug delivery (Moreno-Sastre, Pastor et al. 
2015). 
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1.8 Aims of Study 
 
a) To assess the viability of cell lines after above mentioned time exposure to varying 
surfactant concentrations within the same time frames using the MTT colorimetric assay 
for assessing cell metabolic activity.  
i. NR8383 rat alveolar macrophage cell line 
Phalloidin-TRITC staining will be employed to visualize potential stimulation of 
filamentous actin (F-actin) formation in alveolar macrophages, actin 
polymerization of NR8383 macrophages; stimulation of cytoskeletal rearrangement, 
specifically of directed actin-filled filopodia. 
 
ii. A549 Human Lung carcinoma- Alveolar epithelium cell line 
(For the purpose of an epithelial model) 
 
b) To evaluate the potential anti-inflammatory effects (Cytokine production and Oxidative 
Burst) of 3 exogenous surfactants (2 animal derived and 1 synthetic surfactant) on un-
stimulated and lipopolysaccharide (LPS) stimulated rat alveolar macrophage (AM) cell 
line NR8383 and human alveolar macrophages derived from BAL (bronchoalveolar 
lavage) in varying concentrations and time exposure. 
 
1) Curosurf® - Animal derived (porcine) 
2) Liposurf® - Animal derived (bovine) 
3) Synsurf® - Synthetic 
 
c)  Antimicrobial 
To evaluate and compare the antimicrobial efficacy of individual drug-surfactant combinations 
(Curosurf®, Synsurf®, Liposurf®) at concentrations relevant to the MIC99 in order to 
determine their potential drug-MIC lowering capacity using the MGIT 960 system.  
 
Pathogen and drug list: 
Mycobacterium tuberculosis – Linezolid 
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Linezolid was the chosen antibiotic studied due to its potential repurposing for the treatment 
of MDR-TB. 
 
d)  Biophysical 
 
To study the biophysical performance of surfactant-drug combinations in order to allow for a 
proper evaluation of the significance of the experimental model system, providing a possible 
non-invasive, site-specific, dual drug delivery model via pMDI (pressurised metered dose 
inhaler) form. The Calu-3 lung adenocarcinoma cell line (ATCC® HTB-55™) will be 
investigated as suitable cell-line model for a possible Synsurf® pMDI due to its preferred air-
liquid interface characteristics.  
 
i. To develop a novel device for the deposition of aerosolised surfactant-based particles 
for inhalation onto cultured airway epithelium as well as to validate the compatibility 
with cells. Furthermore, to characterise the transport of an aerosolised form of the 
synthetic surfactant Synsurf®. 
 
Synsurf® was investigated as it is an entirely synthetic pulmonary surfactant containing 
peptides that mimic the action of naturally occurring surfactant proteins SP-B/C and avoids the 
potential risk of animal-derived pathogen transmission. It is also inexpensive and less 
complicated to manufacture since it does not rely on protein purification and harvesting from 
animal sources. Furthermore, pMDI’s provide patients with a versatile, reliable, instantly 
available, self-contained, portable, low cost medical aerosol delivery system. 
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2 CHAPTER 2: Viability Study 
2.1 Introduction 
 
The lungs have become the main targets for the manufacture and processing of pulmonary drug 
administration. Endogenous pulmonary surfactant cover the bronchioles and alveoli. Inhaled 
particles encounter surfactant that may lead to particle coating, modification of its epithelial 
surface chemistry and subsequent cell response (Wallace, Keane et al. 2007, Herzog, Byrne et 
al. 2009). In turn, this interaction may have consequences for the oxidative potential of the 
particles. Similarly, administration of exogenous lung surfactant can influence the lung 
epithelial cell surface as well as the agglomeration state of immune cells within the lung. These 
are factors of possible exogenous surfactant induced cellular modulation on delicately balanced 
intracellular pathways. This could potentially play a role in the induction of the respiratory 
burst and lead to the production of reactive oxygen species (ROS) which, in turn, may induce 
cell death.  
 
Apoptosis, also called programmed cell death, is a type of cell extinction regulated in an orderly 
manner by a series of signal cascades in certain situations, and it is an important physical 
process involved in regulating growth, development, and immune responses (Fan, Han et al. 
2005, Chen, Lai et al. 2008). The induction of apoptosis in tumour cells with exogenous 
surfactant (alongside other treatments) might prove to be an important approach in therapy for 
cancer and immune system diseases that affect the pulmonary system. This approach is gaining 
interest. Badawi and co-workers investigated several novel (non-pulmonary) surfactants on the 
regulation of cancer growth (Badawi, Ismail et al. 2015). Their studies revealed that surfactants 
may have played a role in the regulation of cancer growth as tin-based surfactants displayed 
effective antitumor potency. 
 
Assessing the biological activity of surfactants in cell-based experiments of A549 alveolar 
epithelial carcinoma cells and NR8383 rat alveolar macrophages may indicate a role of 
oxidative stress in the production of inflammatory cytokines and cytotoxic cellular responses 
(see Chapter 3). Evaluating the possible in vitro induction of biological activity in these cells 
could perhaps lead to the better understanding of exogenous surfactant administration and the 
pulmonary response that follow in vivo.  
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The objective of the study was to determine, in the absence of clinical variables, the effect of 
exogenous surfactants on the biogenesis and metabolism as well as morphological changes in 
rat alveolar macrophages NR8383 and A549 type II respiratory epithelial cells. The effects of 
two animal derived and one novel synthetic surfactant were studied at varying concentrations 
and time intervals for the use in formulations applied on the respiratory epithelium by means 
of an in vitro cytotoxicity assay. 
 
The results obtained by studying known exogenous surfactants can then be compared to the 
potential toxicity of future exogenous surfactants not yet registered or approved for use in the 
human respiratory tract. Since it is then possible to determine the cytotoxic potential of new 
surfactants in relation to other surfactants, surfactant design and development could be tailored 
to exclude potential toxic components, thus leading to a more rational formulation of the 
product. The mechanisms of pulmonary surfactants triggering cell death have not yet been 
investigated in detail. The current study therefore aims to clarify any possible unwanted or 
unspecific cellular activity exogenous (mammalian-derived and synthetic) lung surfactant may 
be involved in e.g. the activation of intracellular stress signalling pathways.  
 
2.2 Methods and Materials 
 
Cell Culture 
Both the NR8383 and A549 cell lines were successfully established and viability was 
established 95-98% before each experiment. Both the NR8383 (Rat Alveolar Macrophages, 
ATCC®, Cat. No. CRL-2192™) and the A549 (Lung Carcinoma, ATCC®, Cat. No. CCL-
185™) cell lines were first cultured in 75 cm2 flasks and maintained in a humidified, 5% CO2–
95% atmospheric air incubator at 37°C. The NR8383 cell line media comprised of RPMI 1640 
(Roswell Park Memorial Institute media) supplemented with 10% fetal calf serum, 1% l-
glutamine solution (200 mM), and 1% Penicillin-Streptomycin. The media for the A549 cell 
line comprised of Advanced DMEM supplemented with 5% fetal calf serum, 1% L-glutamine 
solution (200 mM), and 1% Penicillin-Streptomycin, and both were routinely changed twice 
weekly. Cells were seeded to 48-well tissue culture plates at a density of 2.5 × 104 cells/well 
for NR8383 and 2 × 104 cells/well for A549 respectively. Cell viability before each experiment 
was assessed by trypan blue exclusion. Equal parts of 0.4% trypan blue dye was added to the 
cell suspension to obtain a 1 to 2 dilution before cell count. Live cells with intact cell 
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membranes are not coloured however, if cells take up trypan blue, they are considered non-
viable. Cell viability before each experiment was established at ~85-90% before each 
experiment. 
 
Viability assay 
Cell viability was determined by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay and were performed in triplicate with Curosurf®, Synsurf®, Liposurf® 
for 30 min, 1, 4, 12 and 24 hours with final phospholipid (DPPC) concentrations of 25 to 1500 
μg/ml for both cell lines (see Appendix A). The assay measures the ability of the mitochondria 
within living cells to reduce the yellow MTT dye to its purple formazan product. This product 
is then dissolved in isopropanol (1%)/triton (0.1%) solution at a 50:1 ratio; the absorbance 
reading of the resulting solution is proportional to the number of viable cells.  
 
The cells, when established at 80% confluency after seeding, were stimulated according to the 
specific experimental procedure. At the end of the experiment, the individual supernatants from 
the plates containing rat alveolar macrophages were carefully removed and centrifuged and to 
ensure the collection of all the semi-adherent cells. For the adherent A549 epithelial cell line, 
the media only needed to be removed. The cells were then incubated (covered in foil) in 250 
μl of 2.5 mg/ml MTT solution in phosphate buffered saline (PBS) for 2 hours in a humidified, 
CO2 5% – 95% atmospheric air incubator at 37°C. Confirmation of the purple product within 
the cells was observed using a light microscope. 250 μl of isoproponol (1%)/triton (0.1%) 
solution was added to each well to lyse cells and dissolve the formazan product. The plates 
were placed on a slow plate shaker for a few minutes to ensure the product is dissolved. The 
absorbance at 550 nm was measured using a universal microplate reader, EL800 BioTek 
Instruments Inc. The effect of treatment on cell viability was calculated as a percentage of 
optical density relative to the untreated control. 
 
Oxidative Burst 
 
The reactive oxidative intermediate, ROS production, in A549 epithelial cells & AMs, was 
analysed by flow cytometry (see Appendix C). The respective cell lines were treated in culture 
with Curosurf®, Liposurf® and Synsurf® (500 - 1500 µg/ml DPPC) for 12 and 24 hours then 
washed, re-suspended and loaded with the fluorescent probe 2′,7′–dichlorofluorescein acetate 
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(DCFH-DA, 25 µM) (Sigma Aldrich). Esterase cleaves the acetate groups of DFH-DA, thus 
the trapped DCFH is converted to the highly fluorescent 2′,7′–dichlorofluorescein (DCF) in the 
presence of reactive oxygen intermediates. DCFH loaded cells were used as the baseline to 
measure auto fluorescence. The fluorescence of cells was recorded at an excitation wavelength 
of 488 nm and green fluorescence from DCF was measured with a 520 nm band pass filter with 
a 520 nm dichromic mirror. Fluorescence values from cells loaded with DCFH without 
surfactant treatment were standardised at 100 %. Scattering properties and DCF fluorescence 
were analysed by FAC-Scan flow cytometer (FACS Calibur, Becton Dickinson). All 
experiments were repeated at least three times. 
 
Initial gating 
To identify the cells, a FSC-A vs SSC-A dot plot was employed and a gate was drawn around 
the cells to distinguish cells from debris using a polygon gate. All further analysis was 
performed on the population. To determine fluorescent intensity of DCF, a histogram plot was 
used and the entire population was gated using an interval gate. Fluorescent intensity values of 
DCF as analysed as Median Fluorescent Intensity. 
 
DCF was analysed on the BD FACSAria I, on the 488nm laser and detected with the 502LP 
filter and 530/30 bandpass filter. 
 
Statistical Analysis 
One-way analysis of variance (ANOVA) with Tukey's post-test was performed for the 
comparison of multiple treatments and differences were considered significant when P ≤ 0.05. 
The statistical program GraphPad Prism v.5 was used. 
 
Microscopic analysis of F-actin structures of NR8383 
Microscopic analysis of F-actin structures of LPS stimulated NR8383 was completed for post-
24 h treatment with Curosurf®, Synsurf®, Liposurf® in comparison to control and LPS 
stimulated control (1 μg/ml) (see Appendix B). Visualization of potential actin polymerization 
after exposure to surfactants (1) Curosurf®, Synsurf®, Liposurf® with final phospholipid 
concentrations 750 and 1500 μg/ml DPPC (2) LPS at 1 μg/ml (3) Control- Medium for 24h. 
Alveolar Macrophages were allowed to adhere to eight-well glass cell culture slides overnight 
and non-adherent cells were removed before treatment.  
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Staining Procedure 
Cells were washed with warm PBS and fixed with 4% para-formadehyde for 10 minutes and 
washed three times thereafter for 5 minutes with PBS. Cells were incubated with 0.1% triton 
X-100 for 6 minutes at 37°C and thereafter washed three times for 5 minutes with PBS. Cells 
were stained with Phalloidin TRITC (P1951) at 50 μg/ml for 40 minutes at room temperature 
and washed three times for 5 minutes with PBS. Slides were air-dried and examined using the 
Zeiss LSM780 ELYRA PS1 confocal microscope.  
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2.3 Results 
Viability assay 
NR8383 Rat Alveolar Macrophages 
 
The well-established and commonly used cytotoxicity assay, MTT, was utilised to determine 
the dose and time dependent toxic effect of three pulmonary surfactants: Curosurf®, Synsurf® 
and Liposurf® to NR8383 alveolar macrophages. Figures 2.1 - 2.5 show the plots of the 
cytotoxic response.The results show dose-dependent as well as time (exposure) dependent 
cytotoxicity of the surfactants. Decrease in cell viability by exposure to higher phospholipid 
concentrations of surfactants were only recorded from 4h onwards (Figure 2.3). Both Synsurf® 
and Liposurf® displayed a similar trend in dose-dependent cytotoxicity, however, the decrease 
in cell viability was not deemed significant. Synsurf® exhibited the same trend for the 12h 
(Figure 2.4) and 24h (Figure 2.5) time exposure and significant decreases in cell viability were 
seen at phospholipid concentrations of 1000 µg/ml (*** P ≤ 0.001) and 1500 µg/ml (** P ≤ 
0.01) for 12 h and again 1000 µg/ml (* P ≤ 0.05) and 1500 µg/ml (* P ≤ 0.05) for 24h. 
 
 
Figure 2.1: The effect of Curosurf®, Synsurf® and Liposurf® on NR8383 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to untreated NR8383 cells for a 30 min exposure time (n=3). Values represent the percentage to 
control value (100%). 
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Figure 2.2: The effect of Curosurf®, Synsurf® and Liposurf® on NR8383 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to untreated NR8383 cells for a 1 h exposure time (n=3). Values represent the percentage to control 
value (100%). 
 
 
Figure 2.3: The effect of Curosurf®, Synsurf® and Liposurf® on NR8383 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to untreated NR8383 cells for a 4 h exposure time (n=3). Values represent the percentage to control 
value (100%) in comparison to control sample. 
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Figure 2.4: The effect of Curosurf®, Synsurf® and Liposurf® on NR8383 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to untreated NR8383 cells for a 12 h exposure time (n=3). Values represent the percentage to control 
value (100%) in comparison to control sample. (one-way analysis of variance (ANOVA), Tukey's post-test ** P 
≤ 0.01, *** P ≤ 0.01 
 
 
Figure 2.5: The effect of Curosurf®, Synsurf® and Liposurf® on NR8383 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to untreated NR8383 cells for a 24 h exposure time (n=3). Values represent the percentage to control 
value (100%) in comparison to control sample. (one-way analysis of variance (ANOVA), Tukey's post-test * P ≤ 
0.05. 
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A549 Lung Carcinoma 
 
The MTT assay was carried out to determine the dose and time dependent cellular metabolic 
activity of three pulmonary surfactants: Curosurf®, Synsurf® and Liposurf® to the A549 
adenocarcinoma basal epithelial cells. Figures 2.6 - 2.10 show the plots of the cytotoxic 
response.The results show dose-dependent as well as time (exposure) dependent cytotoxicity 
of the surfactants. Decrease in cell viability (* P ≤ 0.05, ** P ≤ 0.01) by exposure to higher 
phospholipid concentrations of Curosurf® and Liposurf® were recorded at 1 h (Figure 2.7). 
Both Synsurf® and Liposurf® displayed a similar trend (not significant) in dose-dependent 
cytotoxicity at 4 h (Figure 2.8) that was also seen in the NR8383 cell line (Figure 2.3). 
Synsurf® exhibited the same trend for the 12 h (Figure 2.9) and 24 h (Figure 2.10) exposure 
time. Significant decrease in cell viability was seen at phospholipid concentrations of 1000 
µg/ml (** P ≤ 0.01) and 1500 µg/ml (*** P ≤ 0.001) for 12 h and at phospholipid 
concentrations of 500 µg/ml, 750 µg/ml (*P < 0.05), 1000 µg/ml (*** P ≤ 0.001) and 1500 
µg/ml (*** P ≤ 0.001) for 24h. 
 
 
Figure 2.6: The effect of Curosurf®, Synsurf® and Liposurf® on A549 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to unstimulated A549 cells for a 30 min exposure time (n=3). Values represent the percentage to 
control value (100%). 
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Figure 2.7: The effect of Curosurf®, Synsurf® and Liposurf® on A549 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to unstimulated A549 cells for a 1 h exposure time (n=3). Values represent the percentage to control 
value (100%). (one-way analysis of variance (ANOVA), Tukey's post-test * P ≤ 0.05, ** P ≤ 0.01  in comparison 
to the control) 
 
 
Figure 2.8: The effect of Curosurf®, Synsurf® and Liposurf® on A549 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to unstimulated A549 cells for a 4 h exposure time (n=3). Values represent the percentage to control 
value (100%). (one-way analysis of variance (ANOVA), Tukey's post-test). 
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Figure 2.9: The effect of Curosurf®, Synsurf® and Liposurf® on A549 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to unstimulated A549 cells for a 12 h exposure time (n=3). Values represent the percentage to control 
value (100%). (one-way analysis of variance (ANOVA), Tukey's post-test, *** P ≤ 0.001 in comparison to the 
control). 
 
 
Figure 2.10: The effect of Curosurf®, Synsurf® and Liposurf® on A549 cell viability in vitro. MTT assay was 
performed to evaluate the cytotoxic effect of varying surfactants at comparable DPPC concentrations in 
comparison to unstimulated A549 cells for a 24 h exposure time (n=3). Values represent the percentage to control 
value (100%). (one-way analysis of variance (ANOVA), Tukey's post-test * P ≤ 0.05, *** P ≤ 0.001 in comparison 
to the control). 
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Oxidative Burst 
NR8383 Rat Alveolar Macrophages 
 
Both animal derived surfactants significantly decreased basal levels of reactive oxygen 
intermediates at phospholipid concentrations of 500–1500 µg/ml compared to the un-treated & 
un-stimulated AMs (Figures 2.11 & 2.12). Curosurf® significantly decreased (P ≤ 0.0001) 
ROS production by 90.05 ± 0.45% - 94.75 ± 1.82%, and Liposurf® decreased (P ≤ 0.0001) 
ROS production by 89.1 ± 1.20% - 96.16 ± 0.44%. No statistical differences were found among 
the varying concentrations nor were differences found between the separate surfactants. 
Synsurf® increased ROS production by 21.6 ± 13.89% at the phospholipid concentration 1500 
µg/ml (Figure 2.13) but significantly decreased (P ≤ 0.001) ROS production by 22.00 ± 3.77% 
- 80.14 ± 6.30% in a dose-dependent manner at decreasing phospholipid concentration of 750 
– 500 µg/ml.  
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Figure 2.11: The effect of Curosurf®; at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. The respective surfactant decreased basal levels of 
oxidative burst in AMs. Values represent inhibition relative to basal AM fluorescence at 100% vs Control (un-
treated & un-stimulated) (n = 5). (one-way analysis of variance (ANOVA), Tukey's post-test **** P ≤ 0.0001 in 
comparison to the control). 
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Figure 2.12: The effect of Liposurf®; at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. The respective surfactant decreased basal levels of 
oxidative burst in AMs. Values represent inhibition relative to basal AM fluorescence at 100% vs Control (un-
treated & un-stimulated) (n = 5). (one-way analysis of variance (ANOVA), Tukey's post-test **** P ≤ 0.0001 in 
comparison to the control). 
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Figure 2.13: The effect of Synsurf®; at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to basal AM 
fluorescence at 100% vs Control (un-treated & un-stimulated) (n = 5). (one-way analysis of variance (ANOVA), 
Tukey's post-test *** P ≤ 0.001 in comparison to the control). 
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The animal derived surfactants, Curosurf® and Liposurf®, and the synthetic surfactant 
(Synsurf®) significantly decreased basal levels of oxidative burst at phospholipid 
concentration of 500 – 1500 µg/ml compared to the LPS-stimulated AMs (Figures 2.14 – 2.16). 
Curosurf® (Figure 2.14) significantly decreased (P ≤ 0.0001) ROS production by 88.53 ± 
9.20% - 95.92 ± 0.81%, and Liposurf® (Figure 2.15) decreased (P ≤ 0.0001) ROS production 
by 48.17 ± 20.7% - 89.8 ± 0.85% in a dose-dependent manner. No statistical differences among 
the varying concentrations were found for Curosurf®. However, less inhibition on LPS 
stimulated ROS production was seen between phospholipid concentrations 1000 µg/ml vs 500 
µg/ml for Liposurf® (P ≤ 0.05). On the other hand, Synsurf® decreased ROS production by 
62.43 ± 21.58% - 88.37 ± 055% at phospholipid concentration of 500–1500 µg/ml compared 
to the LPS-stimulated AMs (Figure 2.16). No statistical differences among the varying 
concentrations were found thus displaying a threshold effect.  
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Figure 2.14: The effect of Curosurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. The respective surfactant decreased LPS levels of 
oxidative burst. Values represent inhibition relative to LPS-stimulated AM fluorescence at 100%. *** P ≤ 0.001 
vs Control (LPS alone) (n = 3). (one-way analysis of variance (ANOVA), Tukey's post-test *** P ≤ 0.001 in 
comparison to the control). 
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Figure 2.15: The effect of Liposurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. The respective surfactant decreased LPS levels of 
oxidative burst. Values represent inhibition relative to LPS-stimulated AM fluorescence at 100%. (one-way 
analysis of variance (ANOVA), Tukey's post-test * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 in comparison to the 
control (LPS alone) (n = 3). 
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Figure 2.16: The effect of Synsurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. The respective surfactant decreased LPS levels of 
oxidative burst. Values represent inhibition relative to LPS-stimulated AM fluorescence at 100%. (one-way 
analysis of variance (ANOVA), Tukey's post-test ** P ≤ 0.01,*** P ≤ 0.001 in comparison to the control (LPS 
alone) (n = 3).  
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A549 Lung Carcinoma 
 
All three exogenous surfactants significantly increased basal levels (absence of LPS) of 
reactive oxygen intermediates at high phospholipid concentrations of 1000 – 1500 µg/ml 
compared to the un-treated & un-stimulated type II epithelia cells. Curosurf® (Figure 2.17) 
significantly increased (P ≤ 0.05) ROS production by 42.14 ± 19.11% at phospholipid 
concentration of 1500 µg/ml and 55.08 ± 18.16% at phospholipid concentration of 1000 µg/ml 
(P ≤ 0.01). Inter-concentration differences were found to statistically significant for 500 µg/ml 
and 1500 µg/ml (P ≤ 0.001), 500 µg/ml and1000 µg/ml (P ≤ 0.001) as well as 500 µg/ml and 
750 µg/ml (P ≤ 0.05). Liposurf® (Figure 2.18) increased (P ≤ 0.01) ROS production by 49.6 ± 
12.16% at phospholipid concentration of 1000 µg/ml and continued that increase to 69.0 ± 
2.11% at 750 µg/ml phospholipids (P ≤ 0.001). Interestingly, at 500 µg/ml phospholipids, ROS 
significantly decreased by 63.99 ± 10.20% compared to the control (P ≤ 0.001). Synsurf® 
(Figure 2.19) increased (P ≤ 0.05) ROS production by 49.5 ± 14.39% at a phospholipid 
concentration of 1500 µg/ml and 43.8 ± 16.84% at 1000 µg/ml phospholipids (P ≤ 0.05) but 
significantly decreased (P ≤ 0.05) ROS production by 43.51 ± 9.76% at 500 µg/ml 
phospholipids compared to the control.  
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Figure 2.17: The effect of Curosurf® at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to basal A549 
fluorescence at 100%. * P ≤ 0.05, ** P ≤ 0.01 vs Control (LPS alone) (n = 3). 
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Figure 2.18: The effect of Liposurf® at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to basal A549 
fluorescence at 100%. ** P ≤ 0.01, *** P ≤ 0.001 vs Control (LPS alone) (n = 3). 
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Figure 2.19: The effect of Synsurf®; at 500 – 1500 µg/ml phospholipids on un-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to basal A549 
fluorescence at 100%. * P ≤ 0.05 vs Control (LPS alone) (n = 3). 
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Curosurf® (Figure 2.20) and Synsurf® (Figure 2.22) significantly decreased LPS stimulated 
levels of oxidative burst at a phospholipid concentration 1500 µg/ml by 58.52 ± 5.23 % (P ≤ 
0.001) and 48.05 ± 8.81% (P ≤ 0.01) respectively compared to the LPS-stimulated type II 
epithelial cells. The phospholipid concentrations 1000 - 500 µg/ml for both Curosurf® and 
Synsurf® displayed no effect on LPS stimulated ROS production. On the other hand, 
Liposurf® decreased ROS production by 41.69 ± 2.58% (P ≤ 0.05) and 48.63 ± 19.45% (P ≤ 
0.05) respectively at phospholipid concentration of 750 and 500 µg/ml compared to the LPS-
stimulated type II epithelial cells (Figure 2.21). No statistical differences were found among 
the varying concentrations. 
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Figure 2.20: The effect of Curosurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to LPS-stimulated 
A549 fluorescence at 100%. *** P ≤ 0.001 vs Control (LPS alone) (n = 3). 
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Figure 2.21: The effect of Liposurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to LPS-stimulated 
A549 fluorescence at 100%. * P ≤ 0.05 vs Control (LPS alone) (n = 3). 
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Figure 2.22: The effect of Synsurf® at 500 – 1500 µg/ml phospholipids on LPS-stimulated oxidative burst 
measured by mean channel green fluorescence of DCF-DA. Values represent inhibition relative to LPS-stimulated 
A549 fluorescence at 100%. ** P ≤ 0.01 vs Control (LPS alone) (n = 3). 
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Correlations 
 
To determine whether the oxidative damage from intracellular ROS production is correlated 
with cell viability, Pearson’s nonparametric correlation was performed (Table 2.1) for the three 
surfactants at their respective phospholipid concentrations (500 – 1500 µg/ml) following the 
24h time exposure. 
 
Graphs were also plotted to correlate the observed increases in the percentages of cells 
containing high intracellular ROS levels and viable cell percentages. Synsurf® displayed a 
strong negative relationship between intracellular ROS levels and viable cell percentages for 
the NR8383 alveolar macrophages. A moderate positive linear relationship was found for 
Curosurf® in the A549 cell line whereas Synsurf® displayed a strong negative linear 
relationship between intracellular ROS levels and viable cell percentages.  
 
Table 2.1: Table showing Pearson's Correlation Coefficient between percentage ROS production and percentage 
cell viability in all three surfactants in both cell lines (unstimulated) at 24h. r, correlation coefficient; r2, squared 
correlation coefficient; significant correlation established at P ≤ 0.05. 
NR8383 [r] [r2] Description P value 
Curosurf® -0.091 0.008 Weak negative linear relationship 0.909 
Liposurf® 0.068 0.005 Weak Positive linear relationship 0.932 
Synsurf® -0.925 0.856 Strong negative linear relationship 0.075 
A549     
Curosurf® 0.653 0.426 Moderate positive linear relationship 0.347 
Liposurf® -0.102 0.011 Weak negative linear relationship 0.898 
Synsurf® -0.761 0.579 Strong negative linear relationship 0.240 
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Stimulation of Actin Structure Formation and Polymerisation in Alveolar Macrophage 
 
 
Figure 2.23: Stimulation of Actin Structure Formation and Polymerisation in LPS stimulated Rat Alveolar 
Macrophage (A) Control (B) 1 μg/ml LPS Stimulated (C)&(G) Synsurf® 1500 μg/ml, 24H (D) Curosurf® 1500 
μg/ml, 24H (E) Curosurf® 1500 μg/ml, 24H Phase-Contrast (F) Liposurf® 1500 μg/ml, 24H 
 
In a qualitative visual assay in which deviations from the untreated state were screened, animal 
derived surfactants stimulated the formation of actin filled structures in a manner similar to that 
of the LPS stimulated macrophages. In this assay, the large majority of untreated macrophages 
showed only cortical staining for F-actin with little, or no, actin-filled cellular processes such 
as filopodia/lamellopodia (Figure 2.23A). Treatment with 1 μg/ml LPS, alveolar macrophages 
were stimulated to polymerise actin with filopodia emanating from one side of the cell and 
actin-associated membrane ruffling on the other side around a flattened lamellopodia (Figure 
2.23B). On the other hand, Synsurf® treated macrophages (Figure 2.23C) were absent of any 
B 
D F E 
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actin polymerisation and displayed similar cortical staining to that of the untreated 
macrophages. At the same concentration, Curosurf® and Liposurf® treated macrophages 
responded with non-directional formation of many short actin filled filopodia. Liposurf® 
(Figure 2.23F) stimulated some long, actin-filled filopodia compared to that of Curosurf®. 
Furthermore, Curosurf® stimulated these non-directional actin-filled filopodia from the broad 
non-directional lamellopodia surrounding the cell and presents vacuole formation similar to 
that of autophagosomes.  
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2.4 Discussion 
 
Short-term MTTs are metabolic assays that measure the viability of a cell population relative 
to the control, untreated cells, but do not provide direct information about total cell numbers. 
Cells are treated with particulates for a predetermined period of time after which soluble yellow 
tetrazolium salts are added (3-(4, 5-dimethylthiazol-2- yl)-2, 5-diphenyltetrazolium bromide) 
for 2h at 37°C. During this process, viable cells with active respiratory mitochondrial activity 
bio-reduce MTT into an insoluble purple formazan product via mitochondrial succinic 
dehydrogenases. Formazan was subsequently solubilised with a detergent and quantified with 
a visible light spectrophotometer. Data is presented as optical density (OD)/control group 
(Hillegass, Shukla et al. 2010). To determine the in vitro effects of concentration and exposure-
time of surfactant on the viability of cells that exist in the human pulmonary system (A549 and 
NR8383 cells), cell proliferation and cell viability was determined. The MTT assay of A549 
and NR8383 cells revealed that when exposed to certain surfactants at higher phospholipid 
concentrations for 12h and 24h (Figure 2.4 - Figure 2.5 and Figure 2.9 - Figure 2.10), there was 
a decrease in cell growth. Our findings show Synsurf® dose dependently inhibited the NR8383 
and the A549 cell growth compared to the control cells. The morphological changes in the 
NR8383 cells did not indicate clear apoptotic bodies for Synsurf®, however, the Curosurf® 
group did show clear cytoplasmic vesicles (Figure 2.23E) despite having decreased 
intracellular ROS production and comparative cell viability to the control group, thus indicating 
that a ROS-independent pathway may be involved (Ray, Huang et al. 2012). After the 4h time 
exposure, both Synsurf® and Liposurf® resulted in 73.71 ± 9.05% and 78.48 ± 6.20% viability 
in the NR8383 cell line respectively. However, only Synsurf® at the highest phospholipid 
concentration of 1500 μg/ml carried on with the same pattern of cell viability for the 12h (65.79 
± 4.5%) and 24h (64.75 ± 3.59%) time exposure. For the A549 cell line, Synsurf® prevented 
colony formation thus indicating a potential surfactant induced cellular modulation. This 
finding is linked to the observed increased presence of intracellular ROS. ROS are universal 
and pleiotropic signalling molecules implicated in the pathogenesis of disease states (Ray, 
Huang et al. 2012), whilst in physiological states, ROS is normally detected at low levels, 
required for normal cellular function (Stowe, Camara 2009). ROS is also a common role player 
in the pathogeneses of a variety of lung disorders such as asthma, COPD, pulmonary fibrosis 
and cancer (Domej, Oettl et al. 2014). 
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Our results revealed a decrease in cell viability percentage as the dose of Synsurf® increased. 
This may suggest that the compounds (phospholipids and polymers of poly-L-lysine bonded 
electrostatically with poly-L-glutamic acid) may exhibit good interaction with the cellular 
membranes due to their surface activity. These mechanisms could include interference with 
enzyme balance, interference with the osmotic balance due to charge density and cationic 
peptide complex or increase cell membrane permeability (Badawi, Ismail et al. 2015). 
 
Another theory to consider is the cellular uptake of surfactants. Modified surfactant protein 
uptake, processing and metabolism may result in a low level increase of mitochondrial activity 
(5 - 10%) in cells exposed to certain surfactants compared to the control as seen in the MTT 
study. It could also be possible that surfactant components therefore inhibit or block signal 
transduction, resulting in a transient or ‘permanent’ switch-off of mitochondrial activity related 
to surfactant dosage.  
 
It has been observed that apoptotic cell death can occur via a number of pathways in cells via 
the extrinsic and intrinsic pathways (Elmore 2007). The data suggests that DPPC may influence 
cellular death pathways as demonstrated by the induction of oxidative stress. The observation 
that DPPC leads to ROS generation in A549 cells suggests a possible switching from a ROS 
independent pathway as described by Chairuangkitti and colleagues (2013), causing cell cycle 
arrest (autophagy) to a ROS dependent pathway culminating in apoptotic cell death 
(Chairuangkitti, Lawanprasert et al. 2013). It has also been proposed that a two-tiered 
mechanism of NR8383 cell death, cell cycle arrest and ROS mediated mitochondrial dependant 
cell death is involved. Previous studies suggest that autophagy protects cells from caspase-
independent death that occurs after Mitochondrial Outer Membrane Permeabilisation (MOMP) 
in the presence of caspase inhibitors (or in this case, DPPC as a permeabilising agent). 
Interestingly this study showed that as long as cellular respiration can still be generated (in this 
case by increased glycolysis caused by elevated GAPDH), cells can use autophagy to survive 
MOMP and the release of cytochrome c and other apoptogenic proteins and recover to continue 
to grow (Colell, Ricci et al. 2007, Thorburn 2008). Thus, increased levels of autophagy can 
protect cells from apoptosis and this kind of caspase-independent death. One can therefore 
speculate that Synsurf® may function via the mitochondrial/caspase pathway due to the 
decrease in mitochondrial activity in the NR8383. However, Curosurf® may elicit an 
autophagy pathway as the mitochondrial activity is preserved but rather the presence of 
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autophagosomes (and not apoptotic bodies) indicate the degradation of organelles. The 
characterisation of cellular morphology is thus a key to distinguish the associations between 
the types of cell death. Apoptosis is usually due to caspase cleavage of cytoskeletal and other 
structural proteins; however, during autophagic cell death the cytoskeleton remains intact and 
is associated with accumulation of large numbers of autophagic vesicles (degraded organelles). 
It is therefore not surprising that there would be close connections between the regulatory 
mechanisms that control autophagy and apoptosis (Galluzzi, Maiuri et al. 2007, Thorburn 
2008). Unfortunately, autophagy can also lead to cell death if cellular degradation remains 
unchecked. Further mechanistic studies are required to determine conclusively if DPPC and/or 
surfactant protein interactions influence pathway switching. The data further suggests that the 
onset of cytotoxicity, or rather cellular proliferation cessation, correlates with the activation of 
two intracellular stress-signalling pathways.  
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3 CHAPTER 3: Immunoactive properties of Synsurf®, 
Curosurf® and Liposurf® 
3.1 Introduction 
 
Alveolar Macrophages (AMs) are the key modulators and effector cells in the pulmonary 
immune response. Their activation influences and creates a cascade response to other divisions 
of the immune system (Martinez, Gordon 2014). It is essential for AMs to respond efficiently 
to a broad range of insults. This requirement places a high burden of responsibility on these 
cells to recognise and respond appropriately to these triggers as to ensure appropriate pro-
inflammatory and anti-inflammatory responses (Yamashita, Veldhuizen et al. 2013). 
 
More than 90% of cells lining the alveolar region are AMs. Human lungs are estimated to 
contain 2.3 × 1010 AMs at a cell density of 17 × 103 cells/ml in the lower respiratory tract (50 
to 100 AMs per alveolus), which places them in a unique sentry position against inhaled 
environmental antigens. They secrete all the main inflammatory cytokines (IL-1β, TNF-α, IL-
6, IL-8 and IL-12) as well as other mediators and chemokines of the pulmonary inflammatory 
response (IL-2, IFN-γ and GM-CSF) (see Chapter 1 section 4: page 24) (García, Rodriguez et 
al. 1999, Nakata, Gotoh et al. 1999). 
 
More importantly, macrophages can develop mixed M1/M2 phenotypes (see Figure 3.1) in 
pathological conditions. Depending on the microenvironment, macrophages can polarise to M1 
(inflammatory) or M2 (anti-inflammatory) phenotypes (Helmke, German et al. 1989). This 
heterogeneity is reflective of the plasticity and versatility of these cells in response to micro-
environmental signal exposure. This characteristic makes macrophages key role players in 
polarised innate and adaptive responses and they do so by orientating adaptive responses in a 
M1 or M2 direction by expressing specialised and polarised effector functions (Mantovani, 
Sica et al. 2004). M1 and M2 signatures do not necessarily exclude each other and often coexist 
in a continuum. Cytokines, chemokines as well as the microenvironment and other 
immunoregulatory cells, interplay and the resultant mixed phenotype depends on the delicate 
balance of these activatory and inhibitory activities (Helmke, German et al. 1989).  
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Figure 3.1: A proposed M1-M2 macrophage model, in which M1 included interferon-gamma (IFN-γ) + 
lipopolysaccharide (LPS) or tumour necrosis factor alpha (TNFα) and M2 was subdivided to accommodate 
similarities and differences between interleukin-4 (IL-4) (M2a), immune complex + Toll-like receptor (TLR) 
ligands (M2b), and IL-10 and glucocorticoids (M2c) (Adapted from (Mantovani, Sica et al. 2004)). 
 
Classically M1 macrophages (see Figure 3.2) produce inducible nitric oxide synthase (iNOS) 
or nitric oxide (NO) as well as reactive oxygen intermediates (ROI) (e.g. ROS) due to arginine 
metabolism. The alternatively activated M2 macrophages (see Figure 3.3), which are divided 
further into groups – M2a, M2b and M2c macrophages, are arginase pathway dominant (except 
M2b) and produce abundant levels of non-opsonic receptors (e.g. the mannose receptor) 
(Mantovani, Sica et al. 2004).  
 
Furthermore, differential cytokine production is a key feature of M1/M2 macrophages. Since 
M1/M2 macrophages are found in a continuum state; the M1 phenotype is typically portrayed 
as exhibiting a IL-12high and IL-10low ratio, whereas M2 macrophages are typically IL-10high 
and IL-12low ratio. M2 macrophages are generally characterised by low production of pro-
inflammatory cytokines (IL-1β, TNFα and IL-6). However, LPS stimulated M2b macrophages 
are an exception, in that they retain high levels of inflammatory cytokine production with 
associated high levels of IL-10 and low IL-12 (Mosser 2003). In mice, it was seen that in spite 
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of their high production of inflammatory cytokines, the M2b macrophages protect mice against 
LPS toxicity (Mosser 1999). 
 
 
Figure 3.2: The chemokine repertoires of polarised M1 macrophages. M1 polarisation is accompanied by 
production of inflammatory CC chemokines and IFN-γ-responsive chemokines that recruit Th1, Tc1 and NK cells, 
and coordinate a type I immune response particularly suited for intracellular pathogen killing. Abbreviations: 
IFN-γ, interferon-γ; iNOS, inducible nitric oxide synthase; NK, natural killer cells; ROI, reactive oxygen 
intermediates; Th1, Type 1 T helper cells (adapted from (Mantovani, Sica et al. 2004)). 
 
 
o Intracellular pathogens 
o Tumour resistance 
o Pro-inflammatory  
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Figure 3.3: The chemokine repertoires of polarised M2 macrophages. IL-4 and IL-13 exposure sustains M2a 
polarisation, which is accompanied by production of chemokine agonists at CCR3, CCR4 and CCR8, consequent 
recruitment of eosinophils, basophils and Th2 cells, and organization of a type II immune response. M2b 
polarisation is critically dependent on exposure to immune complexes and TLR or IL-1R agonists, and it is 
characterised by selective production of CCL1, with consequent recruitment of Tregs and immunoregulation. 
Exposure to IL-10 drives M2c polarisation, which is characterised by CCL16 and CCL18 production and 
consequent recruitment of eosinophils and naïve T cells, respectively. Induction of CXCL13 requires co-
stimulation by IL-10 and LPS. Abbreviations: Ba, basophils; Eo, eosinophils; IC, immune complexes; IL-1β, 
interleukin-1beta; IL-4, interleukin-4; MR, mannose receptor; Treg, regulatory T cells (adapted from (Mantovani, 
Sica et al. 2004)). 
 
 
 
 
o Tissue repair 
o Immunoregulation 
o Allergy 
o Tumour Promotion 
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IL-10 (see Figure 3.4) has been described as a key role player and promoter of macrophage 
polarization within the M2 populations; however, it is not only limited to inhibiting 
proinflammatory cytokines. It has been noted that IL-10, in the presence of LPS or alone, can 
activate four distinctive transcriptional pathways and is thus, more than a mere deactivator. 
These are specific to (i) control and deactivate inflammation which includes suppressing 
inflammatory cytokine release and other activator molecules, (ii) the regulation of 
cytokine/receptor signalling involving the suppressor of cytokine signalling 3 (SOCS3) and 
PI3-K isoforms, (iii) remodelling the extracellular matrix, (iv) lymphoid tissue neogenesis and 
B-cell function. Therefore, IL-10-stimulated M2b macrophages are responsible for the 
regulation of inflammation and immunity (Mantovani, Sica et al. 2004). 
 
 
Figure 3.4: IL-10 signalling promotes the rapid phosphorylation of JAK1 in an AMPK-dependent manner. The 
influence of AMPK on JAK1 phosphorylation is indirect (dotted line). Activation of JAK1 then leads to the 
phosphorylation and activation of STAT3 (Tyr705), which positively regulates STAT3 (Ser727) phosphorylation. 
This is critical for SOCS3 production. In addition, AMPK also promotes the activation of PI3K simultaneously 
by enhancing the phosphorylation of the p55 subunit (indirectly, as indicated by the dotted line). Consequently 
leading to an increase in mTORC1 activity. MTORC1 activation leads to an increase in phosphorylation of STAT3 
(Ser727), which further enhances STAT3 transcriptional activity. It is proposed that STAT3-regulated genes 
possibly include SOCS3, which in turn suppress TLR-activated inflammatory cytokine production (adapted from 
(Zhu, Brown et al. 2015). Abbreviations: JAK/STAT, Janus Kinase/Signal Transducer and Activator of 
Transcription; SOCS3, Suppressor of cytokine signalling 3. 
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When considering the surfactant-associated proteins’ interactions with macrophages, the 
mystery becomes speculative regarding how the specific proteins interact with certain surface 
receptors. The ability of surfactant proteins to interact and modify the downstream cascade 
action of these proteins may influence alveolar macrophage polarisation. As discussed in 
Chapter 1, SP-A and SP-D are potent modulators of macrophage function and may also 
suppress clearance of apoptotic cells through activation of the transmembrane receptor signal 
inhibitory regulatory protein α (SIRPα) (Janssen, McPhillips et al. 2008).  
 
Nguyen and colleagues reported that short-term (10 min – 2 h) exposure of SP-A to human 
macrophages decreases TLR-mediated TNF-α production by inhibiting the activity of 
signalling kinases (Akt and MAPKs) required for NF-κB transcriptional activation (Figure 3.5). 
These studies model the initial exposure of macrophages to SP-A and do not account for the 
fact that AMs are constantly exposed to surfactant in the alveolus (Nguyen, Rajaram et al. 
2012). This constant exposure results in the constant ligand binding of these surfactant proteins 
to different receptors on the alveolar macrophage cell surface. Studies have reported that the 
SP-A and SP-D may act in a dual manner, to enhance or suppress the inflammatory cascade 
depending on their binding domains on different receptors (Gardai, Xiao et al. 2003).  
 
It has been suggested that the globular heads of SP-A may bind to CD14 and TLR2 (and TLR4) 
thus suppressing stimulation by LPS (Chiba, Sano et al. 2001, Murakami, Iwaki et al. 2002). 
The conflicting reports of surfactant proteins’ inflammatory mediator induction (Ofek, Mesika 
et al. 2001) or suppression (Arias-Diaz, Garcia-Verdugo et al. 2000) has become a paradox that 
is supported by the hypothesis that the orientation of the SP-A and SP-D on their respective 
receptors determine whether they induce or suppress inflammation; but this is yet to be proven.  
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Figure 3.5: Pulmonary surfactant-associated protein A (SP-A) and SP-D are able to block toll-like receptors TLR2 
and TLR4 interactions with their respective ligands, as well as their interactions with the TLRs which prevents 
the activation of nuclear factor-κB (NF-κB) and the initiation of the inflammatory response. Binding of surfactant 
proteins to signal-regulatory protein-α (SIRPα) recruits SH2 domain-containing protein tyrosine phosphatase 1 
(SHP1) and activates Ras homolog gene family, member A (RHOA), which inhibits phagocytosis (adapted from 
(Hussell, Bell 2014). 
 
Both Chiba et al. (2001) and Murakami et al. (2002) support the model in which both the 
surfactant proteins A and D bind to signal inhibitory regulatory protein α (SIRPα) activating 
the downstream blockade of the pro-inflammatory cascade. When taking all of the evidence 
into consideration, it suggests that SP-A and SP-D help maintain the non- or anti-inflammatory 
pulmonary environment due to their globular head stimulating the ITIM (immune-receptor 
tyrosine-based inhibitory motif) -containing SIRPα. In contrast, however, these same domains 
also interact with PAMPs on the surface of foreign organisms, apoptotic cells and cell debris, 
which then allows for the presentation of their collagenous tails to the CD91 domains on the 
AMs. Thus initiating the rearrangement of the AMs’ cytoskeleton, ingestion, and the pro-
inflammatory cascade (Gardai, Xiao et al. 2003).  
 
This is thus indicative that surfactant associated proteins have unexpected, yet pivotal roles in 
the regulation of immunomodulatory processes.  
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3.1 Materials and Methods 
3.1.1 NR8383 Cell Culture 
The NR8383 AMs were first cultured in 75 cm2 flasks and maintained in a humidified, 5% 
CO2–95% atmospheric air incubator at 37°C. The media, comprised of RPMI 1640 (Roswell 
Park Memorial Institute media)supplemented with 10% fetal calf serum, 1% L-glutamine 
solution (200 mM), and 1% Penicillin-Streptomycin (PENSTREP), and was routinely changed 
twice weekly. Cells were seeded to 12-well tissue culture plates at a density of 2.5 × 105 
cells/well. Cell viability before and after each experiment was assessed by trypan blue 
exclusion. The viability was consistently greater than 95% in all detected samples before 
seeding as well as after treatment (see Chapter 2: Viability Study page 88). Routine 
mycoplasma testing was performed to guarantee no contamination risk (see Appendix D).  
 
Inflammatory Cytokines 
To evaluate the anti-inflammatory effects of exogenous surfactants, Curosurf®, Liposurf® and 
Synsurf® were standardised to equivalent phospholipid concentrations, 100 - 1500 μg/ml and 
incubated with LPS - (1 μg/ml) stimulated and un-stimulated NR8383 AMs over 24 hours. 
 
The changes in cytokines were analysed by using a multiplex (V-PLEX) rat cytokines’s 
electrochemiluminescence-based ELISA kit (Meso Scale Discovery®) as per manufacturer’s 
instructions (*duplicate assay). The values were first calculated for picogram cytokine per 
milliliter (pg/ml) of sample, and then converted into microgram (μg/ml) where applicable. 
 
Inflammatory Cytokines 
One-way analysis of variance (ANOVA) with Tukey's post-test was performed for the 
comparison of multiple treatments and differences were considered significant when P ≤ 0.05. 
The statistical program GraphPad Prism v.5 was used. 
 
List of Cytokines: IL-1β, TNF-α, IL-6, IL-10, KC-GRO 
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3.1.2 Detection of protein expression by proteomics 
 
Digests 
In-solution Digest 
All reagents were analytical grade or equivalent. Samples were reduced by adding 50 mM 
triscarboxyethyl phosphine (TCEP; Fluka) in 100 mM Triethylammonium bicarbonate 
(TEAB) (final concentration 5 mM TCEP) for 30 minutes at room temperature. Following 
reduction, cystein residues were modified to methylthio forms using 200 mM methane 
methylthiosulphonate (MMTS; Sigma) in 100 mM TEAB (final concentration 20 mM) for 30 
minutes. After modification, the samples were diluted to 98 µL with 100 mM TEAB. Proteins 
were digested by adding 5 µL trypsin (Promega) solution (1 µg/µL) and incubating for 18 hours 
at 37 °C. The samples were dried down and resuspended in 100 µL 2% acetonitrile 
(Fluka):water; 0.1% formic acid (FA; Sigma). 
 
Desalting 
Residual digest reagents were removed using an in-house manufactured C18 stage tip (Empore 
Octadecyl C18 extraction discs; Supelco). The 20 µL sample was loaded onto the stage tip after 
activating the C18 membrane with 30 µL methanol (Sigma) and equilibration with 30 µL 2% 
acetonitrile:water; 0.05% FA. The bound sample was washed with 30 µL 2% 
acetonitrile:water; 0.1% FA before elution with 30 µL 50% acetonitrile:water 0.1% FA. The 
eluate was evaporated to dryness. The dried peptides were dissolved in 20 µL 2% acetonitrile: 
water; 0.1% FA for LC-MS analysis 
 
Liquid chromatography 
Dionex nano-RSLC 
Liquid chromatography was performed on a Thermo Scientific Ultimate 3000 RSLC 
instrument equipped with a 0.5cm x 300µm C18 trap column and a 40 cm x 75 µm in-house 
manufactured C18 column (Luna C18, 3.6 µm; Phenomenex) analytical column. The loading 
solvent system employed was: 2% acetonitrile: water: 0.1% FA; Solvent A: 2% 
acetonitrile:water: 0.1% FA and Solvent B: 100% acetonitrile:0.1% FA. Samples were loaded 
onto the trap column using loading solvent at a flow rate of 15 µL/min from a temperature 
controlled autosampler set at 7 ºC. Loading was performed for 5 min before the sample was 
eluted onto the analytical column. Flow rate was set to 500 nL/minute and the gradient 
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generated as follows: 2.0% - 10% B over 5 min; 5% -25% B from 5 - 50 minutes using 
Chromeleon non-linear gradient 6, 25% - 45% from 50-65 minutes, using Chromeleon non-
linear gradient 6. Chromatography was performed at 50°C and the outflow delivered to the 
mass spectrometer through a stainless steel nano-bore emitter. 
 
Mass spectrometry 
Mass spectrometry was performed using a Thermo Scientific Fusion mass spectrometer 
equipped with a Nanospray Flex ionisation source. The sample was introduced through a 
stainless steel emitter. Data was collected in positive mode with spray voltage set to 2kV and 
ion transfer capillary set to 275 °C. Spectra were internally calibrated using polysiloxane ions 
at m/z = 445.12003 and 371.10024. MS1 scans were performed using the orbitrap detector set 
at 120 000 resolution over the scan range 350 - 1650 with automatic gain control (AGC) target 
at 3 E5 and maximum injection time of 40 ms. Data was acquired in profile mode. MS2 
acquisitions were performed using monoisotopic precursor selection for ions with charges +2 
-+6 with error tolerance set to +/- 10 ppm. Precursor ions were excluded from fragmentation 
once for a period of 30s. Precursor ions were selected for fragmentation in higher-energy 
collisional dissociation (HCD) mode using the quadrupole mass analyser with HCD energy set 
to 32.5%. Fragment ions were detected in the orbitrap mass analyser set to 15 000 resolutions. 
The AGC target was set to 1E4 and the maximum injection time to 45 ms. The data was 
acquired in centroid mode. 
 
Data Analysis 
The raw files generated by the mass spectrometer were imported into Proteome Discoverer 
v1.4 (Thermo Scientific) and processed using the SequestHT algorithm included in Proteome 
Discoverer. Data analysis was structured to allow for methylthio as fixed modification as well 
as asparagine/glutamine (NQ) deamidation,methionine (M) oxidation. Precursor tolerance was 
set to 10 ppm and fragment ion tolerance to 0.02Da. The databased used was the rat database 
obtained from Uniprot. The results files were imported into Scaffold 1.4.4 and identified 
peptides validated using the X!Tandem search algorithm included in Scaffold. Peptide and 
Protein validation were done using the Peptide and Protein Prophet algorithms. Protein 
quantitation were done performing a t-test on the paired data with the Benjamini-Hochberg 
correction was applied. 
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Functional Enrichment Analysis 
The STRING (Search Tool for the Retrieval of Interacting Genes) database v10.5 used 
(http://string-db.org) aims to provide a critical assessment and integration of protein–protein 
interactions, including direct (physical) as well as indirect (functional) associations.  
 
Proteins that were uniquely identified in one particular treatment group were subjected to 
enrichment analysis using the String database (string-db.org, accessed [27 September 2017]) 
with the Rattus norvegicus whole proteome as the background dataset. Enrichment for GO 
terms and protein domains was carried out for each set of unique proteins. 
 
In the Enrichment widget, STRING displays every functional pathway/term that can be 
associated to at least one protein in the network that allows for network visualization and 
statistical analysis of a user-supplied protein list. The terms were sorted by their enrichment P-
value. The P-values were corrected for multiple testing using the method of Benjamini and 
Hochberg. 
 
3.1.3 Human Bronchoalveolar lavage samples 
The bronchoalveolar sampling (BALS) for this study was performed by Prof. Pierre Goussard 
(Head of Clinical Unit: Paediatric Pulmonology, Department of Paediatrics and Child Health, 
Stellenbosch University and Tygerberg Children’s Hospital. Ethics Number: N13/07/099) and 
collected from children deemed not to have infectious conditions (i.e. Tuberculosis or HIV). 
The collected samples where from children with structural problems that underwent routine 
bronchoalveolar sample collection for other investigatory purposes.  
 
After informed consent, BALS collection was performed after topical anesthesia with 4010 
lidocaine spray. A flexible fiber optic bronchoscope was introduced through the upper airway 
and wedged in a segment of the right middle lobe. One 4 - 8 ml of BAL aliquot per patient was 
aspirated with gentle hand suction and collected for this study.  
 
3.1.4 Isolation and Cultivation of Alveolar Macrophages 
Isolated or cultured AMs from bronchoalveolar lavage may have a certain percentage of 
contaminant cell types; thus, mononuclear cells were isolated by Histopaque-1077 (Sigma, St. 
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Louis, MO) density gradient centrifugation of whole BALS. After isolation, AMs were allowed 
to adhere thus separating possible Lymphocytes from the population.  
 
Inflammatory Cytokines 
To evaluate the anti-inflammatory effects of exogenous surfactants, Curosurf®, Liposurf® and 
Synsurf® were standardised to equivalent phospholipid concentrations, 500 - 1500 μg/ml and 
incubated with LPS- (1 μg/ml) stimulated and un-stimulated human AMs over 24 hours. The 
changes in cytokines were analysed as previously described by using a multiplex (V-PLEX) 
human cytokines’s electrochemiluminescence-based ELISA kit (Meso Scale Discovery®) as 
per manufacturer’s instructions. The values were first calculated for picogram cytokine per 
milliliter (pg/ml) of sample, and then converted into microgram (μg/ml) where applicable. 
 
List of Cytokines: IL-1β, IL-2, TNF-α, IL-6, IL-8, INF-γ, GM-CSF, IL-10, IL-12 
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3.2 Results 
3.2.1 Effect of Surfactant on LPS stimulated and non-stimulated NR8383 Alveolar 
Macrophage Cytokine Secretion 
 
The basal levels of TNF-α from the culture supernatant in the non-stimulated NR8383 AMs 
supernatant concentrations measured at 24 h in the presence of surfactants are seen in Table 
3.1. TNF-α secretion increased in the presence of the three independent surfactants, however, 
significant increases compared to the control (basal levels) were only found for Liposurf® at 
phospholipid concentrations of 100 & 500 µg/ml respectively. Curosurf® displayed a 
concentration dependent decrease in cytokine production whereas Synsurf® displayed a 
threshold effect (concentrations not exceeding 0.938 ± 0.2120 pg/ml). Liposurf® displayed a 
statistically significant increase (P < 0.05) in TNF-α production at concentrations of 100 & 500 
µg/ml phospholipids, compared to the control (Figure 3.6). It was found that Curosurf® 
significantly decreased (P < 0.05) TNF-α release compared to Liposurf® at phospholipid 
concentrations of 1500 µg/ml. Synsurf® also displayed a significant increase (P < 0.05) in 
TNF-α release compared to Curosurf® at phospholipid concentrations of 750 µg/ml; however, 
no other differences were seen among the surfactants. Basal levels of IL-1β were found to be 
below detection. Basal IL-6 pro-inflammatory cytokine levels were only evident in the lower 
concentration groups for Curosurf® and Synsurf®. 
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Table 3.1: The mean ± SEM of non-stimulated NR8383 AMs produced TNF-α and IL-6. Supernatant 
concentrations measured at 24h in the presence or absence of surfactants (100 - 1500 µg/ml total phospholipids) 
(one-way analysis of variance (ANOVA), Tukey's post-test * P < 0.05). 
  
Control 
Concentration of 
DPPC (μg/ml) 
Curosurf® Synsurf® Liposurf® 
 TNF- α (pg/ml) 
Below detection 
 pg/ml 
100 0.443 ± 0.269 0.690 ±0.176 0.912 ± 0.148* 
250 0.042 ± 0.250 0.737 ±0.051 0.569 ± 0.056 
500 0.051 ± 0.228 0.738 ±0.066 0.923 ± 0.127* 
750 Below detection 0.938 ± 0.212 0.553 ± 0.015 
1000 0.014 ± 0.154 0.914 ± 0.297 0.473 ± 0.309 
1500 0.013 ± 0.001 0.547 ± 0.258 0.791 ± 0.174 
 IL-6 (pg/ml) 
Below detection 
pg/ml 
100 0.554 ± 0.506 0.416 ± 0.367 Below detection 
250 0.699 ± 0.651 Below detection Below detection 
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Figure 3.6: Effects of surfactants on non-stimulated TNF-α production. TNF-α in cell supernatant by NR8383 
AMs in the presence of A) Curosurf®; B) Liposurf®, & C) Synsurf® at 100 – 1500 µg/ml phospholipids. (One-
way analysis of variance (ANOVA), Tukey's post-test B) * P < 0.05, # P < 0.05). 
A 
B 
C 
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Table 3.2 displays the LPS (1 µg/ml)-stimulated TNF-α (Figure 3.7) and IL-1β (Figure 3.8) 
supernatant concentrations measured at 24 h in the presence of surfactants (100 - 1500 µg/ml 
total phospholipids). Basal supernatant concentrations for TNF-α and IL-1β from LPS-
stimulated NR8383 AMs were 3.038 ± 0.0275 ng/ml and 1.317 ± 0.028 µg/ml, respectively. 
Surfactant-treated cells secreted significantly less (*P < 0.0001) TNF-α and IL-1β at 24 h 
versus the LPS stimulated un-treated cells at phospholipid concentration of 250 - 1500 µg/ml. 
The exception was found for TNF-α in the lower phospholipid concentrations (100 and 250 
µg/ml), where Curosurf® and Liposurf® displayed no statistical significant difference in 
cytokine production compared to the control. However, Synsurf® at a phospholipid 
concentration of 100µg/ml significantly increased (#P < 0.0001) TNF-α secretion (Figure 
3.7C) to 4.224 ± 0.040 ng/ml and Curosurf® at a phospholipid concentration of 100µg/ml 
significantly increased (#P < 0.0001) IL-1β secretion (Figure 3.8C) to 1.95 ± 0.062 ng/ml.  
 
When considering inter-surfactant differences, Curosurf® decreased TNF-α release 
significantly (P < 0.001) more than Liposurf® at phospholipid concentrations 250 - 1000 µg/ml 
as well as compared to Synsurf® at phospholipid concentration of 100 ug/ml (P < 0.001). No 
differences were seen for Curosurf® vs Synsurf® at phospholipid concentration of 250 µg/ml; 
however, Synsurf® decreased TNF-α release significantly (P < 0.001) more than Curosurf® at 
phospholipid concentrations 500 - 750 µg/ml and at 1000 - 1500 µg/ml (P < 0.01) as well as 
compared to Liposurf® at phospholipid concentrations 250 - 1500 µg/ml (P < 0.001). 
 
Liposurf® IL-1β secretion was significantly less (P < 0.001) than Curosurf® for phospholipid 
concentrations 100, 250, 750, 1000, and 1500 µg/ml but to a lesser extent for 500 µg/ml. 
Synsurf® IL-1β secretion was also found to be significantly less (P < 0.001) than Curosurf® 
and Liposurf® for all phospholipid concentrations (Table 3.2).  
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Table 3.2: The mean ± SEM of LPS (1 µg/ml)-stimulated NR8383 AMs production of TNF-α and IL-1β. 
Supernatant concentrations measured at 24h in the presence or absence of surfactants (100 - 1500 µg/ml total 
phospholipids) (one-way analysis of variance (ANOVA), Tukey's post-test * P < 0.05, *** P < 0.001, **** P < 
0.0001). 
  
LPS Control 
Concentration of 
DPPC (μg/ml) 
LPS + Curosurf® LPS + Synsurf® LPS + Liposurf® 
 TNF- α (ng/ml) 
3.038 ± 0.0275 
ng/ml 
100 2.991 ± 0.159 4.224 ± 0.040 3.182 ± 0.079 
250 1.839 ± 0.162*** 1.576 ± 0.110**** 2.867 ± 0.078 
500 1.08 ± 0.009**** 0.104 ± 0.006**** 1.839 ± 0.084**** 
750 0.704 ± 0.025**** 0.043 ± 0.002**** 1.778 ± 0.018**** 
1000 0.489 ± 0.025**** 0.024 ± 0.002**** 1.713 ± 0.0885**** 
1500 0.406 ± 0.031**** 0.019 ± 0.001**** 1.887 ± 0.036**** 
     
 IL-1β (ng/ml) 
1.317 ± 0.028 
ng/ml 
100 1.949 ± 0.062**** 0.982 ± 0.005**** 1.325 ± 0.02 
250 0.778 ± 0.029**** 0.469 ± 0.012**** 1.215 ± 0.005* 
500 0.406 ± 0.004**** 0.102 ± 0.001**** 0.498 ± 0.004**** 
750 0.371 ± 0.003**** 0.048 ± 0.0004**** 0.529 ± 0.010**** 
1000 0.298 ± 0.010**** Below detection**** 0.446 ± 0.010**** 
1500 0.387 ± 0.007**** Below detection**** 0.597 ± 0.003**** 
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Figure 3.7: Effects of surfactants on LPS-stimulated TNF-α production (ng/ml). TNF-α in cell supernatant by 
LPS-stimulated NR8383 AMs in the presence of A) Curosurf®; B) Liposurf®, & C) Synsurf® at 100 – 1500 
µg/ml phospholipids. (One-way analysis of variance (ANOVA), Tukey's post-test A) * P < 0.0001 B) * P < 0.0001, 
C) * P < 0.0001, #P < 0.0001 . 
A 
B 
C 
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Figure 3.8: Effects of surfactants on LPS-stimulated IL-1β production (ng/ml). IL-1β in cell supernatant by LPS-
stimulated NR8383 AMs in the presence of A) Curosurf®; B) Liposurf®, & C) Synsurf® at 100 – 1500 µg/ml 
phospholipids. (One-way analysis of variance (ANOVA), Tukey's post-test A) * P < 0.0001, #P < 0.0001 B) * P < 
0.05, #P < 0.0001 C) * P < 0.0001. 
A 
B 
C 
Stellenbosch University  https://scholar.sun.ac.za
133 
 
Table 3.3 and Figure 3.9 display the LPS (1 µg/ml)-stimulated NR8383 AM IL-6 supernatant 
concentrations measured at 24 h in the presence of surfactants (100 - 1500 µg/ml total 
phospholipids). Basal supernatant concentrations for IL-6 from LPS-stimulated NR8383 AMs 
was 4.519 ± 0.218 ng/ml. Surfactant-treated cells secreted significantly less IL-6 versus the 
LPS stimulated un-treated cells (* P < 0.0001). In Figure 3.9, Both Liposurf® (B) Synsurf® 
(C) and displayed a threshold inhibition for stimulated IL-6 production at phospholipid 
concentration of 500 µg/ml (#, Figure 3.9B & C). Whereas Curosurf® (A) displayed a similar 
threshold inhibition for LPS-induced IL-6 secretion but a minimal significant difference was 
seen between 500 - 750µg/ml and 1000 – 1500 µg/ml (# P < 0.05, Figure 3.9A).  
 
When considering inter-surfactant differences (Table 3.3), Curosurf® as well as Synsurf® 
were able to inhibit LPS-induced IL-6 secretion significantly better than that of Liposurf® at 
phospholipid concentrations 100 - 1500 µg/ml (P < 0.001). Synsurf® exposed AMs IL-6 
secretion was significantly less (P < 0.001) than that of Curosurf® at 100 – 750 µg/ml 
phospholipids and only minimally significant at 1000 µg/ml (P < 0.05). No significant 
difference was seen in IL-6 secretion for Synsurf® and Curosurf® at 1500 µg/ml 
phospholipids.  
 
Table 3.3: The mean ± SEM of LPS (1 µg/ml)-stimulated NR8383 AMs production of IL-6. Supernatant 
concentrations measured at 24h in the presence or absence of surfactants (100 - 1500 µg/ml total phospholipids) 
(one-way analysis of variance (ANOVA), Tukey's post-test *** P < 0.001, **** P < 0.0001). 
 
 
LPS Control 
Concentration of 
DPPC (μg/ml) 
LPS + Curosurf® LPS + Synsurf® LPS + Liposurf® 
 IL-6 (ng/ml) 
4.519 ± 0.218 
ng/ml 
100 2.859 ± 0.05**** 2.199 ± 0.019**** 3.358 ± 0.122*** 
250 0.907 ± 0.048**** 0.241 ± 0.0005**** 2.009 ± 0.085**** 
500 0.413 ± 0.006**** 0.004 ± 0.0006**** 0.896 ± 0.014**** 
750 0.331 ± 0.016**** 0.001 ± 0.0003**** 0.744 ± 0.006**** 
1000 0.177 ± 0.002**** 0.001 ± 0.001**** 0.646 ± 0.011**** 
1500 0.150 ± 0.002**** Below detection**** 0.609 ± 0.003**** 
Stellenbosch University  https://scholar.sun.ac.za
134 
 
Control 100 250 500 750 1000 1500
0
2
4
6
IL-6 Curosurf + LPS 1ug/ml
*
#
Concentration of DPPC g/ml
C
o
n
c
e
n
tr
a
ti
o
n
 n
g
/m
l
 
Control 100 250 500 750 1000 1500
0
2
4
6
IL-6 Liposurf + LPS 1ug/ml
*
#
Concentration of DPPC g/ml
C
o
n
c
e
n
tr
a
ti
o
n
 n
g
/m
l
 
Control 100 250 500 750 1000 1500
0
2
4
6
IL-6 Synsurf + LPS 1ug/ml
*
#
Concentration of DPPC g/ml
C
o
n
c
e
n
tr
a
ti
o
n
 n
g
/m
l
 
Figure 3.9: Effects of surfactants on LPS-stimulated IL-6 production (ng/ml). IL-6 in cell supernatant by LPS-
stimulated NR8383 AM in the presence of A) Curosurf®; B) Liposurf®; & C) Synsurf® at 100 – 1500 µg/ml 
phospholipids. (One-way analysis of variance (ANOVA), Tukey's post-test A) * P < 0.0001, #P < 0.05 B) *P < 
0.05, #Threshold C) * P < 0.0001, #Threshold. 
A 
B 
C 
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Table 3.4 and Figure 3.10 displays the LPS (1 µg/ml)-stimulated KC/GRO (neutrophil chemo-
attractant) supernatant concentrations were measured at 24 h in the presence of surfactants (100 
- 1500 µg/ml total phospholipids) as seen in Table 3.4. Basal supernatant concentrations for 
KC/GRO from LPS-stimulated NR8383 AMs was 0.6225± 0.014 ng/ml. Surfactant-treated 
cells secreted significantly less KC/GRO versus the LPS stimulated un-treated cells (* P < 
0.0001). Both Liposurf® (Figure 3.10B) and Synsurf® (Figure 3.10C) displayed a threshold 
inhibition for stimulated KC/GRO production at phospholipid concentration of 500 µg/ml (# P 
< 0.0001). Whereas Curosurf® (Figure 3.10A) displayed a similar threshold inhibition for 
stimulated KC/GRO production at a higher phospholipid concentration of 250 µg/ml (# P < 
0.0001).  
 
When considering inter-surfactant differences (Table 3.4), Synsurf® displayed significantly 
less stimulated KC/GRO secretion compared to both Curosurf® and Liposurf® at phospholipid 
concentrations 100 - 1500 µg/ml (P < 0.001). Curosurf® and Liposurf® displayed no 
differences in KC/GRO secretion at phospholipid concentrations 100 - 250 µg/ml as well as 
1000 – 1500 µg/ml. However, Liposurf® stimulated less KC/GRO secretion than Curosurf® 
at phospholipid concentrations 500 (P < 0.001) and 750 µg/ml (P < 0.01).  
 
Table 3.4: The mean ± SEM of LPS (1 µg/ml)-stimulated NR8383 AMs KC/GRO. Supernatant concentrations 
measured at 24h in the presence or absence of surfactants (100 - 1500 µg/ml total phospholipids) (one-way 
analysis of variance (ANOVA), Tukey's post-test *** P < 0.001, **** P < 0.0001). 
LPS Control 
Concentration of 
DPPC (μg/ml) 
LPS + Curosurf® LPS + Synsurf® LPS + Liposurf® 
 KC/GRO (ng/ml) 
0.623 ± 
0.014ng/ml 
100 0.407± 0.012*** 0.210± 0.001**** 0.416 ± 0.010**** 
250 0.246± 0.024**** 0.105± 0.004**** 0.272 ± 0.004**** 
500 0.241± 0.002**** 0.014± 0.001**** 0.172 ± 0.001**** 
750 0.220± 0.017**** 0.004± 0.0003**** 0.172 ± 0.002**** 
1000 0.200± 0.014**** 0.005± 0.00003**** 0.166 ± 0.001**** 
1500 0.180± 0.004**** Below detection**** 0.157 ± 0.010**** 
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Figure 3.10: Effects of surfactants on LPS-stimulated KC/GRO production (ng/ml) in LPS-stimulated NR8383 
AM cell supernatant in the presence of A) Curosurf®; B) Liposurf®, & C) Synsurf® at 100 – 1500 µg/ml 
phospholipids. (One-way analysis of variance (ANOVA), Tukey's post-test A) * P < 0.0001, #Threshold, B) *P < 
0.0001, #Threshold, C) * P < 0.0001, #Threshold. 
C 
A 
B 
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The anti-inflammatory cytokine IL-10 was also measured in the LPS (1 µg/ml)-stimulated AMs 
supernatant. Concentrations were measured at 24 h in the presence of the three surfactants (100 
- 1500 µg/ml total phospholipids). Only the Liposurf® treated AMs showed detectable signals 
of IL-10 production at the lower phospholipid concentration of 100 – 500 µg/ml (Figure 3.11) 
and these were found to be statistically significant (P < 0.05) compared to the LPS stimulated 
un-treated AMs (control) although no differences were found among the concentration groups.  
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Figure 3.11: Effects of Liposurf® on LPS-stimulated NR8383 AMs production of IL-10 at 100 – 500 µg/ml 
phospholipids. ). (One-way analysis of variance (ANOVA), Tukey's post-test * P < 0.05). 
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3.2.2 Proteomics 
 
The total protein repertoire with the unique and overlapping protein expression observed in the 
AMs exposed to Curosurf®, Liposurf®, and Synsurf® is shown in Figure 3.12. Table 3.5 and 
Figure 3.13 display the total protein repertoire with the statistically significant, overlapping up- 
and down-regulated expression observed in the AMs. Curosurf® displayed 32 unique protein 
expressions (Table 3.6), whereas Liposurf® (Table 3.8) and Synsurf® (Table 3.9) displayed 
25 and 21 respectively. 
 
 
 
Figure 3.12: The total protein repertoire and the unique and overlapping protein expression observed in AMs 
exposed to C, Curosurf®, L, Liposurf®, and S, Synsurf® ( synthetic surfactant highlighted). 
It is noted that these proteins are not all associated with immunomodulatory functions. 
However, it is imperative to grasp that surfactant exposure to AMs may have more profound 
effects on other molecular regulatory processes than was initially assumed. Furthermore, it is 
vital that one takes into consideration the dynamic complexity of protein regulatory processes 
of which an investigatory attempt such as this only captures a static time frame. 
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Table 3.5: The number of up- and down-regulated proteins that are differentially expressed for CTR (Control), C (Curosurf®), L (Liposurf®) and S (Synsurf®) based on 
proteomic quantification (n=3). Down-regulated expression           , Up-regulated expression , levels unquantified          . 
Bio View: Identified Proteins Accession Number 
ANOVA Test (P-
Value) (p <= 0.05) 
Quantitative Profile 
Heme oxygenase 1 HMOX1_RAT 0.0002 CTR high C high L high S low 
Heterogeneous nuclear ribonucleoprotein HNRPD_RAT 0.03 CTR high C high L high S low 
Eukaryotic translation initiation factor 6 IF6_RAT 0.042 CTR high C high L high S low 
MHC class Ib antigen O19445_RAT 0.019 CTR high C high L high S low 
Voltage-dependent anion-selective channel protein 3 VDAC3_RAT 0.007 CTR high C high L high S low 
ATP5H_RAT ATP synthase subunit d, mitochondrial ATP5H_RAT 0.022 CTR high C high L high S low 
Glyceraldehyde-3-phosphate dehydrogenase G3P_RAT 0.033 CTR low C high L high S high 
Cystatin-B CYTB_RAT 0.005 CTR low C high L high S high 
MAP4_RAT Isoform 2 of Microtubule-associated 
protein 4 
Q5M7W5-2 0.014 CTR low C high L high S high 
Calcineurin B homologous protein 1 CHP1_RAT 0.021 CTR low C high L high S high 
Pcbp2 protein Q6AYU2_RAT 0.026 CTR high C low L high S high 
Embigin EMB_RAT 0.038 CTR high C low L high S high 
Arginase-1 ARGI1_RAT 0.002 CTR high C high L low S low 
RNA-binding motif protein, X chromosome 
retrogene-like 
RMXRL_RAT 0.040 CTR high C high L low S low 
Cnpy3 protein B2RYF8_RAT 0.037 CTR high C high L low S low 
Protein Tln1 G3V852_RAT 0.006 CTR low C high L high S low 
Fructose-bisphosphate aldolase A ALDOA_RAT 0.001 CTR low C high L high S low 
Plectin 6 Q6S3A0_RAT 0.034 CTR low C high L high S low 
High density lipoprotein binding protein (Vigilin) Q3KRF2_RAT 0.032 CTR low C high L high S low 
Gamma-enolase ENOG_RAT < 0.00010 CTR low C high L high S low 
Chaperonin containing Tcp1, subunit 6A (Zeta 1) Q3MHS9_RAT 0.013 CTR low C high L high S low 
Protein Rrbp1 F1M853_RAT 0.013 CTR low C high L high S low 
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Protein Sptbn1 G3V6S0_RAT 0.027 CTR low C high L high S low 
Perilipin Q5U2U5_RAT 0.001 CTR low C high L high S low 
Destrin DEST_RAT 0.033 CTR low C high L high S low 
Spna2 protein Q6IRK8_RAT 0.021 CTR low C high L high S low 
40S ribosomal protein S12 RS12_RAT 0.036 CTR low C high L high S low 
Dynamin-1-like protein DNM1L_RAT 0.014 CTR low C high L high S low 
Septin-9 (Fragment) F1LN75_RAT 0.012 CTR low C high L high S low 
Proliferation-associated 2G4 Q6AYD3_RAT 0.026 CTR low C high L high S low 
Epithelial protein lost in neoplasm F1LR10_RAT 0.036 CTR low C high L high S low 
Protein Tpd52 F1MAB9_RAT 0.032 CTR low C high L high S low 
Single-stranded DNA-binding protein G3V7K6_RAT 0.031 CTR low C high L high S low 
40S ribosomal protein S10 RS10_RAT 0.022 CTR low C high L high S low 
Protein Vps4b Q4KLL7_RAT 0.013 CTR low C high L high S low 
ARPC5_RAT Actin-related protein 2/3 complex 
subunit 5 
Q4KLF8 0.011 CTR low C high L high S low 
Septin-2 SEPT2_RAT 0.040 CTR low C high L high S low 
Protein Chd4 E9PU01_RAT 0.050 CTR low C high L high S low 
Fabp4 protein Q5XFV4_RAT 0.012 CTR low C high L high S low 
Isoform Crk-I of Adapter molecule crk CRK_RAT 0.014 CTR low C high L high S low 
Lipoprotein lipase LIPL_RAT 0.036 CTR low C high L high S low 
Crk-like protein CRKL_RAT 0.016 CTR low C high L high S low 
Protein Dhx58 D3ZD46_RAT 0.023 CTR low C high L high S low 
Glyceraldehyde-3-phosphate dehydrogenase D3ZWV2_RAT 0.033 CTR low C high L high S low 
cAMP-dependent protein kinase type II-beta 
regulatory subunit 
KAP3_RAT 0.029 CTR low C high L high S low 
Granulocyte-macrophage colony stimulating receptor 
alpha 
Q701L2_RAT 0.006 CTR low C high L high S low 
SEPT9_RAT Isoform 2 of Septin-9 Q9QZR6-2 0.018 CTR low C high L high S low 
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D3ZUC9_RAT Oxidative-stress responsive 1 
(Predicted) 
D3ZUC9_RAT 0.030 CTR low C high L high S low 
ELOB_RAT Transcription elongation factor B 
polypeptide 2 
P62870 0.011 CTR low C high L high S low 
Small glutamine-rich tetratricopeptide repeat-
containing protein 
SGTA_RAT 0.001 CTR low C high L high S low 
Peroxiredoxin-1 PRDX1_RAT 0.028 CTR low C high L low S high 
Protein U2af1 Q3KR55_RAT 0.048 CTR low C high L low S high 
Protein Hnrnpa0 F1M3H8_RAT 0.025 CTR low C high L low S high 
Elongation factor 1-alpha 1 EF1A1_RAT 0.038 CTR high C low L high S low 
Actin-related protein 2 ARP2_RAT 0.006 CTR high C low L high S low 
Unconventional myosin-Ic MYO1C_RAT 0.043 CTR high C low L high S low 
HtrA serine peptidase 2 B0BNB9_RAT 0.011 CTR high C low L high S low 
Thioredoxin THIO_RAT 0.019 CTR high C low L low S high 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial 
SDHA_RAT 0.035 CTR high C low L low S high 
LDLR chaperone MESD MESD_RAT 0.0003 CTR high C low L low S high 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial 
C1QBP_RAT 0.006 CTR high C low L low S high 
Cytochrome c oxidase subunit 4 isoform 1, 
mitochondrial 
COX41_RAT 0.018 CTR high C low L low S high 
Lymphocyte cytosolic protein 1 OS Q5XI38_RAT 0.050 CTR low C low L high S high 
V-type proton ATPase subunit B, brain isoform VATB2_RAT 0.033 CTR low C low L high S high 
40S ribosomal protein S5 B0BN81_RAT 0.040 CTR low C low L high S high 
Catenin (Cadherin associated protein), delta 1 
(Predicted), isoform CRA_a 
D3ZZZ9_RAT 0.003 CTR low C low L high S high 
Heterogeneous nuclear ribonucleoprotein Q HNRPQ_RAT 0.017 CTR low C low L high S high 
Apoptosis regulator BAX G3V8T9_RAT 0.046 CTR low C low L high S high 
Hematopoietic cell specific Lyn substrate 1 Q68FX4_RAT 0.042 CTR low C high L low S low 
GTP-binding nuclear protein Ran RAN_RAT 0.008 CTR low C high L low S low 
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Ncf4 protein B2RZ98_RAT 0.012 CTR low C high L low S low 
Protein LOC100912427 F1LPL7_RAT 0.019 CTR low C high L low S low 
40S ribosomal protein S17 RS17_RAT 0.001 CTR low C high L low S low 
Protein Tom1 Q5XI21_RAT 0.010 CTR low C high L low S low 
Elongation factor 1-delta EF1D_RAT 0.028 CTR low C high L low S low 
Engulfment and cell motility 1, ced-12 homolog (C. 
elegans) (Predicted), isoform CRA_a 
D3ZY46_RAT 0.005 CTR low C high L low S low 
LRRGT00066 Q6TUH8_RAT 0.002 CTR low C high L low S low 
Protein Snx6 B5DEY8_RAT 0.010 CTR low C high L low S low 
Protein Syap1 Q6AYB6_RAT 0.002 CTR low C high L low S low 
Pyrroline-5-carboxylate reductase 3 P5CR3_RAT 0.003 CTR low C high L low S low 
AP-1 complex subunit beta-1 G3V9N8_RAT 0.033 CTR low C high L low S low 
Prefoldin 5 (Predicted), isoform CRA_a B5DFN4_RAT 0.047 CTR low C high L low S low 
Protein-L-isoaspartate(D-aspartate) O-
methyltransferase 
PIMT_RAT 0.006 CTR low C high L low S low 
Isoform Alpha of Interleukin-18 IL18_RAT 0.046 CTR low C high L low S low 
Protein Pin4 M0RCP9_RAT 0.019 CTR low C high L low S low 
GrpE protein homolog 1, mitochondrial GRPE1_RAT 0.002 CTR low C high L low S low 
Protein Lsm12 D4A8G0_RAT 0.001 CTR low C high L low S low 
ATP-dependent Clp protease proteolytic subunit M0RAD5_RAT 0.036 CTR low C high L low S low 
MAT2B_RAT Methionine adenosyltransferase 2 
subunit beta 
MAT2B_RAT 0.044 CTR low C high L low S low 
AHNAK 1 (Fragment) Q38PF9_RAT 0.033 CTR low C high L low S low 
Mitochondrial import inner membrane translocase 
subunit Tim13 
TIM13_RAT 0.023 CTR low C high L low S low 
Coiled-coil domain-containing protein 22 CCD22_RAT 0.026 CTR low C high L low S low 
Purine nucleoside phosphorylase PNPH_RAT 0.025 CTR high C low L low S low 
Lipid phosphate phosphatase-related protein type 2 F1LRA5_RAT 0.008 CTR high C low L low S low 
Catalase CATA_RAT 0.049 CTR high C low L low S low 
ADP/ATP translocase 2 ADT2_RAT 0.007 CTR high C low L low S low 
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Interferon-induced GTP-binding protein Mx1 MX1_RAT < 0.00010 CTR high C low L low S low 
Ras-related protein Rab-1A E9PU16_RAT 0.017 CTR high C low L low S low 
N(4)-(Beta-N-acetylglucosaminyl)-L-asparaginase ASPG_RAT < 0.00010 CTR high C low L low S low 
Guanylate binding protein 2 Q5PQW8_RAT < 0.00010 CTR high C low L low S low 
Interferon-induced protein with tetratricopeptide 
repeats 3 
Q6AYE7_RAT 0.0002 CTR high C low L low S low 
26S proteasome non-ATPase regulatory subunit 1 PSMD1_RAT 0.016 CTR high C low L low S low 
ADP/ATP translocase 1 Q6P9Y4_RAT 0.007 CTR high C low L low S low 
Monocyte differentiation antigen CD14 O88955_RAT 0.022 CTR high C low L low S low 
Interleukin-1 alpha IL1A_RAT < 0.00010 CTR high C low L low S low 
Eukaryotic translation initiation factor 5A-1 IF5A1_RAT 0.048 CTR low C low L high S low 
Biliverdin reductase B (Flavin reductase (NADPH)) B5DF65_RAT 0.001 CTR low C low L high S low 
Eukaryotic translation initiation factor 2, subunit 2 
(Beta) 
Q6P685_RAT 0.020 CTR low C low L high S low 
Perilipin M0RA08_RAT 0.039 CTR low C low L high S low 
Protein Diap1 F1M775_RAT 0.040 CTR low C low L high S low 
Protein Snrpa Q5U214_RAT 0.013 CTR low C low L high S low 
Glutathione S-transferase alpha-3 GSTA3_RAT 0.021 CTR low C low L high S low 
Ethylmalonic encephalopathy 1 B0BNJ4_RAT 0.004 CTR low C low L high S low 
WW domain binding protein 2, isoform CRA_b G3V721_RAT 0.019 CTR low C low L high S low 
Syntaxin-7 STX7_RAT 0.047 CTR low C low L high S low 
Cysteine and glycine-rich protein 1 CSRP1_RAT 0.013 CTR low C low L high S low 
LOC684322 protein B2RZ97_RAT 0.002 CTR low C low L high S low 
COP9 signalosome complex subunit 8 CSN8_RAT 0.042 CTR low C low L high S low 
Clathrin light chain A CLCA_RAT 0.003 CTR low C low L high S low 
Glia maturation factor beta GMFB_RAT 0.007 CTR low C low L high S low 
Putative phospholipase B-like 2 PLBL2_RAT 0.001 CTR low C low L high S low 
Olfactory receptor Q6ZMA1_RAT 0.0002 CTR low C low L high S low 
Voltage-dependent anion-selective channel protein 1 VDAC1_RAT 0.001 CTR low C low L low S high 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
144 
 
Synaptic vesicle membrane protein VAT-1 homolog VAT1_RAT 0.026 CTR low C low L low S high 
Ab2-162 Q7TP54_RAT 0.001 CTR low C low L low S high 
Protein S100-A10 S10AA_RAT 0.021 CTR low C low L low S high 
Ferritin (Fragment) Q5FVS1_RAT 0.001 CTR low C low L low S high 
Protein Itih2 D3ZFH5_RAT 0.015 CTR low C low L low S high 
Aldose reductase ALDR_RAT 0.023 CTR low C low L low S high 
Ras-related protein Rab-11B RB11B_RAT 0.014 CTR low C low L low S high 
V-type proton ATPase subunit C 1 VATC1_RAT 0.011 CTR low C low L low S high 
NOL1/NOP2/Sun domain family, member 2 
(Predicted) 
D4A3S8_RAT 0.038 CTR low C low L low S high 
Protein Serpinc1 Q5M7T5_RAT 0.038 CTR low C low L low S high 
Growth/differentiation factor 15 GDF15_RAT < 0.00010 CTR low C low L low S high 
Anamorsin  CPIN1_RAT No significance CTR low C high L high S high 
Ubiquitin-like-conjugating enzyme ATG3 ATG3_RAT No significance     
Annexin Q6IRJ7_RAT No significance     
Bcl-x short Q9WUI5_RAT No significance     
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Figure 3.13: Total protein–protein interaction (PPI) network of surfactant exposed LPS-stimulated NR8383 AMs visualised by STRING v10.5. In this view, only associated 
proteins are shown and the colour saturation of the edges represents the confidence score of a functional association. 
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Table 3.6: List of proteins expressed in the Curosurf® exposed LPS-stimulated NR8383 AMs only. 
Bio View: Identified Proteins Accession Number 
Glyceraldehyde-3-phosphate dehydrogenase G3P_RAT 
Chaperonin containing Tcp1, subunit 6A (Zeta 1) Q3MHS9_RAT 
Hematopoietic cell specific Lyn substrate 1 Q68FX4_RAT 
GTP-binding nuclear protein Ran RAN_RAT 
Interferon-induced GTP-binding protein Mx1 MX1_RAT 
Epithelial protein lost in neoplasm F1LR10_RAT 
Ncf4 protein B2RZ98_RAT 
Protein LOC100912427 F1LPL7_RAT 
Arginase-1 ARGI1_RAT 
40S ribosomal protein S17  RS17_RAT 
Protein Tom1 Q5XI21_RAT 
MAP4_RAT MAP4_RAT 
Elongation factor 1-delta  EF1D_RAT 
Engulfment and cell motility 1, ced-12 homolog (C. elegans) 
(Predicted), isoform CRA_a  
D3ZY46_RAT 
LRRGT00066  Q6TUH8_RAT 
Protein Snx6  B5DEY8_RAT 
Interferon-induced protein with tetratricopeptide repeats 3 Q6AYE7_RAT 
RNA-binding motif protein, X chromosome retrogene-like RMXRL_RAT 
Protein Syap1 Q6AYB6_RAT 
Pyrroline-5-carboxylate reductase 3 P5CR3_RAT 
AP-1 complex subunit beta-1  G3V9N8_RAT 
Prefoldin 5 (Predicted), isoform CRA_a B5DFN4_RAT 
Protein-L-isoaspartate(D-aspartate) O-methyltransferase PIMT_RAT 
Isoform Alpha of Interleukin-18 IL18_RAT 
Protein Pin4 M0RCP9_RAT 
GRPE1_RAT GrpE protein homolog 1, mitochondrial  GRPE1_RAT 
Protein Lsm12 D4A8G0_RAT 
ATP-dependent Clp protease proteolytic subunit M0RAD5_RAT 
Methionine adenosyltransferase 2 subunit beta MAT2B_RAT 
AHNAK 1 (Fragment) Q38PF9_RAT 
Mitochondrial import inner membrane translocase subunit 
Tim13 
TIM13_RAT 
Coiled-coil domain-containing protein 22 CCD22_RAT 
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Figure 3.14: Protein–protein interaction (PPI) network visualised by STRING v10.5 for Curosurf® exposed LPS-
stimulated NR8383 AMs. In this view, only associated proteins are shown and the colour saturation of the edges 
represents the confidence score of a functional association. 
 
The above STRING network is visualised from Table 3.6 for Curosurf®. The proposed 
statistical enrichment analysis in Figure 3.14 of annotated functions for protein–protein 
interactions (PPI) was investigated further. The functional PPI enrichment (GO terms) for 
Curosurf® that displayed any significance (P value: 5.57 x 10-3) was associated with the 
molecular function for the biosynthesis of amino acids, but more specifically for arginase 
activity (arginine metabolism) (False discovery rate (FDR) 6.89E-04). According to this data 
and the co-expression of IL-18 and IL-6 (albeit decreased) within the Curosurf® population, 
another PPI enrichment analysis (P value: 1.3 x 10-6) was run with these proteins separately 
(Figure 3.15).  
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Figure 3.15: Protein–protein interaction (PPI) network visualised by STRING v10.5 for Curosurf® exposed LPS-
stimulated NR8383 AMs. In this view, only associated proteins are shown and the colour saturation of the edges 
represents the confidence score of a functional association.     Red nodes indicate first shell interactors of direct 
physical association;  White nodes indicate second shell interactors of indirect functional association. 
 
Figure 3.15 displays the STRING network for the selected PPI for Curosurf® exposed LPS-
stimulated AMs. The proposed statistical enrichment analysis for Figure 3.15 displayed a PPI 
enrichment P value of 1.3 x 10-6. The functional PPI enrichment (GO terms) associated with 
this network can be seen in Table 3.7; all of which are associated with the positive regulation 
of cytokine production (FDR 5.17E-08) and the positive regulation of apoptotic process (FDR 
1.02E-06) (See Chapter 2: Viability Study).  
 
 
 
 
 
0
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Table 3.7: The GO term (biological process) enrichment analysis for Curosurf® exposed LPS-stimulated NR8383 AMs is seen below. The proposed statistical enrichment 
analysis of annotated functions for protein–protein interaction (PPI) P-value: 1.3 x 10-6 and the false discovery rates (FDR) are included relative to presentation that would 
occur by chance. 
#Pathway ID Pathway description 
Observed gene 
count 
False 
discovery rate 
Matching proteins in your 
network (labels) 
GO.0001819 Positive regulation of cytokine production 6 5.17E-08 Casp1, Ifng, Il10, Il13, Il18, Il6 
GO.0050670 Regulation of lymphocyte proliferation 5 1.87E-07 Ifng, Il10, Il13, Il18, Il6 
GO.0043065 Positive regulation of apoptotic process 6 1.02E-06 Casp1, Ifng, Il10, Il18, Il6, Nlrc4 
GO.0050714 Positive regulation of protein secretion 5 1.02E-06 Casp1, Ifng, Il10, Il13, Il6 
GO.0050864 Regulation of B cell activation 4 1.02E-06 Ifng, Il10, Il13, Il6 
GO.0002700 
Regulation of production of molecular mediator of immune 
response 
4 1.99E-06 
Ifng, Il10, Il13, Il6 
GO.0046427 Positive regulation of JAK-STAT cascade 4 1.99E-06 Ifng, Il10, Il13, Il6 
GO.0050671 Positive regulation of lymphocyte proliferation 4 2.05E-06 Ifng, Il13, Il18, Il6 
GO.0050707 Regulation of cytokine secretion 4 4.02E-06 Casp1, Ifng, Il10, Il6 
GO.0032731 Positive regulation of interleukin-1 beta production 3 5.60E-06 Casp1, Ifng, Il18 
GO.0002684 Positive regulation of immune system process 5 1.19E-05 Ifng, Il13, Il18, Il6, Nlrc4 
GO.0006954 Inflammatory response 5 1.19E-05 Il10, Il13, Il18, Il6, Nlrc4 
GO.0002639 Positive regulation of immunoglobulin production 3 1.26E-05 Ifng, Il13, Il6 
GO.0048660 Regulation of smooth muscle cell proliferation 4 1.32E-05 Ifng, Il13, Il18, Il6 
GO.0032722 Positive regulation of chemokine production 3 1.46E-05 Ifng, Il18, Il6 
GO.2000377 Regulation of reactive oxygen species metabolic process 4 1.60E-05 Ifng, Il10, Il18, Il6 
GO.0009617 Response to bacterium 5 2.95E-05 Casp1, Ifng, Il13, Il18, Nlrc4 
GO.0050871 Positive regulation of B cell activation 3 2.95E-05 Ifng, Il13, Il6 
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GO.0050730 Regulation of peptidyl-tyrosine phosphorylation 4 3.02E-05 Ifng, Il13, Il18, Il6 
GO.0006955 Immune response 5 3.73E-05 Il10, Il13, Il18, Il6, Nlrc4 
GO.0042102 Positive regulation of T cell proliferation 3 4.00E-05 Ifng, Il18, Il6 
GO.0050778 Positive regulation of immune response 4 4.11E-05 Ifng, Il13, Il6, Nlrc4 
GO.0042035 Regulation of cytokine biosynthetic process 3 4.28E-05 Ifng, Il10, Il6 
GO.0001781 Neutrophil apoptotic process 2 4.67E-05 Ifng, Il6 
GO.0042531 Positive regulation of tyrosine phosphorylation of STAT protein 3 4.94E-05 Ifng, Il13, Il6 
GO.0045321 Leukocyte activation 4 4.94E-05 Casp1, Ifng, Il13, Il6 
GO.0043066 Negative regulation of apoptotic process 5 8.33E-05 Il10, Il13, Il18, Il6, Nlrc4 
GO.0050715 Positive regulation of cytokine secretion 3 8.61E-05 Casp1, Ifng, Il10 
GO.0032680 Regulation of tumor necrosis factor production 3 9.73E-05 Ifng, Il10, Il18 
GO.0045428 Regulation of nitric oxide biosynthetic process 3 9.73E-05 Ifng, Il10, Il6 
GO.0006952 Defence response 5 0.000101 Ifng, Il13, Il18, Il6, Nlrc4 
GO.0001817 Regulation of cytokine production 4 0.000119 Casp1, Ifng, Il13, Il18 
GO.0032675 Regulation of interleukin-6 production 3 0.00012 Ifng, Il10, Il6 
GO.0051222 Positive regulation of protein transport 4 0.000156 Casp1, Ifng, Il10, Il13 
GO.0050708 Regulation of protein secretion 4 0.000169 Casp1, Ifng, Il10, Il13 
GO.0001780 Neutrophil homeostasis 2 0.000176 Ifng, Il6 
GO.2000379 Positive regulation of reactive oxygen species metabolic process 3 0.000226 Ifng, Il18, Il6 
GO.0045073 Regulation of chemokine biosynthetic process 2 0.000268 Ifng, Il6 
GO.0045348 Positive regulation of MHC class II biosynthetic process 2 0.000268 Ifng, Il10 
GO.0002250 Adaptive immune response 3 0.000281 Ifng, Il18, Il6 
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Table 3.8: List of proteins expressed in the Liposurf® exposed LPS-stimulated NR8383 AMs only. 
Bio View: Identified Proteins Accession Number 
Fructose-bisphosphate aldolase A ALDOA_RAT 
Cystatin-B CYTB_RAT 
Eukaryotic translation initiation factor 5A-1 IF5A1_RAT 
Purine nucleoside phosphorylase PNPH_RAT 
Elongation factor 1-alpha 1 EF1A1_RAT 
Biliverdin reductase B (Flavin reductase (NADPH)) B5DF65_RAT 
Catalase CATA_RAT 
Actin-related protein 2 ARP2_RAT 
Eukaryotic translation initiation factor 2, subunit 2 (Beta) Q6P685_RAT 
Protein Vps4b Q4KLL7_RAT 
Perilipin M0RA08_RAT 
Protein Diap1 F1M775_RAT 
Protein Snrpa PE=2 SV=1 Q5U214_RAT 
HtrA serine peptidase 2 B0BNB9_RAT 
Glutathione S-transferase alpha-3 GSTA3_RAT 
Ethylmalonic encephalopathy 1 B0BNJ4_RAT 
WW domain binding protein 2, isoform CRA_b G3V721_RAT 
Syntaxin-7 STX7_RAT 
Cysteine and glycine-rich protein 1 CSRP1_RAT 
LOC684322 protein B2RZ97_RAT 
COP9 signalosome complex subunit 8 CSN8_RAT 
Clathrin light chain A CLCA_RAT 
Glia maturation factor beta  GMFB_RAT 
Putative phospholipase B-like 2  PLBL2_RAT 
Olfactory receptor Q6ZMA1_RAT 
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Figure 3.16: Protein–protein interaction (PPI) network visualised by STRING v10.5 for Liposurf® exposed LPS-
stimulated NR8383 AMs. In this view, only associated proteins are shown and the colour saturation of the edges 
represents the confidence score of a functional association. 
 
The above STRING network is visualised from Table 3.8 for Liposurf®. The proposed 
statistical enrichment analysis in Figure 3.16 of annotated functions for the PPI was 
investigated further. The functional PPI enrichment (GO terms) for Liposurf® that displayed 
any significant enrichment value (P value: 3.87 x 10-4) was associated with the biological 
process (GO:0071822; Actr2, Actr3, Aldoa, Arpc5, Cat, Eef1a1, Vamp8) of protein complex 
subunit organisation (FDR 0.0367) that is linked to actin polymerisation of the structural 
cytoskeleton (FDR 3.65E-06) and the regulation thereof. This is verified in Figure 2.23F 
(Chapter 2, page 92) where the rearrangement of the cytoskeleton can be seen via the formation 
of filopodia/lamellopodia.  
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Table 3.9: List of proteins expressed in the Synsurf® exposed LPS-stimulated NR8383 AMs only. 
Bio View: Identified Proteins Accession Number 
Voltage-dependent anion-selective channel protein 1  VDAC1_RAT 
Peroxiredoxin-1 PRDX1_RAT 
Synaptic vesicle membrane protein VAT-1 homolog  VAT1_RAT 
Ab2-162 Q7TP54_RAT 
Thioredoxin THIO_RAT 
Protein S100-A10 S10AA_RAT 
Ferritin (Fragment)  Q5FVS1_RAT 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial  
SDHA_RAT 
LDLR chaperone MESD MESD_RAT 
Protein Itih2 D3ZFH5_RAT 
Aldose reductase ALDR_RAT 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial 
C1QBP_RAT 
Ras-related protein Rab-11B RB11B_RAT 
V-type proton ATPase subunit C 1 VATC1_RAT 
NOL1/NOP2/Sun domain family, member 2 (Predicted) D4A3S8_RAT 
Protein Serpinc1 Q5M7T5_RAT 
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX41_RAT 
Calcineurin B homologous protein 1 CHP1_RAT 
Growth/differentiation factor 15 GDF15_RAT 
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Figure 3.17: Protein–protein interaction (PPI) network visualised by STRING for Synsurf® exposed LPS-
stimulated NR8383 AMs. In this view, only associated proteins are shown and the colour saturation of the edges 
represents the confidence score of a functional association. 
 
The above STRING network is visualised from Table 3.9 for Synsurf®. The proposed 
statistical enrichment analysis in Figure 3.17 of annotated functions for PPI was investigated 
further. The functional PPI enrichment (GO terms) for Synsurf® that displayed any significant 
enrichment value (P value: 1.14 x 10-6) was associated with the biological process of oxidation-
reduction (GO:0055114) with a FDR of 2.76E-03. This biological process is linked to the 
molecular function of oxidoreductase activity (GO:0016491) with a FDR of 1.42E-05 and the 
regulation thereof (Table 3.10).  
 
Table 3.10: The GO term (biological process) enrichment analysis for Synsurf® exposed LPS-stimulated NR8383 
AMs is seen below. The proposed statistical enrichment analysis of annotated functions for protein–protein 
interaction (PPI) P-value: 1.14 x 10-6 and the false discovery rates (FDR) are included relative to presentation that 
would occur by chance. 
#Pathway 
ID 
Pathway 
description 
Observed 
gene count 
False discovery 
rate 
Matching proteins in your 
network (labels) 
GO:0055114 
Oxidation-
reduction 
7 
2.76E-03 
Cox4i1, Fth1, Prdx1, Sdha, Sdhb, 
Txn1, Vat1 
GO:0016491 
Oxidoreductase 
activity 
8 
1.42E-05 
Cox4i1, Fth1, Prdx1, Sdha, Sdhb, 
Sdhd, Txn1, Vat1 
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Figure 3.18: The proposed protein–protein interaction (PPI) network visualised by STRING v10.5 for combined 
surfactant exposed LPS-stimulated NR8383 AMs. In this view, associated proteins are connected and the colour 
saturation of the edges represents the confidence score of a functional association. STRING displays every 
functional pathway/term that can be associated. The (biological process) enrichment analysis as seen in Table 
3.11. 
 
The proposed PPI interaction for surfactant exposed LPS-stimulated AMs related to the 
inflammatory process only can be seen in Figure 3.18. The proposed statistical enrichment 
analysis (P value: 1.37 x 10-8) for the annotated functions was investigated further and can be 
seen in Table 3.11. Although not all proteins were found to be present in the separate surfactant 
groups, associated proteins are automatically included due to functional regulatory relevance 
in said pathway. One can therefore assume that these proteins are regulated via association.  
 
 
Stellenbosch University  https://scholar.sun.ac.za
156 
 
Table 3.11: GO term (biological process) enrichment analysis for combined surfactant exposed LPS-stimulated NR8383 AMs (only relevant GO terms are included). Protein–
protein interaction (PPI) enrichment analysis P value: 1.37 x 10-8 and false discovery rate included relative to presentation that would occur by chance. 
 
 
#Pathway ID 
Pathway 
description 
Observed 
gene 
count 
False 
discovery rate 
Matching proteins in your network (labels) 
GO.0002376 
Immune system 
process 
19 3.53E-17 
Arhgef2, B2m, C1qbp, Card9, Ctsh, Eif2ak2, Fcer1g, Hck, Il1a, Lgals3, Nlrx1, Oasl, Otub1, Pnp, 
Psma1, Ptk2b, Skap2, Tollip, Trim28 
GO.0006955 
Immune response 16 1.01E-16 
Arhgef2, C1qbp, Card9, Ctsh, Eif2ak2, Fcer1g, Hck, Il1a, Lgals3, Lyn, Nlrx1, Oasl,Pnp, Ptk2b, 
Tollip, Trim28 
GO.0045087 
Innate immune 
response 
12 1.06E-13 
Arhgef2, C1qbp, Card9, Eif2ak2, Hck, Lgals3, Lyn, Nlrx1, Oasl, Ptk2b, Tollip, Trim28 
GO.0006952 Defence response 14 6.58E-12 Arhgef2, C1qbp, Card9, Eif2ak2, Fcer1g, Hck, Il1a, Lgals3, Lyn, Nlrx1, Oasl, Ptk2b, Tollip, Trim28 
GO.0002682 
Regulation of 
immune system 
process 
11 1.74E-08 
B2m, C1qbp, Card9, Ctsh, Eif2ak2, Fcer1g, Il1a, Pnp, Psma1, Ptpre, Tap1 
GO.0002250 
Adaptive immune 
response 
6 4.33E-07 
C1qbp, Ctsh, Fcer1g, Ifng, Il18, Il6 
GO.0042981 
Regulation of 
apoptotic process 
12 4.33E-07 
C1qbp, Card9, Ctsh, Eif2ak2, Fcer1g, Hck, Ifng, Il18, Lgals3, Lyn, Ptk2b, Tnf 
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Due to the involvement of NOS and Arginase in L-Arginine metabolism for M2 polarised AMs, 
it is therefore necessary to include them within their own PPI network (enrichment P value: 2.9 
x 10-2) which can be seen in Figure 3.19. These PPIs are central in the arginine metabolic 
process (FDR 1.24E-05) and to the INF-γ cellular response (FDR 1.78E-05). All surfactant 
exposed LPS stimulated AMs showed NOS2 expression, however, only the Curosurf® group 
displayed significant upregulated Arginase I.  
 
 
 
Figure 3.19: Protein–protein interaction (PPI) network visualised by STRING v10.5 for NOS2 and Arg. In this 
view, associated proteins are connected and the colour saturation of the edges represent the confidence score of a 
functional association. STRING analysis displays every functional pathway/term that can be associated. Red 
nodes indicate first shell interactors of physical association;        White nodes indicate second shell interactors of 
function association. 
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3.2.3 Effect of Surfactant on Human BAL derived Macrophages’ Cytokine Secretion 
 
After informed consent, a total of 30 paediatric patients’ BAL samples were collected. After 
sample processing and cell counting, the desirable samples were seeded in appropriate densities 
for the treatment protocol. Other, less desirable cell populations were discarded from the study. 
 
As shown in Figure 3.20, the representative hematoxylin and eosin (H&E) staining indicate 
different cell populations found in BAL samples. Figure 3.20A & B demonstrated a greater 
population of neutrophils, such populations were excluded from the current study as 
macrophage initiated cytokine release was focused on. Figure 3.20C & D indicates the optimal 
cell population that was used as a standard for the appropriation of the study. 
 
Figure 3.20: H&E staining of human BAL sample after mononuclear cell isolation from patient diagnosed with 
asthma (A) & (B) and a healthy patient with an airway obstruction (C) & (D); M: Macrophage, N: Neutrophil, 
Eos: Eosinophil, MD: Mucus debris. Scale bar represents: (A) & (B) 50µm, (C) 100 µm, (D) 500 px. 
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N 
N 
M 
MD 
MD 
MD 
M 
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A B 
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Table 3.12 - Table 3.20 represent the results of stimulated macrophage secretion of the nine 
inflammatory cytokines studied. Comparison of the different surfactants studied with regards 
to inflammatory and anti-inflammatory cytokine secretion did not reveal significant differences, 
therefore, data representation is more effective within descriptive statistical analysis.  
 
Although the aim of this determination was to assess spontaneous release of cytokines by LPS-
stimulated AM due to surfactant exposure, it should be noted that under these conditions 
cytokines produced by the actual adherence of AMs to the polystyrene dishes might act as 
modulatory factors as indicated by the control. 
 
Overall comparison of the secretion of the different cytokines revealed that under LPS 
stimulated conditions, AMs secrete low amounts of IL-1β (in the 0.25 – 200 pg/106 cells range), 
IL-2 (0.1 - 7 pg/ml) and IFN-γ (5 pg/ml). Increased GM-CSF (100 pg/ml), TNF-α and IL-6 
(400 - 600 pg/106 cells) and large amounts of IL-8 (3.5 ng/106 cells) were seen. The pro- 
inflammatory cytokine secretion was decreased (compared to control levels) in all three 
surfactant groups after 24h exposure.  
 
The anti-inflammatory cytokines, IL-10 and IL-12, were also seen to be secreted at low levels 
under LPS-stimulated conditions but exhibited the opposite nature to the pro-inflammatory 
cytokines by an increasing in secretion when exposed to surfactants.  
 
Table 3.12: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated IL-1βin BAL-derived human alveolar macrophage supernatant concentrations measured 
at 24h in the presence of surfactants. 
IL-1β (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 3 7 7 7 
Mean 176.45 168.87 118.01 97.60 
SD 305.32 292.62 210.07 166.01 
P25 0.09 0.30 0.34 0.27 
P50 0.25 0.39 1.29 0.60 
P75 529 495.5 300.5 332 
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Table 3.13: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated IL-2 in BAL-derived human alveolar macrophage supernatant concentrations measured 
at 24h in the presence of surfactants. 
IL2 (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 3 5 5 7 
Mean 7.61 5.16 4.38 10.91 
SD 1126 7.77 5.84 19.03 
P25 0.0170 0.14 0.22 0.14 
P50 0.0722 0.38 0.022 0.31 
P75 1951 7.25 8.86 27.45 
 
 
 
Table 3.14: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated IL-6 in BAL-derived human alveolar macrophage supernatant concentrations measured 
at 24h in the presence of surfactants. 
IL6 (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 3 7 6 6 
Mean 650.4 452.78 321.08 265.70 
SD 1126 815.29 634.03 412.02 
P25 0.0170 0.17 0.07 0.14 
P50 0.0722 0.29 0.18 0.24 
P75 1951 1134 341 759.5 
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Table 3.15: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated IL-8 in BAL-derived human alveolar macrophage supernatant concentrations measured 
at 24h in the presence of surfactants. 
IL8 (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 3 7 7 7 
Mean 3588 3193.71 3139.73 3101.79 
SD 6020 5153.64 5081.01 4997.25 
P25 55.35 89 84.5 95.75 
P50 169.0 249.5 251 198.5 
P75 10540 10532.5 10316.5 10273 
 
 
Table 3.16: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated TNF-α in BAL-derived human alveolar macrophage supernatant concentrations 
measured at 24h in the presence of surfactants. 
TNF-α (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 1 6 4 6 
Mean 462 120.73 110.01 56.87 
SD - 195.09 181.01 99.96 
P25 - 0.08 0.10 0.08 
P50 - 0.13 30.98 0.13 
P75 - 273.5 219.93 95.35 
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Table 3.17: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated INF-γin BAL-derived human alveolar macrophage supernatant concentrations 
measured at 24h in the presence of surfactants. 
INF-γ (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 2 5 4 5 
Mean 5.771 1.93 3.06 1.12 
SD 8.039 2.50 4.80 0.85 
P25 0.0864 0.28 0.45 0.55 
P50 5.771 0.49 0.82 0.60 
P75 11.46 2.57 5.68 1.75 
 
 
Table 3.18: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated GM-CSF in BAL-derived human alveolar macrophage supernatant concentrations 
measured at 24h in the presence of surfactants. 
GM-CSF (pg/ml) 
 Control Curosurf® Liposurf® Synsurf® 
N 3 7 7 7 
Mean 114.1 84.50 61.89 62.33 
SD 197.3 157.67 129.10 107.94 
P25 0.1176 0.28 0.21 0.06 
P50 0.2565 0.35 0.42 0.22 
P75 342.0 183 86.3 184 
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Table 3.19: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of LPS 
(1 µg/ml)-stimulated IL-10 in BAL-derived human alveolar macrophage supernatant concentrations measured at 
24h in the presence of surfactants. 
IL10 
 Control Curosurf® Liposurf® Synsurf® 
N 1 5 4 5 
Mean 0.186 18.05 15.58 4.88 
SD - 29.70 29.76 8.36 
P25 - 0.1244 0.11435 0.157 
P50 - 0.176 1.012 0.1635 
P75 - 21.25 31.0475 4.55 
 
 
Table 3.20: The mean, SD (standard deviation), P25 (25th percentile), P50 (median), & P75 (75th percentile) of 
LPS (1 µg/ml)-stimulated IL-12 in BAL-derived human alveolar macrophage supernatant concentrations 
measured at 24h in the presence of surfactants. 
IL12 
 Control Curosurf® Liposurf® Synsurf® 
N 2 4 4 5 
Mean 2.930 20.10 15.39 16.14 
SD 3.966 39.377 18.07 22.08 
P25 0.1259 0.24 0.21 0.34 
P50 2.930 0.56 12.74 0.35 
P75 5.735 39.95 30.58 33.7 
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3.3 Discussion 
3.3.1 NR8383 Rat Alveolar Cell Line 
 
It has been established that pulmonary surfactant has immunomodulatory properties in addition 
to its function as a surface tension modulator. As surfactant replacement therapy for premature 
infants with RDS is standard care, and with its growing interest in other forms of lung diseases 
as well as its potential role in drug delivery, there is much demand for determining whether 
exogenous surfactant preparations demonstrate similar anti-inflammatory properties as seen in 
native surfactants (Kerecman, Mustafa et al. 2008).  
 
The present study demonstrates the effects of two exogenous surfactants from animal sources 
(Curosurf® and Liposurf®) and a synthetic surfactant (Synsurf®) on pro-inflammatory 
cytokine (TNF-α, IL-1β, IL-6) and chemokine (KC/GRO) secretion, oxidative burst and protein 
expression in the NR8383 AM cell line. This AM cell line was chosen as it provides a 
homogenous source of immune cells that has the ability to display consistent inflammatory 
responses to stimulation. The results demonstrate that Curosurf®, Liposurf® and Synsurf® 
decrease secretion of the pro-inflammatory cytokines, TNF-α, IL-1β, and IL-6 in LPS- 
stimulated AMs in a dose dependent manner. Additionally, all three surfactants inhibit the 
oxidative burst of stimulated AMs by decreased ROS production (see Chapter 2, page 98). 
However, there was increased cytokine secretion in the un-stimulated, surfactant treated AMs 
indicating a detrimental response elicited by lower phospholipid concentrations rather than a 
protective nature of higher phospholipid concentrations as seen in stimulated AMs. This 
suggests that surfactant or surfactant components alone, have the ability to modulate the 
inflammatory cascade within the AMs.  
 
The surfactant-induced decrease in TNF-α and IL-1β levels may represent surfactant binding 
to LPS or LPS receptors. This inhibition was evident when AMs were treated with surfactant 
during LPS-stimulation; however, the surfactant-induced increase in the un-stimulated AMs 
suggests that LPS receptor block does not sufficiently explain the suppression of cytokine 
secretion.  
 
The mechanisms by which exogenous surfactants modulate the inflammatory cascade in AMs 
are unclear and are thus critical to elucidate when the complex interplay of interactions among 
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the inflammatory cytokines (inducer or suppressor effects of one cytokine against another) are 
involved in inflammatory pulmonary conditions.  
 
3.3.2 Proteomics 
 
Macrophages at the different activation statuses undergo immunometabolic changes to 
differentially express a series of intracellular markers and secretory cytokines/chemokines. 
These secretory proteins can be linked to regulation of inflammation, tissue repair, T- and B-
cell proliferation, phagocytosis and antimicrobial activity (Sang, Brichalli et al. 2014). 
 
All three surfactant exposed LPS stimulated AMs displayed upregulation of cystatin. Cystatin 
is implicated in INFγ induced production of NO by activated macrophages. Kitamura and 
colleagues showed that IL-6-mediated signalling reduced cystatin expression and MHC class 
II αβ dimer molecule levels (Kitamura, Kamon et al. 2005). However, the MHC class Iβ was 
found to be upregulated within the Curosurf® and Liposurf® group suggesting natural 
surfactant interference. In the Synsurf® group, MHC class Iβ was downregulated. The 
decreased levels of IL-6 within the Synsurf® treated AMs, alongside the cystatin could 
therefore explain the downregulated MHC class Iβ. These MHC class Iβ molecules presents 
peptides to T cells, bridging the innate and acquired immunity that provides insight into the 
origins of acquired immunity (Rodgers, Cook 2005). Verdot and colleagues also suggested that 
cystatin stimulated TNF-α and IL-10 release by IFN-γ-activated murine peritoneal 
macrophages (Verdot, Lalmanach et al. 1999). These observations by Verdot and colleagues 
could be of importance regarding surfactant influence on AM cystatin concentrations involved 
in the upregulation of TNF-α, IL-10 and NO synthesis; thus, pointing out a new effect-
relationship between surfactant induced cystatins, cytokines, inflammation and immune 
responses (Kopitar-Jerala 2006). 
 
The only statistical functional enrichment for Synsurf® was associated with the oxidation-
reduction pathway. ROS is known for being a down-stream by-product of the inflammatory 
response and contributes to cell viability (See Chapter 2, page 87) but it also serves in the 
multifaceted regulation of inflammatory processes via physiological roles in signalling. One of 
the key role role-players that was found to be upregulated in the Synsurf® group was 
Peroxiredoxin-1 (Prx1). ROS production is critical for appropriate cellular responses to prevent 
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further oxidative damage and to maintain cell survival; however, when an excessive amount of 
cell damage has occurred, the cell usually enters a form of cell death (autophagy or apoptosis) 
(Morgan, Liu 2011). Prx1 belongs to a family of anti-oxidants that protects the cell from 
metabolically produced ROS that trigger toxic mechanisms within the cell if the signal is 
exacerbated, continues, or if it occurs at the wrong cell cycle interval and region of the cell 
(Nathan, Cunningham-Bussel 2013). In this context, a similar trend seen by Robinson and 
colleagues, Prx1 might have an unanticipated, but yet, a very specific and important role in 
Synsurf® exposed LPS stimulated macrophages (Robinson, Hutchinson et al. 2010). Prx1 may 
also contribute to the modulation of immune responses by involving Th2-responses via the 
induction of alternatively activated macrophages (Knoops, Argyropoulou et al. 2016). It has 
been proposed by Kim and colleagues that Prx1 may also inhibit NO production by suppressing 
the ROS/NF-κB/iNOS (NOS2) signalling pathway (Kim, Park et al. 2013). When taking the 
visualised PPI network for Synsurf® (Figure 3.17) into consideration and the association with 
NOS2 via Thioredoxin 1 (Trx1), it is then possible to hypothesise that the decrease in cytokine 
production in the Synsurf® exposed LPS stimulated macrophages occurs via redox signalling 
by the upregulation of Trx1.  
Trx1 is another oxidative, stress-limiting protein that was found to be upregulated within the 
Synsurf® group. Trx1 is able to scavenge ROS within the cytosol and nucleus of the cell to 
diminish oxidative stress. However, Trx1 seems to play dual and opposing roles in the 
activation and repression of NF-κB signalling. It is one of the most important cellular 
antioxidants with anti-inflammatory and anti-apoptotic properties capable of inhibiting IκB 
degradation within the cytoplasm (see Figure 3.4) (Djavaheri-Mergny, Javelaud et al. 2004, 
Morgan, Liu 2011) but is also, in turn, able to regulate NF-κB activation through 
denitrosylation (-nitrosyl (–SNO)) of the p65 subunit (Kelleher, Sha et al. 2014). Kelleher and 
colleagues demonstrated quantification of Trx1 protein expression, SNO-p65 formation and 
NF-κB activity in lung cell lysates and found that Trx1 legitimates cytokine-mediated 
denitrosylation of p65 and therefore its secondary role in NF-κB activation associated with 
LPS-induced airway inflammation. Furthermore, by Trx-1’s ability to limit nuclear ROS levels 
it in turn deems itself as a transcription regulatory factor by affecting ROS-associated NF-κB 
activation (El Hadri, Mahmood et al. 2012). 
Trx1 might also promote macrophage differentiation into the macrophage M2 anti-
inflammatory phenotype. Thereby significantly reducing the LPS induced inflammatory M1 
macrophages as indicated by the Synsurf® dose-dependent decrease TNFα and IL1β 
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expression. This statement is supported by similar findings by El Hadri et al. and Billiet et al. 
Both groups demonstrated the induced downregulation of nuclear translocation of activator 
protein-1 and Ref-1 via Trx1 that led to the shift in phenotype pattern of lesional macrophages 
to predominantly M2 over M1 and subsequently the secretion of proinflammatory cytokines 
(Billiet, Furman et al. 2005, El Hadri, Mahmood et al. 2012). Although no M2 associated 
cytokines were detected in the Synsurf® exposed macrophages, the up-regulation of Trx1 could 
be indicative to the promotion of a polarisation switch still to occur thereby repressing 
transcriptional activation of pro-inflammatory cytokines via the ERK/MAP kinase pathway. It 
is then practical to assume that Synsurf® exposed LPS stimulated AMs upregulates Trx1 
activity thereby prompting Trx-dependent IκB degradation, downregulating the transcription 
of pro-inflammatory cytokines. 
Moreover, Trx can be regarded as an adaptive response as it possibly acts as a chaperone to 
arginase (utilising L-arginine) by protecting the enzyme from inhibition via reactive oxygen 
and nitrogen intermediates (Nakamura, Nakamura et al. 2005). Thus maintaining arginase in a 
catalytically active state, preserves its activity and blunts excessive NOS2 activity (McGee, 
Kumar et al. 2006, Song, Kim et al. 2008, Lucas, Czikora et al. 2013). Taken together, all of 
these redox activities could make Synsurf® a potent and versatile mediator of inflammation 
and can possibly be proposed as a therapeutic candidate for the treatment of several pulmonary 
inflammatory disorders where Trx1 may ameliorate the cytotoxic response. 
Ferritin Heavy Chain (FHC) is the second-most well-known NF-κB target that protects the cell 
from oxidative damage and Ferritin (Q5FVS1_RAT) was found to be co-upregulated in 
Synsurf® alongside the above mentioned (Down regulated in Curosurf® and Liposurf®). Due 
to its characteristic of being an iron storage protein, it cannot scavenge ROS directly but can 
however, protect the cell from iron-mediated oxidative damage by preventing generation of 
highly reactive •OH radicals via Fenton reactions (Morgan, Liu 2011). Thus, preventing the 
generation of more highly reactive species (O2•- and •OH) and promoting the breakdown of 
H2O2 into water by peroxidases and catalases (Torti, Torti 2002). However, in this case, 
Catalase (CATA_RAT) was downregulated in Synsurf®. Besides its ability to promote cell 
growth, there have been reports that suggest that catalase could be the target of inhibitory p50 
homodimers since its promoter is bound by p50 in unstimulated cells and catalase is down-
regulated when NF-κB activation occurs (Schreiber, Jenner et al. 2006, Morgan, Liu 2011). 
Thus, in this instance, it could be that even though there is evidence that NF-κB activation via 
stimulated AM is decreased, it is still too high for catalase to be upregulated. 
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The only statistical functional enrichment for Curosurf® was associated with the biosynthesis 
of amino acids (KEGG pathway for proline (not included)), but more specifically for arginine 
metabolism. Arginase-1 converts L-arginine into L-ornithine and urea (Figure 3.21) and is a 
key enzyme of the urea cycle in the liver but it also has an unexpected role in cells and tissues 
that lack a complete urea cycle. Arginase-1 is also expressed in the airways where it has the 
biological function of regulating NO synthesis in bronchial epithelial cells, endothelial cells 
and AMs (Maarsingh, Pera et al. 2008). It competes with NOS for the utilisation of the common 
substrate L-arginine in activated M2 macrophages thus supressing the cytotoxic response in 
these cells.  
 
 
Figure 3.21: L-Arginine metabolism catalysed by arginase and NOS. L-Arginine is a substrate of both NOS, 
yielding and L-citrulline, and arginase, which in turn produces L-ornithine and urea. Arginase regulates the 
production of NO by competing with NOS for their common substrate. On the other hand NOHA, an intermediate 
in the NO synthesis catalysed by NOS, inhibits arginase activity. In addition, the arginase product L-ornithine is 
the precursor of L-proline. Abbreviations: NO, nitric oxide; NOHA, N ω N ω  -hydroxy-l-arginine; NOS, nitric 
oxide synthase; OAT, Ornithine aminotransferase; P5C, pyrroline-5-carboxylate (adapted from (Maarsingh, Pera 
et al. 2008)). 
 
Asthma, chronic obstructive pulmonary disease, cystic fibrosis, and pulmonary hypertension 
are several lung diseases associated with increased arginase activity suggesting a common 
feature that underlines these disease’s pathophysiologies (Maarsingh, Pera et al. 2008, Lucas, 
Czikora et al. 2013). With anomalies concerning the delicate homeostasis of NO and 
exaggerated tissue repair in various inflammatory airway diseases, reduced lung function can 
occur leading to airway hyper-responsiveness and/or airway remodelling that takes place in the 
above-mentioned conditions (Maarsingh, Pera et al. 2008).  
The presence of upregulated arginase-1 within the Curosurf® exposed AMs (downregulated in 
the Liposurf® and Synsurf® exposed AM) indicates a proposed M1/M2 phenotypic switch and 
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M2 polarisation (specifically M2c, see Figure 3.3). This is due to the probable utilisation of L-
arginine for the down-stream biosynthesis of proline via L-ornithine that leads to increased cell 
proliferation (Satriano 2004, Mantovani, Biswas et al. 2013). It is therefore assumed that 
Curosurf® exposed LPS stimulated AMs upregulates arginase-1 activity and therefore induces 
M2 phenotypic switch and M2c polarisation; consequently, downregulating the innate M1 
phenotype’s pro-inflammatory cytokines. 
Moreover, Coiled-coil domain-containing protein 22 (CCD22) was found to be upregulated in 
Curosurf® and Synsurf® exposed LPS stimulated AMs (However, downregulated in 
Liposurf®), thus suggesting that these two surfactants share a mixed M1/M2 phenotype 
population. This protein is involved in the regulation of NF-κB signalling by promoting 
ubiquitination of IκB-kinase subunit IκB thus leading to its subsequent proteasomal 
degradation and NF-κB activation (see Figure 3.4) (Niemand, Nimmesgern et al. 2003). Since 
CCD22 is downregulated in Liposurf® and exposed LPS stimulated AMs; and Liposurf® 
exposed AMs elicited IL10 production (see Figure 3.11), it is therefore acceptable to assume 
that the NF-κB signalling and subsequent pro-inflammatory cytokine (innate M1 phenotype) is 
deterred by the JAK/STAT pathway at lower phospholipid concentrations. The proposed 
subsequent production of SOCS3 interrupts the ubiquitination of the IκB-kinase subunit leading 
to NF-κB deactivation and halts pro-inflammatory cytokine production (Niemand, 
Nimmesgern et al. 2003). Contradictory, its function may also involve association with Copper 
Metabolism Domain Containing 1 (COMMD1) and a Cullin–RING (CUL1) -dependent E3 
ubiquitin ligase complex down-regulation of NF-κB activity via degradation of NF-κB subunits 
by facilitating substrate binding to the ligase and stabilising the interaction between SOCS1 
and p65 subunit of NF-κB (Maine, Mao et al. 2007). IκB proteins play an important role in 
regulating the nuclear pool of NF-κB; however, it is likely that other factors and pathways are 
involved in this process in cells that are IκB protein deficient (Tergaonkar, Correa et al. 2005, 
Maine, Mao et al. 2007).  
It is also important to mention here that the pleiotropic cytokine, IL-6, elicits pro- and anti-
inflammatory properties. All three surfactant exposed LPS stimulated AMs secreted low levels 
of IL-6 (Figure 3.9); however, Liposurf® exposed AMs secreted significantly more IL-6 than 
its counterparts (Table 3.3). IL-6 trans-signalling (with soluble IL-6 receptors) could thus be 
involved within the Liposurf® exposed AMs, explaining the higher TNF-α levels (Figure 3.7) 
that blunt the anti-inflammatory effects compared to the TNF-α levels of Curosurf® and 
Synsurf® (Scheller, Chalaris et al. 2011). This may offer the explanation as to the presence of 
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the anti-inflammatory cytokine IL-10 in the Liposurf® exposed AMs as another mechanism 
was employed to resolve the upregulated inflammatory cascade.  
The second enrichment analysis that displayed significant PPI for upregulated IL-18 and the 
presence of IL-6 (see Figure 3.15) for Curosurf® exposed AMs is associated with the positive 
regulation of cytokine production as well as the regulation of the apoptotic process. IL-18 acts 
as bridge to link the innate immune response by priming Th1 polarisation and priming NK cells 
(see Figure 3.2) (Slaats, ten Oever et al. 2016). Autophagy is a cellular process that plays a 
crucial role in environmental adaptation and cellular remodelling and is characterised by the 
formation of autophagosomes (double-membrane vesicles that capture and transport 
cytoplasmic material to acidic compartments where material is degraded by hydrolytic 
enzymes) (Ravikumar, Futter et al. 2009, Duque, Descoteaux 2014). However, it is also been 
recognised in the mediation of cellular cytokine secretion for those proteins that otherwise do 
not have a leader peptide as to enter the classical secretory pathway such as IL-1β and IL-18 
(Jiang, Dupont et al. 2013). In this case, both the autophagy related protein 3 (Atg3) (not 
significantly expressed) and Ras-related protein Rab-11b were present but down regulated in 
all three surfactant exposed AMs groups (except Rab-11b for Synsurf®) indicating causal 
autophagocytosis in response to the increased cytokine production. These autophagic proteins 
are essential in regulating immune responses in a “house-keeping” manner by digestion of 
dysfunctional mitochondria and thereby preventing excess production of mitochondrial ROS. 
Secondly, autophagy is also responsible for translocating IL-1β and IL18-containing vesicles 
(inflammasome complexes) for degradation, thus removing unwanted inflammatory proteins. 
(Duque, Descoteaux 2014, Netea-Maier, Plantinga et al. 2016). Ras-related protein Rab-11b, 
which was found to be upregulated in Synsurf® exposed LPS stimulated AMs, may initiate a 
phenotype switch from M1 to M2 macrophages, which secrete anti-inflammatory cytokines 
such as TGF-β and IL-10 (autophagy inducer), as seen by Jiang and colleagues in the presence 
of apoptotic neutrophils thereby mediating resolution of inflammation (Jiang, Liu et al. 2017).  
The paradox that originates from the complex interactions between the apoptosis and 
autophagy remains a subject of considerable debate due to the therapeutic potential for cancer 
treatments. As the autophagic process occurs as cell maintenance and can act as a process for 
both cell protection and initiate cell death, elucidating the molecular mechanisms and 
connections between autophagy and apoptosis, may bring to light if one process controls the 
other (Gump, Thorburn 2011). The apoptosis regulator BAX protein, also known as bcl-2-like 
protein 4, was found to be upregulated in both the Liposurf® and the Synsurf® exposed LPS 
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stimulated AMs but down regulated in Curosurf®. Bcl2 family members act as apoptotic 
regulators; therefore, drugs that activate BAX hold promise as anticancer treatments by 
inducing apoptosis in cancer cells (Liu, Ding et al. 2016). This suggests that a pulmonary 
surfactant may be useful as a possible chemotherapeutic drug carrier for site-specific 
pulmonary cancer treatment. Dibbert and colleagues saw that neutrophils however, expressed 
little or no Bax under inflammatory conditions and concluded that Bax deficiency occurs at 
both mRNA and protein levels. Bax deficiency thus appears to be a general hallmark of 
neutrophils associated with delayed apoptosis via cytokine mediation (Dibbert, Weber et al. 
1999). However, AMs in the presence of Synsurf® and Liposurf® seem to overcome this 
deficiency and thereby apoptotic irregularity. Furthermore, traces of the inhibitor of apoptosis 
protein (IAP) anamorsin was also present in all three surfactant exposed LPS stimulated AMs 
groups (not significant). IAPs have anti-apoptotic effects in the cell via the involvement in 
negative control of cell death upon cytokine withdrawal (via STAT3, see Figure 3.22). These 
findings create a complicated paradigm where autophagy and apoptosis might be role players 
in a complex balancing act wherein autophagy alters the extent and kinetics of apoptosis and 
apoptosis may alter the autophagy occurrence in a stressed cell population thus explaining the 
presence of both pro- and anti-apoptotic regulators in a cell population. Determining the 
important interactions in autophagy’s regulation of cell death is necessary in therapy when 
endeavouring to protect healthy cells and to initiate death in diseased cells (Gump, Thorburn 
2011). 
 
Stellenbosch University  https://scholar.sun.ac.za
172 
 
 
Figure 3.22: The proposed dual autophagy-apoptosis pathway due to surfactant combinational treatment on AMs 
promoted by the JAK-STAT signalling pathway. 
Dynamin-1-like protein (Drp1) (upregulated in Curosurf® and Liposurf®, downregulated in 
Synsurf®) is involved in several important aspects of mitochondria’s morphology and size 
which are also relevant in T cell signalling. When Drp1 is upregulated, it impairs mitochondrial 
transport and mitochondrial dynamics (↑ ROS) thus causing mitochondrial dysfunction and 
fragmentation resulting in apoptosis or aberrant autophagy. The downregulated Drp1 in the 
Synsurf® exposed LPS stimulated AMs could also have led to reduced ROS production, 
reducing the transcriptional activity of NF-κB (Reddy, Reddy et al. 2011, Röth, Krammer et al. 
2014). It is important to mention that just because a protein regulates autophagy and also affects 
how efficiently a cell can undergo apoptosis, does not necessarily mean that it was the process 
of autophagy that affected apoptosis (Thorburn 2008, Eisenberg-Lerner, Bialik et al. 2009). 
Thus, it is important to underline the very complex participation of signalling pathways in 
surfactant exposed cells, as cells are programmed to undergo autophagy (apoptosis if 
autophagic threshold is reached) to limit their pro-inflammatory potential (Savill 1997). The 
connections between autophagy and apoptosis within surfactant exposed AMs might have more 
to do with “how” cells die, rather than changing whether or not they do die, thus modestly 
decreasing toxins and caspase activation. The latter was not detected within the surfactant 
exposed AMs.  
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3.3.3 Human BAL derived Macrophages’ Cytokine Secretion 
 
Selection of the subjects studied here was based on criteria unanimously accepted in the 
literature. In particular, the AMs from healthy controls and those from patients with classic 
types of non-diseased airway obstructions (heterogeneous population). The clinical 
characteristics together with the data on the BAL of the cases studied were similar to those 
reported in the literature. Once the present study had been judged suitable, the next step was to 
standardise the characteristics of cell culture and the concentrations of the different surfactants. 
Due to the small sample size of healthy patients, a standardised concentration was maintained 
as to keep statistical integrity regarding pool size. First, the mono-nuclear fraction 
(macrophages and lymphocytes) was separated of >90% neutrophils, erythrocytes, cellular 
detritus and dead cells by a density gradient, already reported in the literature for the separation 
of AMs and adapted accordingly (Ferro, Kern et al. 1987). The next step was to separate AMs 
from lymphocytes which is mainly due to the capacity of AMs to adhere to polystyrene dishes. 
Both methods permit the direct study of cytokine production by AMs. However, the results 
obtained should be interpreted with caution and understanding as adherence itself is able to 
stimulate the production of these types of inflammatory mediators (Rolfe, Kunkel et al. 1992, 
García, Rodriguez et al. 1999).  
 
Such an interpretation is featured in the low relationship between LPS stimulated release of IL-
1β, IL-2, IL-6 and IL-8 and their spontaneous secretion during prolonged exposure to LPS in 
combination with surfactant. Synsurf® displayed an approximate two-fold decrease in IL-1β 
release (97.60 pg/ml) compared to control levels (176.45 pg/ml) whereas both natural 
surfactants displayed minimal decreases (Table 3.12). After 24h, TNF-α levels (Table 3.16) 
decreased within the cell supernatant of the surfactant treated AMs. The Curosurf® (120.73 
pg/ml) and Liposurf® (110.01 pg/ml) groups displayed an approximate four-fold decrease in 
TNF-α release compared to control levels (462 pg/ml); whereas, Synsurf® (56.87 pg/ml) 
displayed a much larger, eight-fold, inhibitory effect on stimulated TNF-α release. TNF-α and 
IL-1β release by macrophages are “acute response” cytokines that promote neutrophilic and 
eosinophilic inflammation. Although they are not directly chemo-attractive agents, they may 
directly or indirectly stimulate the upregulation of relevant secondary cytokines (Table 3.18: 
GM-CSF) and cell adhesion molecules. The increased presence of TNF-α and IL-1β may 
synergistically amplify the expression of IL-6 (Table 3.14) and IL-8 (Table 3.15) (Ishii, Fujii 
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et al. 2004). This being said, it has been seen that peak TNF-α and IL-1β AM release occurs 
between approximately 8 - 12 h after initial exposure (Kerecman, Mustafa et al. 2008). This 
may explain the rather low LPS stimulated levels of these cytokines at 24 h compared to that 
of their downstream-regulated cytokines IL-6 and IL-8 (although both IL-6 and IL-8 are 
decreased within all three the surfactant groups) which may reach their peak concentrations 
much later. IL-6 was also found to be at much lower levels compared to IL-8. A previous study 
witnessed a similar phenomenon and elucidated that the relationship between basal secretion 
in culture and initial spontaneous release for IL-8 was much higher, intermediate release for 
IL-6 and low release for TNF-α. This once again suggests that adherence to the plastic culture 
plate is a very important stimulus in the secretion of IL-8 and, to a lesser extent, that of IL-6 
(García, Rodriguez et al. 1999). 
 
Both the natural surfactants decreased secretory levels of IL-2 (Table 3.13) whereas cell 
supernatant levels of IL-2 where increased when exposed to Synsurf®. It is important note that 
IL-2 activates several different pathways that mediate the flow of mitogenic and survival-
promoting signals (Benczik, Gaffen 2004). Moreover, IL-2 induces JAB/SOCS1/SSI-1 that in 
turn inhibits IL-2 signalling (Sporri, Kovanen et al. 2001). SOCS1 is involved in the negative 
regulation of cytokines and initiates an anti-inflammatory response via the regulation of 
homeostasis. Thus indicating that IL-2 also has anti-inflammatory properties, as does other pro-
inflammatory cytokines, such as IFN-γ (Bachmann, Kopf 2002). Levels of IFN-γ secretion 
(Table 3.17) decreased almost 3-fold when AMs were exposed to Curosurf® and Synsurf®; 
however, only an approximate 2-fold decrease in the presence of Liposurf® was witnessed. 
IFN-γ is important for the clearance of bacteria by recruiting many other cells (e.g. NK cells) 
but some reports indicate that IFN-γ is crucial for the cell cycle arrest in macrophage cell cycles 
that provides a survival signal, and others suggest that it serves as a pro-apoptotic signal. There 
have been many advances in the understanding of cell cycle control and apoptosis within 
isolation; however, the inter-relationship between these intimately related processes concerning 
protective immunity and immunopathology are yet to be fully understood (Schroder, Hertzog 
et al. 2004). 
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3.4 Conclusion 
 
There have been many hypothesises regarding the specific surfactant proteins that may be 
responsible for the role in blunting the inflammatory response and elicit a protective nature. 
However, this study shows how Synsurf®, a synthetic peptide containing surfactant, displayed 
the same “protective” nature, and even more so, to that of animal derived SP-B/C containing 
surfactants. One can then conclude that the initial hypothesis regarding the protective nature 
that is linked to the protein content in natural surfactants may be deemed as “not fully supported” 
as these new findings suggest non-specific lipid or synthetic peptide protection with AMs as 
seen by Synsurf®. Furthermore, the elucidation of the mechanisms involved in this cyto-
protective nature of pulmonary surfactants may offer a window into a patient-specific, 
individualised treatment option for inflammatory pulmonary disorders.  
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4 CHAPTER 4: In Vitro Activities of Linezolid in Combination 
with various Surfactants against Mycobacterium tuberculosis 
 
4.1 Introduction 
 
Tuberculosis (TB) infects almost all organs of the human body, but its the most common form 
is that of pulmonary TB. Worldwide, it was estimated that 9.6 million people were infected 
with TB in 2014 and South Africa has been reported to be the sixth highest regarding incidence 
and the eighth highest regarding estimated prevalence (World Health Organization 2015). In 
cases of pulmonary tuberculosis, pathological variations that have been observed range from 
crucial regions of alveolar collapse to areas of pneumonia and atelectasis. These pathologies 
are also associated clinically with lung surfactant dysfunction as seen in cases of adult and 
neonatal respiratory distress syndrome (Chimote, Banerjee 2005). Mycobacterium tuberculosis 
bacteria (M.tb), the causative agents for TB, lodge themselves within the alveolar space and 
some have the ability to invade, multiply and survive within alveolar macrophages. The 
alveolar spaces are lined with pulmonary surfactant creating the proximity for possible 
interactions of the M.tb bacilli surface and the surfactant constituents. The major component 
of the mycobacterial exterior is a lipid rich capsule. Cord factor, or trehalose dimycolate (TDM), 
forms the thick lipid coat barrier surrounding bacteria. This consequently shields them from 
the immune system's response and antibiotics. These cell wall lipids have the ability to 
spontaneously be released into the culture medium or via simple gentle mechanical abrasion. 
Similarly, these lipids within the cord factor may detached and shed into the pulmonary alveolar 
space, where they could interact with the pulmonary surfactant system (Ryan, Akinbi et al. 
2006) and previous studies have shown that the protective barrier might be compromised by 
exposing the bacteria to certain surfactants (Stoops, Arora et al. 2010). Although the feasibility 
of using surfactants for treating M.tb infections in mice was demonstrated many years ago, 
there was a decline in interest in the treatment of the disease as well as other novel treatment 
possibilities (Cornforth, Hart et al. 1955). However, recent studies investigated the effects of 
lung surfactant on the bactericidal activity of amoxicillin against Staphylococcus aureus and 
Streptococcus pneumoniae, and ceftazidime and tobramycin against Klebsiella pneumoniae, 
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Pseudomonas aeruginosa, S. aureus, and S. pneumonia (van't Veen, Mouton et al. 1995). This 
ultimately led to the renewed interest to test the use of exogenous surfactant as a vehicle for 
antibiotic delivery to the lung. As surfactants have the potential to overcome natural resistance 
of M.tb to antibiotics they can also act as permeabilising agents and allow for better penetration 
of drugs through mycobacterial barriers. In this regard a study by Risin and colleagues showed 
that treatment of TB with isoniazid (INH) was enhanced by administering surfactant as an 
aerosol into the lungs and thus established proof of principle that surfactants alone applied as 
an aerosol can also reduce the bacterial count in lungs infected with M.tb (Risin, Hunter et al. 
2014). This may be due to the mycolic acid found on the surface of M.tb bacilli that are 
moderate surface active agents which collapse at surface pressures between 20 and 40 mN/m 
(Ryan, Akinbi et al. 2006). 
 
When considering oral therapy for TB treatment, there is a significant hepatic metabolism that 
may lead to insufficient concentration of the anti-TB drugs within the alveolar spaces and 
macrophages where M.tb tend to hide. Therefore, targeted aerosolised antitubercular drug 
delivery may prove efficient in treating local lung TB infections (Patil-Gadhe, Kyadarkunte et 
al. 2014). Liposomal dry powder formulations for inhalation (LDPI) have shown many 
advantages and promising features in localising targeted particles within the respiratory tract; 
so much so, that the liposomal formulation of inhalable amikacin, named “Arikace”, has been 
approved as an orphan drug. It received orphan drug status in Europe for the treatment of 
bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients in July 
2006. Another example of an orphan drug is the use of ciprofloxacin inhalation for the treatment 
of non-cystic fibrosis bronchiectasis (BE) that has been approved by the US Food and Drug 
Administration (FDA) (Cipolla, Blanchard et al. 2016). These two inhalation liposomal 
formulations are currently under phase III and phase IIb clinical trial development stage, 
respectively (Patil-Gadhe, Kyadarkunte et al. 2014).  
 
Silverman and colleagues (2005), however, reported an inhibition of antibacterial activity of 
daptomycin alongside pulmonary surfactant interaction in vitro for Streptococcus pneumoniae. 
They explained that the interaction between daptomycin and pulmonary surfactant is a direct 
consequence of its mechanism of action. Daptomycin directly inserts into the membrane of 
gram-positive bacteria and artificial lipid vesicles. Pulmonary surfactant composition differs to 
that of most eukaryotic membranes but it does contain approximately 10% PG that is a 
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prominent component of the gram-positive bacterium’s plasma membrane (White, Frerman 
1967, Goerke 1998). PC lipid vesicles may allow for more interaction with daptomycin; 
however, negatively charged PG significantly enhances insertion into the cell membrane. 
Daptomycin has a direct insertion into the surfactant aggregates in vitro due to the calcium 
dependent surfactant interaction. This evidence supports the model that daptomycin is unable 
to distinguish between surfactant layers and the small surface area of target pathogens within 
the lung. Insertion into the surfactant layer is predicted to be an essentially irreversible process 
resulting in sequestration of the antibiotic(Silverman, Mortin et al. 2005), and therefore 
rendering it inactive. This may be the first example of a pulmonary surfactant-specific 
mechanism which results in the failure of an antibiotic whereas further studies otherwise 
support the opposite. It is therefore important to take the antibiotic target into consideration 
when aiming to employ surfactant-associated therapy, as membrane targets seem to be 
disordered whereas nuclear/intracellular targets are not. It is also important to take the 
characteristics of different infection sites into consideration when one looks at antimicrobial 
susceptibility as these sites may also affect pharmacodynamics activity of the antibiotics in 
question (Sauermann, Schwameis et al. 2009). 
 
The oxazolidinones represent a unique class of totally synthetic antimicrobial agents (they are 
not formed from natural product) that were first discovered in the 1970s but re-investigated in 
1996 resulting in linezolid’s discovery. For that reason, there are currently no pre-existing 
specific resistance genes among gram-positive bacteria (Moellering 2003). These agents also 
have a unique mechanism of action that precludes cross-resistance with currently available 
agents. Linezolid is the first oxazolidinone developed and approved for clinical use and is an 
inhibitor of bacterial ribosomal protein synthesis (mRNA synthesis). It prevents the formation 
of a 70S initiation complex by binding to domain V on the 50S ribosomal subunit near its 
interface with the 30S unit (Huang, Liu et al. 2008). Many compounds have been tested for 
their activity in vitro against M.tb strains; however, intracellular bacteria complicate optimal 
chemotherapy predictions. This is due to the fact that compounds depend on a series of 
pharmacokinetic and pharmacodynamic factors such as penetration, accumulation and 
bioavailability of the drugs inside cells for bacteria to be available to susceptibility. 
 
The recent increasing incidence of multidrug- and extensively drug resistant TB (MDR/XDR-
TB) worldwide necessitated the development of novel anti-mycobacterial agents. When 
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Linezolid was introduced in the treatment of multidrug-resistant Streptococcus pneumonia 
(Silver, Bostian 1990), it also led to its use with other second- and third-line drugs to treat 
patients with MDR/XDR-TB. Moreover, it has the ability to enter macrophages and thus has 
intracellular activity (Wang, Zhao et al. 2014).This is an important feature when it is to be used 
against mycobacteria that cause chronic infections and require long-term therapy (Leach, 
Brickner et al. 2011).  
 
This study reports the in vitro testing of two natural and one synthetic pulmonary surfactant on 
the anti-mycobacterial effect of Linezolid against a standard H37Rv M.tb strain as well as the 
resistant X51 M.tb strain. The approach of investigating an alternative treatment option for 
pulmonary tuberculosis that alters the bacteria’s cell membrane, and therefore its protective 
barrier, may prove exogenous surfactants as vehicles for drug delivery. The effects of various 
pulmonary surfactants on the action of the antimicrobial agent Linezolid against M.tb have not 
been described before. 
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4.2 Materials and Methods 
 
All experiments with infectious material were carried out in a category-3 biosafety laboratory. 
 
 
 
Linezolid used in this study was obtained as pure substances (Lot #015M4715V (CAT# 
PZ0014) Sigma-Aldrich Co., St. Louis, MO) and the dilution series was prepared in PBS (pH 
7.4). 
4.2.1 Mycobacterium species isolates 
Clinical isolates of M. tuberculosis R51 XDR strain and M. tuberculosis H37Rv reference 
strain, banked in the Department of Medical Biochemistry (SU), was cultured on L-J slant 
cultures and used for MGIT analysis. Quality control was carried out by coexistent 
determination of the MICs.  
 
4.2.2 Mycobacterium Culture and Growth Inhibition 
For drug-resistant strains from South Africa, mycobacterial growth was measured by using 
mycobacterial growth indicator tubes (MGIT). Mycobacterial inocula were prepared from 
cultures of all strains grown on Lowenstein Jensen (LJ) slants. Cell suspensions were prepared 
in saline and the turbidity adjusted to 0.5 McFarland units. A 1:5 dilution of the bacterial 
suspension was prepared, and 0.5 ml of the suspension was inoculated into MGIT tubes 
containing test and control compounds. For mycobacterial growth evaluation, the MGIT 960 
system (Becton Dickinson, Sparks, MD) was used, where M. tuberculosis growth is observed 
through fluorescent changes due to oxygen consumption during mycobacterial growth (Rusch-
Gerdes et al. & Becton Dickinson and Company). One-tenth millilitre of serially diluted 
(S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-
oxazolidinyl]methyl] acetamide 
H37Rv Strain R51 Strain 
 
1 µg/ml 
Figure 4.1: Minimum Inhibitory Concentration Linezolid. 
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compound was added to the MGIT tube containing 7H9 culture medium, with the final DMSO 
concentration not exceeding 1.2%. Incubation at 37 °C was continued in the MGIT system, and 
the growth units (GU) were monitored daily. For MIC99 evaluations, a 1% bacterial control 
culture was prepared in a drug-free MGIT tube and the MIC99 of the compound determined 
relative to the growth units of the control (GU = 400). When the GU of the growth control were 
400 and the GU of the drug-containing tube were more than 400, the results were defined as 
showing resistance, and when the GU of the drug-containing tube were less than 400, the results 
were considered to show susceptibility. 
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4.3 Results 
 
Table 4.1: M.tb H37Rv clinical isolate drug susceptibility testing with Linezolid at established MIC99 (1 μg/ml) 
with various exogenous surfactants (R, resistant; S, susceptible). Abbreviations: MIC99, minimum inhibitory 
concentration; PBS, Phosphate-buffered saline. 
COMPOUND CONCENTRATION 
(μg/ml) 
GROWTH UNITS 
(Day 8) 
SUSCEPTIBILITY 
MIC99 (µg/ml) 
Control - 400  
H37Rv with PBS solvent - 13816  
INH 0.05 μg/ml 0 S 
Linezolid 1 μg/ml 377 S 
Linezolid 0.5  μg/ml 4674 R 
Linezolid 0.25  μg/ml 12878 R 
Linezolid 0.125  μg/ml 12030 R 
Linezolid + Curosurf® 1 μg/ml 0 S (enhanced) 
Linezolid + Curosurf® 0.5  μg/ml 3242 R 
Linezolid + Curosurf® 0.25  μg/ml 13276 R 
Linezolid + Curosurf® 0.125  μg/ml 12180 R 
Linezolid + Synsurf® 1 μg/ml 94 S (enhanced) 
Linezolid + Synsurf® 0.5  μg/ml 4773 R 
Linezolid + Synsurf® 0.25  μg/ml 12783 R 
Linezolid + Synsurf® 0.125  μg/ml 14515 R 
Linezolid + Liposurf® 1 μg/ml 143 S (enhanced) 
Linezolid + Liposurf® 0.5  μg/ml 3706 R 
Linezolid + Liposurf® 0.25  μg/ml 13176 R 
Linezolid + Liposurf® 0.125  μg/ml 11228 R 
Curosurf® only 1 % 10674 R 
Synsurf® only 1 % 17589 R 
Liposurf® only 1 % 14252 R 
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Table 4.2: M.tb X51 clinical isolate drug susceptibility testing with Linezolid at established MIC (1 μg/ml) with 
various exogenous surfactants (R, resistant; S, susceptible). Abbreviations: MIC99, minimum inhibitory 
concentration; PBS, Phosphate-buffered saline. 
COMPOUND CONCENTRATION 
(μg/ml) 
GROWTH UNITS 
(Day 8) 
SUSCEPTIBILITY 
MIC99 (µg/ml) 
Control - 400  
X51 with PBS solvent - 12861  
Linezolid 1 μg/ml 0 S 
Linezolid 0.5  μg/ml 714 R 
Linezolid 0.25  μg/ml 6727 R 
Linezolid 0.125  μg/ml 9164 R 
Linezolid + Curosurf® 1 μg/ml 0 S 
Linezolid + Curosurf® 0.5  μg/ml 622 R 
Linezolid + Curosurf® 0.25  μg/ml 6131 R 
Linezolid + Curosurf® 0.125  μg/ml 10191 R 
Linezolid + Synsurf® 1 μg/ml 0 S 
Linezolid + Synsurf® 0.5  μg/ml 1255 R 
Linezolid + Synsurf® 0.25  μg/ml 6316 R 
Linezolid + Synsurf® 0.125  μg/ml 11684 R 
Linezolid + Liposurf® 1 μg/ml 0 S 
Linezolid + Liposurf® 0.5 μg/ml 301 S (enhanced)  
Linezolid + Liposurf® 0.25  μg/ml 5762 R 
Linezolid + Liposurf® 0.125  μg/ml 9021 R 
Curosurf® only 1 % 12892 R 
Synsurf® only 1 % 13420 R 
Liposurf® only 1 % 13333 R 
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4.4 Discussion 
 
Linezolid, in combination with the animal derived surfactants (Curosurf® & Liposurf®) and 
the synthetic surfactant (Synsurf®), displayed a certain degree of enhanced activity in both 
strains at certain concentrations compared to their unformulated counterparts in vitro. No 
decrease in Linezolid activity was witnessed when in combination with exogenous surfactant. 
There have been many suggestions and postulations as to why M.tb displays increased 
susceptibility to drugs when combined with various surfactants. Stoops and colleagues (Stoops, 
Arora et al. 2010) suggested that surfactants act as “permeabilising agents” and therefore are 
proficient enough in removing the TDM coat that acts as M.tb’s first line of defence. For this 
reason, increased drug permeability into the intracellular space of the bacteria takes place rather 
than increasing its own activity. This could be the very reason why Linezolid displays the 
increased activity in combination with surfactant even at lower MIC concentrations compared 
to Linezolid alone for both the H37Rv strain (Table 4.1) and the X51 strain (Table 4.2). Taking 
the surfactant proteins into consideration, SP-A and SP-D may facilitate the clearance of 
bacteria through numerous mechanisms. SP-A and SP-D may also act as opsonins to enhance 
bacterial phagocytic removal in vivo. Additionally, these collectins appear to exhibit anti-
microbial effects on bacteria by potentially increasing the permeability of their membranes 
(Glasser, Mallampalli 2012). Both SP-A and SP-D bind to LPS, but each interacts with LPS 
via different mechanisms: SP-D binds to LPS through the core oligosaccharides, whereas SP-
A binds to the lipid A domain. SP-D binds Gram-positive bacteria though peptidoglycan and 
lipoteichoic acid, however, SP-A is unable to interact with these parts but instead utilises the 
extracellular adhesin protein, Eap, on Gram-positive S. aureus for opsonisation as reported by 
Sever-Chroneos et al. (Sever-Chroneos, Krupa et al. 2011). These collectins promote 
phagocytosis indirectly, by stimulating the activity of alveolar macrophages (Lemos, 
McKinney et al. 2011). S. aureus is opsonized by SP-A, and this allows for the interaction with 
the recognised SP-A receptor 210 (SP-R210) on alveolar macrophages for phagocytosis (Sever-
Chroneos, Krupa et al. 2011). SP-R210, opsonised by SP-A, is also involved in eradicating 
Mycobacterium bovis (bacillus Calmette–Guerin) (Levine, Whitsett 2001). Furthermore, a 
study performed by Pasula and colleagues suggested that SP-A could mediate M.tb attaching 
to AMs in a Ca2+-dependent manner (Pasula, Downing et al. 1997). However, in a comparative 
study by Lemos and colleagues (2011), it was reported that the roles of SP-A and SP-D in M.tb 
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infection is not essential for immune control of M.tb in a low-dose, aerosol challenge, murine 
model of TB (Lemos, McKinney et al. 2011). 
 
There have also been reports that SP-B may also, although limited, be a participant in the innate 
host defence. Ryan et al. (2006) reported that SP-B, isolated from human BALF, killed clinical 
isolates of Gram-positive and Gram-negative bacteria in a dose-dependent manner. They too 
investigated synthetic peptide derivatives of SP-B, that exhibited a more discerning bactericidal 
tendency by means of selective lysed bacterial membranes. It was suggested that SP-B interacts 
with the surface of the lipid bilayer via amphipathic α helices. Therefore, the selectivity 
between native SP-B and the synthetic peptide derivatives could be due to the mechanism of 
action that has been proposed for a large number of cationic antibiotic peptides (Chimote, 
Banerjee 2005). For example, the proposed model by Shai (2002) argues that peptides act on 
bacterial membranes in four main steps (not discussed here) based on the electrostatic 
interactions and interfacial hydrophobicity of sufficient levels and accumulation of cationic SP-
B peptides (Shai 2002). However, Ryan et al.(2006) reported that only the cationic synthetic 
peptides were attracted to the negatively charged membranes forming permeabilising 
oligomers; whereas, native SP-B is able to permeabilise both anionic and zwitterionic 
membranes, even at low protein densities (Ryan, Akinbi et al. 2006).  
 
Synsurf® used in this study, is a synthetic lung surfactant containing polymers of poly-L-lysine 
electrostatically bonded with poly-L-glutamic acid (~50% neutralisation), to give a cationic 
peptide complex. The two-stranded polymer containing a percentage of basic lysyl side chains 
participate in the formation of protein-phospholipid bonds. The construct also has a degree of 
hydrophobicity in the neutralised double-stranded portion of the molecule forming antiparallel 
-sheet aggregates that interacts with the phospholipid bilayer; thus, mimicking some structural 
and/or functional properties of SP-B (Gray, Vander Velde et al. 1994, van Zyl, Smith 2013b, 
Shafer 1974, Hartmann, Galla 1978). Moreover, it is known that polycations are able to disrupt 
outer membranes of bacteria (Vaara 1992). In this regard, it was previously reported that M. 
smegmatis and M. tuberculosis display high sensitivity to the bactericidal activity of polylysine 
on its own (Delihas, Riley et al. 1995). However, our results show that the cationic polymer 
construct with poly-L-glutamic acid in Synsurf® only displayed antimycobacterial activity in 
combination with linezolid. This finding is also similar to the results shown with the natural 
surfactants tested in this study. Although experiments using surfactant in live bacterial cultures 
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are complex and can be difficult to interpret, we have shown previously that surfactants 
significantly enhance the permeability of drugs across different epithelia (Viljoen 2005). Taken 
together, it therefore remains possible that the cationic peptide construct of Synsurf® is able to 
initiate translocation and cause an increase in membrane permeabilisation in M.tb bacilli in 
order to initiate the enhanced antimycobacterial effect of linezolid. 
 
In summary, the benefit of combining linezolid with a surfactant’s antibacterial potential, as 
indicated in this study, may be useful to improve site-specific drug administration that could 
allow for lower dosages and minimizing subsequent systemic adverse-effects in the treatment 
of resistant strains to current chemotherapy regimens. 
 
4.5 Conclusion 
 
The fundamental limitations of this study have to be taken into consideration. Various 
surfactants were used instead of human surfactant; furthermore, the concentration of the 
exogenous surfactant used in this study was significantly lower than the concentration of 
pulmonary surfactant that would be found lining the epithelium. One can therefore conclude 
that the concentration of pulmonary surfactant, as well as SP-B, in vivo may further influence 
antibiotic activity. However, regardless of concentrations, the surfactants display an impact on 
the antibiotic activity, the findings of which potentially are of clinical relevance but which must 
be investigated further in clinical settings. The effects of exogenous surfactants on the 
microbiology within the human lung in vivo have yet to be investigated as well. Although this 
is only a first step to study the changes in susceptibility of linezolid combined with exogenous 
surfactants to M.tb, the finding holds positive ramifications towards the development of a 
surfactant loaded with linezolid and other antitubercular drugs in the treatment of one of the 
most dreaded diseases. 
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5 CHAPTER 5: Investigating the Calu-3 cell line as a model 
for the delivery, deposition and transport of the pMDI form 
of Synsurf® 
 
5.1 Introduction 
 
There has been considerable effort invested in generating aerosols for pulmonary delivery over 
the last 10 years. In this regard, administering clinically relevant dosages of inhaled drug and 
control of lung-regional distribution thereof has proven to be challenging. Moreover, the 
pharmaceutical industry relies on suitable in vitro models for evaluation of drug absorption and 
metabolism as an alternative to testing in animals. The aim of inhalation of drugs for pulmonary 
disease therapy is to increase the local drug concentration by avoiding systemic toxicity of said 
compounds. Three essential variables should therefore be considered. Firstly, precision of the 
drug targeting specific regions within the lung, preventing drug deposition and loss in the upper 
respiratory tract. Secondly, uniform drug deposition in the lung that allows for reliable drug 
dosing, even under varied conditions and diseases. Thirdly, aiming for consistency in that 
uniform drug deposition occurs throughout the device’s life span. When considering these 
principal pillars of lung deposition of aerosols, improved understanding of the delivery devices 
and active compounds is required (Georgopoulos, Mouloudi et al. 2000). However, the lung is 
a complex organ that the functioning of which is regulated by multiple factors such as the 
structure of the epithelia, the physicochemical properties of the drug as well as the type of 
delivery system used. Although improved drug deposition remains an important aim, enhanced 
therapeutic effects do not necessarily follow. Studies of drug deposition in vitro may reveal the 
fate of deposited particles on respiratory epithelia, which may allow for a better understanding 
of similar happenings in vivo (Haghi, Traini et al. 2014). However, the physical features of the 
respiratory system, as well as its metabolic activity and drug efflux systems constitute a barrier 
against drug absorption and therefore are vital components for the study of drug transport and 
potential site for drug toxicity (Florea, Cassara et al. 2003). 
The human bronchial adenocarcinoma, Calu-3 cell line, due to its simple reproducible process 
and similarity in vivo physiology, has become the alternative investigatory model for the in 
vitro study of proximal airway respiratory exposure to better understand determinants that 
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influences pulmonary drug dissolution, absorption, metabolism and efficacy (Ong, Traini et al. 
2013, Harcourt, Haynes 2013). Several studies have validated Calu-3 cells as suitable model 
for investigating drug and ion transport due to their well-formed differentiated, polarised, 
electrically resistant cell layers (Shen, Finkbeiner et al. 1994, Foster, Avery et al. 2000, Meindl, 
Stranzinger et al. 2015). From a drug delivery perspective, the objective in this study was to 
investigate whether the use of two formulations of the synthetic surfactant Synsurf [S], 
combined with linezolid, is suitable as a carrier and drug delivery agent for inhalation. Although 
the idea to use lung surfactant as a carrier agent was proposed several years ago with a 
tobramycin-surfactant mixture, where it was shown in our previous studies that Synsurf 
enhances the permeability of drugs such as 17-estradiol, hydrocortisone, dexamethasone, 
zidovudine and isoniazid across porcine bronchial tissue (Viljoen 2005). This new synthetic 
lung surfactant contains the amphipathic phospholipid DPPC and surface-active 
phosphatidylglycerol, as well as 1-hexadecanol and tyloxapol and a polymer peptide complex 
of poly-L-lysine and poly-L-glutamic acid. Although various drugs have been tested in 
combination with lipid particles, the synthetic lung surfactant Alveofact was the first 
liposomal product to reach the market in 15 to 20 years (Beija, Salvayre et al. 2012).  
 
The aim of this study was therefore to test linezolid combined with Synsurf in a pressurised 
metered dose inhaler (pMDI) utilising a Calu-3 cell line as target model. To our knowledge, 
this is an unexplored area with regards to the drug.  
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5.2 Materials and Methods 
 
Reagents and Standards 
HPLC grade acetonitrile (Romil, UK), MilliQ water (Millipore, Milford, MA, USA) and 
ammonium acetate (Analytical, Merck, Darmstadt, Germany) were used in the mobile phase. 
The rest of the analyte standards and linezolid were supplied by Sigma Aldrich (St. Louis, MO, 
USA). Standards were made up volumetrically and appropriately diluted in 50% acetonitrile. 
The rest of the standards were made up to 0.005 mg/L, 0.05 mg/L, 0.5 mg/L, 2.5 mg/L, 5 mg/L, 
25 mg/L, 50 mg/L and 250 mg/L to fall within the expected concentration range that it may 
occur in samples which had been diluted ten times.  
 
Culture of Calu-3 Cells 
The Calu-3 cell line (ATCC® HTB-55™) (passage 33–36) was first cultured as a polarised 
liquid-covered culture in 75 cm2 flasks and maintained in a humidified, 5% CO2–95% 
atmospheric air incubator at 37°C before subcultured in 12 cm diameter Transwell© inserts 
(0.33 cm2 polyester, 0.4 μm pore size) from Costar. Culture medium comprised of Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 1% nonessential 
amino acid solution (×100), 1% L-glutamine solution (200 mM), and 1% Penicillin-
Streptomycin. 
 
Cells cultured on Transwell© supports were seeded at a density of 5×105 cells/cm2 and were 
introduced into the apical surface of the Transwell© support in 0.2 ml medium with 2 ml 
medium added to the basolateral chamber. The cells were incubated at 37 °C, 5% CO2 for 24hrs. 
For air-liquid interface culture, the cell culture medium was removed on day 2 post-seeding. 
The cell layers were evaluated through light microscopy with a Nikon TMS Inverted Phase 
Contrast Microscope (Nikon, Japan). Trans-epithelial electrical resistance (TEER) was 
measured using an EVOM2 chopstick electrode and EVOM2 Epithelial Voltohmeter (World 
Precision Instruments, USA). Pre-warmed medium (0.2 ml, 37°C) was added to the apical 
chamber before returning cells to the incubator to equilibrate for a further 30 min, and then 
measuring the electrical resistance. TEER was calculated by subtracting the resistance of a cell-
free culture insert with correction for the surface area of the Transwell© cell culture support. 
When the trans-epithelial electrical resistance had reached a value of >700 Ω*cm2 in submersed 
culture, it was considered confluent. In air-liquid interface culture, the medium (1.5 ml) in the 
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basolateral compartment was changed every 2 – 3 days. 0.5 ml and 1.5 ml media were added 
to the apical and the basolateral compartment respectively for TEER measurements. Prior to 
the reading cells were equilibrated for 30 min in the incubator.  
 
TEER values were calculated as follows (Equation 1): 
 
TEER ( * cm2) = (Sample – blank resistance, given in ) * membrane area, given in cm2 
 
Blank resistance is defined as the resistance of the membrane without cells and the membrane 
area for 12-well inserts is calculated to be 1.12 cm2/well. 
 
 
Figure 5.1: Calu-3 air-liquid interface cell culture. 
 
Cell Surface Staining 
Alcian blue staining was employed for the detection of glycoproteins. Cell layers were washed 
twice with 100 ml HBSS and fixed for 10 min by using 2.5% (v/v) glutaraldehyde in 0.1 M 
sodium cacodylate buffer. The cells were washed again with HBSS and 100 ml alcian blue 
stain [1% (w/v) alcian blue in 3% (v/v) acetic acid/water at pH 2.5] added for 1 h. The dye was 
then removed and cell layer washed with HBSS until the rinsate ran clear. 
 
Surfactant preparations 
Two synthetic surfactant preparations were used in the study; (i) Synsurf® prepared as 
described previously by van Zyl and colleagues (prep 1)and (ii) Synsurf formulated with the 
addition of 2 wt% cholesterol (prep 2) (Van Zyl, Smith et al. 2013a). Both formulations were 
then freeze-dried for further use in the pressurized metered dose inhaler (pMDI). 
 
Synsurf® pMDIs 
Canisters were filled with a 1:1 ratio of linezolid to Synsurf® (prep 1 & 2). Hydrofluoroalkane 
(HFA) propellant (Mexichem-Fluor, Runcorn) was added and the canisters were sealed with a 
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Pamasol Manual Crimper and Filler (DH Industries, Essex, UK). Three canisters were 
conveyed as: L= linezolid alone, LP1= linezolid + Synsurf® prep 1, and LP2= linezolid + 
Synsurf® prep 2. 
 
Synsurf® preparation: 
Prep1:DPPC 1200.5 mg (♯2); PG 120.5 mg; P-Lys 40.003 mg; P-Glu 12.66 mg; Cet-OH 
133.5 mg 
Prep 2:DPPC 1202.3 mg (♯2); PG 120.8 mg; P-Lys 40.56 mg; P-Glu 12.98 mg; Cet-OH 132.2 
mg; Cholesterol 24.3 mg (2 wt%) 
 
 
 
Figure 5.2: (A) pMDI with mouth-piece and canisters containing surfactant and relevant drug. (B) Illustration 
showing that the size of the canister stem and pin hole for the actuator in an albuterol chlorofluorocarbon-propelled 
metered-dose inhaler (MDI) differs from the hydrofluoroalkane-propelled MDI. The actuator of the 
chlorofluorocarbon-propelled MDI cannot be used interchangeably with the actuator of a hydrofluoroalkane-
propelled MDI, and vice versa. (Illustration courtesy of James B Fink, MSc, RRT, FAARC.) (Georgopoulos, 
Mouloudi et al. 2000). 
 
Scanning electron microscopy (SEM), cell surface morphology and pMDI drug deposition 
The Calu-3 Transwells© were placed in the fixative solution, 2.5% glutaraldehyde and 0.5 g 
potassium ferrocyanide dissolved in 50 ml normal strength culture media (without serum) post 
pMDI actuation. The fixative was not added to the apical layer as to avoid possible “emulsion” 
of surfactant. Rather, the apical side of the Transwell© was covered within a glass dome with 
fixative solution in neighbouring wells and fixed via gaseous means for 2 hours. Cells were 
then washed with serum-free media and post-fixed with 1% osmium tetroxide + 1% potassium 
ferrocyanide for 1 hour at room temperature on the apical and basolateral side. Cells were 
A B 
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washed twice with distilled water over 15 minutes. The membranes were carefully cut out and 
placed in small glass vials and stained with 2% aqueous uranyl acetate for 1 hour in the dark. 
Membranes were further washed with acetone 50, 70 and 90% each one over 10 minutes and 
then twice with 100% acetone, followed by one 15 minute wash with an equal mix of acetone 
and Hexamethyldisilazane  (HMDS) and then two final 15 minute washes with HMDS. They 
were left partially covered overnight and subsequently sputter coated with gold to achieve a 
thickness of approximately 20 nm (Edwards Sputter Coater S150B, Edwards High Vacuum, 
Sussex, UK). Imaging was performed using scanning electron Microscopy (JOEL 
SEM6480LV system, Tokyo, Japan). 
 
In vitro aerosol deposition studies using a NGI device and dissolution analysis 
A multistage cascade Next Generation Impactor™ (Copley Scientific) (NGI), for testing 
metered-dose inhalers was used. The impaction plates of the NGI were modified to 
accommodate 6 transwells at 3 stages. This allowed the study of different particle size fractions. 
The loaded device was connected to the throat of the NGI via a moulded mouthpiece. Testing 
was performed at a 60L min-1 flow rate with a 5 second exposure time after each actuation. A 
dissolution assay of samples in the basolateral Transwell© was performed upon each actuation 
(n=2). Samples were vortexed for 30 seconds with HBSS buffer, Sigma Aldrich (St. Louis, MO, 
USA), containing HEPES (10 mM) and a 0.025% TWEEN and then centrifuged for 10 min at 
3000 rpm. Supernatants (±1 ml) were then transferred to HPLC vials. At the end of the 
experiment, the surface of the Calu-3 cells were washed with buffer and residual apical drug 
collected for analysis. This allowed for the calculation of total drug deposited via the 
cumulative sum of all samples. 
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Figure 5.3: Next Generation Impactor™ (Copley Scientific). (Right Top) Stage 1: 1 hole; 14.3 mm. Stage 3: 24 
holes; 2.185 mm. Stage 5: 152 holes; 0.608mm. Stage 7: 630 holes; 0.206 mm. (Right Bottom) Stage 2: 6 holes; 
4.88 mm. Stage 4: 52 holes; 1.207 mm .Stage 6: 396 holes; 0.323 mm. MOC 4032 holes 70 micron 
 
Sample preparation 
Samples from dissolution assays were vortexed for 30 seconds, centrifuged on a Hermle 
Z160M centrifuge (LASEC, SA) for 10 min at 3000 rpm and the supernatant (±1ml) was 
transferred to an HPLC vial. 
 
Analyses of Linezolid by LC-MS  
A Waters Synapt G2 quadrupole time-of-flight mass spectrometer (Waters Corporation, 
Milford, MA, USA), fitted with a Waters Acquity UPLC and photo diode array detector (PDA) 
was used for LC-MS analyses. Separation was achieved on a Waters BEH Amide UPLC 
column (2.1 x 100 mm, 1.7 μm) at a temperature of 35°C. Solvent A consisted of 10mM 
Ammonium acetate in water, solvent B consisted of 10mM Ammonium acetate in 95% 
acetonitrile. The gradient consisted of a flow rate 0.25 ml/min, starting with 95% B to 40% B 
over 9 minutes, applying gradient curve 7, followed by re-equilibration to initial conditions 
over 5 minutes. Electrospray ionization was done in the negative mode, using a capillary 
voltage of 2.5 kV, a cone voltage of 15 V, desolvation temperature of 250°C and desolvation 
gas (N2) flow of 650 L/h. The rest of the MS settings were optimised for best sensitivity. Data 
was acquired in MSE mode, consisting of a scan using a low collision energy and a scan using 
a collision energy ramp from 25-60 V, which has the added advantage of acquiring low energy 
molecular ion data as well as fragmentation data for all analytes over time. Data was collected 
using a scan rate of 0.2 seconds over the range m/z 100 - 1000. Leucine enkaphalin was used 
as lock mass for accurate mass determination on the fly using a lock mass flow rate of 0.002 
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ml/min, acquiring lock mass data every 20 seconds. Sodium formate was used to calibrate the 
instrument. The PDA detector was set to scan over the range: 220 - 450 nm. 
 
Drug permeability 
The transport of compounds across Calu-3 cells is typically expressed in terms of the apparent 
permeability coefficient (Papp) measured in the absorptive apical to basolateral (Ap - Bl) 
direction and is calculated using Equation 5.1:  
 
Equation 5.1: 
 
 
Where dQ/dt is the linear transport rate of the compound, A is the surface area of the cell layer 
and C0 is the initial compound concentration in the donor chamber. 
 
Statistical Analysis 
All results are expressed as mean ± standard deviation of at least two replicate experiments. 
Data were analysed by GraphPad Prism, Version 5, statistical software package (GradPad 
Software Inc, San Diego, CA, 92130 USA). Analysis of variance (ANOVA) one-way (with 
Tukey’s post hoc analysis) was utilised to test for significance (which was quoted at the level 
of P ≤ 0.05) between treatment groups. 
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5.3 Results 
 
Transepithelial resistance 
Calu-3 cells were grown at the air interface to allow monolayer differentiation, and experiments 
were performed between days 11 and 14 when TEER reached values between 750 - 1000Ω*cm2 
(Figure 5.4). These conditions have previously been established by Haghi et al. (Haghi, Young 
et al. 2010). After the high TEER was determined and thus the presence of tight junction 
proteins confirmed, the surface properties of Calu-3 cells were studied by SEM pre- and post 
pMDI impactor actuation. Alcian Blue staining of the Calu-3 cells cultured at air-liquid 
interface was employed to indicate the presence and increasing concentration of membrane 
transporter proteins (Figure 5.5). 
 
 
Figure 5.4: Trans-epithelial electrical resistance in Calu-3 cells at ALI. 
 
 
Figure 5.5: Alcian Blue staining of the Calu-3 cells cultured at ALI indicating the presence and increasing 
concentration of membrane transporter proteins (A) Day 1 (B) Day 7 (C) Day 14. 
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Transepithelial drug transport 
The average particle size (D50) for the NGI™ stages was established as follows: Stage 2: 4.46 
μm; Stage 3: 2.82 μm and Stage 4: 1.66 μm at a flow rate of 60 L/min (Copley Scientific 2017). 
Uptake and transport experiments with linezolid were performed 14 days after seeding and 
trans-epithelial flux measurements were performed as well as the total amount of trans-
epithelial drug transported and cellular uptake were calculated.  
Apparent permeability for the three separate preparations in the absorptive direction (apical-to-
basal) were determined for 240 minutes (after a 20 min pre-incubation to establish a state of 
linear flux). Fluxes are expressed as ng/mm2/min. The passive (paracellular) route across the 
epithelium was estimated by repeated linezolid flux determinations that indicated steady-state 
diffusion.  
Since these parameters are difficult to control i.e. the amount of recovered sample (start 
concentration in apical compartment, volume and the amount of samples within each NGI™ 
chamber), the initial compound concentration (C0) in the donor chamber was established at the 
end of each uptake experiment (4 h). The total amount of linezolid collected from the basal 
compartment, as well as drug remaining on the cell surface and inside the cells were summed 
to represent total deposited mass (Haghi, Traini et al. 2013). 
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Figure 5.6: Total drug masses deposited on Calu-3 cell monolayer for , stage 2; , stage 3; and , stage 4. (n = 2, 
mean ± standard deviation (SD)) (one-way analysis of variance (ANOVA), Tukey's post-test P ≤ 0.0001). 
 
Figure 5.6 displays the total drug masses deposited on Calu-3 cell monolayer. One-way analysis 
of variance showed that the amounts of L deposited in the single preparation and in combination 
preparations (LP1 & LP2) were similar in stages 2 and 3. However, significant differences in 
deposited mass was found in stage 4 for L (452.50 ± 32.01 ng) vs. LP1 (363.96 ± 6.18 ng) and 
L vs. LP2 (235.59 ± 6.05 ng) and LP1 (363.96 ± 6.18 ng) vs. LP2 (235.59 ± 6.05 ng). This 
could be due to the increased weight/size of the combination preparations and the relative 
distance travelled to stage 4 (illustrates lower lung deposition) which could indicate the role of 
impaction rather than sedimentation for larger molecules.  
 
*** 
*** 
*** 
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Figure 5.7: The relative transport rate (Papp) measured for Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid 
+ Prep 2 (LP2) across the Calu-3 Transwell© in Stage 2. (one-way analysis of variance (ANOVA), Tukey's post-
tests P  ≤  0.05, no significance seen). 
 
Figure 5.7 displays the relative transport rate (Papp) of linezolid measured for L, LP1 and LP2 
across the Calu-3 Transwell© in Stage 2. Initial transport rates for L, LP1 and LP2 were found 
to be similar at Papp values of 1.95 x 10
-4 (±0.30) ng.mm-2.min-1, 1.93 x 10-4 (±0.60) ng.mm-
2.min-1, and 1.51 x 10-4 (±0.96) ng.mm-2.min-1 respectively. In Figure 5.8, L and LP1 presented 
similar initial Papp values of 1.64 x 10
-4 (±0.61) ng.mm-2.min-1 and 1.67 x 10-4 (±0.01) ng.mm-
2.min-1 in stage 3 again; whereas LP2 displayed a significantly lower (P ≤ 0.05) Papp value of 
5.9 x 10-6 (±0.60) ng.mm-2.min-1. Stage 4 represented in Figure 5.9, shows similar initial 
transport rates for L, LP1 and LP2 at Papp values of 2.20 x 10
-4 (±0.18) ng.mm-2.min-1, 2.02x10-
4 (±0.41) ng.mm-2.min-1,and 1.96 x 10-4 (±0.85) ng.mm-2.min-1 respectively. These transport 
rates were also similar to those found in stage 2 (Figure 5.7).  
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Figure 5.8: The relative transport rate (Papp) measured for Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid 
+ Prep 2 (LP2) across the Calu-3 Transwell© in Stage 3. (one-way analysis of variance (ANOVA), Tukey's post-
test * P  ≤ 0.05). 
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Figure 5.9: The relative transport rate (Papp) measured for Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid 
+ Prep 2 (LP2) across the Calu-3 Transwell© in Stage 4. (one-way analysis of variance (ANOVA), Tukey's post-
test P  ≤ 0.05, no significance seen). 
 
Analysis of the transport after 4 h showed that 74.77 ± 9.50% mass percentage of linezolid from 
the single preparation (L) was detected in the basal chamber for stage 2. The percentage of 
linezolid detected in the basal chamber from the combination preparation LP1 (92.22 ± 0.25%) 
was significantly higher than from the combination preparation LP2 (56.42 ± 10.28%) for stage 
2 (Figure 5.10). Stage 3 (Figure 5.11) showed very similar mass percentage after transport at 4 
h of linezolid in the basal chamber for the single preparation L (86.50 ± 9.75%), and the 
combination preparations LP1 (72.55 ± 7.92%) and LP2 (88.31 ± 1.32%), respectively. The 
mass percentage of linezolid detected in the basal chamber for stage 4 (Figure 5.12) after 4 h 
* 
* 
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showed significant difference between the combination preparations LP1 (90.79 ± 0.55%) and 
LP2 (71.27 ± 12.98%), however, no difference was seen for the single preparation L 
(84.05 ± 3.44%).  
As seen in Figure 5.10, analysis of the epithelial cell contents revealed that after 4 h, 
18.35 ± 11.75% of linezolid from the single preparation (L), 5.00 ± 1.36% from the 
combination preparation, LP1, and a significant increased amount of 35.75 ± 6.27% from the 
combination preparation, LP2, were found in the epithelial cells at stage 2. Therefore, at the 
end of the experiment, 7.84 ± 0.08% of linezolid from L, 2.46 ± 0.97% from the combination 
preparation LP1, and 7.16 ± 2.4% from the combination preparation LP2, respectively, 
remained on the surface of the epithelial cells. The amount of linezolid that remained on the 
surface of the epithelial cells from LP2 significantly increased (P  ≤  0.05) to that of LP1. The 
mass percentage remaining of linezolid in the single preparation L was also found to be 
statistically more than that of LP1 (Figure 5.11).  
 
Figure 5.10: Percentage of total drug mass in the basal chamber, remaining on the cell surface, and inside the 
cells after 4 h after deposition of Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid + Prep 2 (LP2) at stage 2. 
(n = 2, mean ± standard deviation (SD)) (n = 3, mean ± SD) (one-way analysis of variance (ANOVA), Tukey's 
post-tests, * P  ≤ 0.05, ** P  ≤ 0.01 ). , % in the basal compartment at 240 min; , % on cells at 240 min; , % 
in cells at 240 min. 
 
** 
* * 
* 
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The mass percentage of linezolid remaining in the epithelial cell contents after 4 h for stage 3 
can be seen in Figure 5.11. Linezolid from LP1 (27.34 ± 10.19 %) was significantly higher than 
that of linezolid from L (8.31 ± 4.79%) and LP2 (9.72 ± 0.24%), respectively. A similar mass 
percentage of linezolid remaining on the cell surface of the apical compartment was detected 
in stages 3 and 4 for all three preparations. The epithelial cell content of linezolid for the single 
preparation L was similar to stages 2 and 3 at 13.89±1.63 mass percentage at stage 4. The mass 
percentage (stage 4) of linezolid remaining in the epithelial cell contents from the combination 
preparation LP2 (22.22 ± 8.37%) was found to be statistically higher than that of linezolid from 
combination preparation LP1 (8.28 ± 0.27%). Stage 4 (Figure 5.12) showed a similar pattern 
in the differences of mass percentage for drug remaining within epithelial cell lysate contents 
for LP1 vs LP2 (P ≤ 0.05). This direct comparison indicates the effect of drug combination 
type on cellular uptake and transport. 
 
 
Figure 5.11: Percentage of total drug mass in the basal chamber, remaining on the cell surface, and inside the 
cells after 4 h after deposition of Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid + Prep 2 (LP2) at stage 3. 
(n = 2, mean ± standard deviation (SD)) (n = 3, mean ± SD) (one-way analysis of variance (ANOVA), Tukey's 
post-tests, * P  ≤ 0.05). , % in the basal compartment at 240 min; , % on cells at 240 min; , % in cells at 
240 min. 
 
* * 
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Figure 5.12: Percentage of total drug mass in the basal chamber, remaining on the cell surface, and inside the 
cells after 4 h after deposition of Linezolid (L), Linezolid + Prep 1 (LP1) and Linezolid + Prep 2 (LP2) at stage 4. 
(n = 2, mean ± standard deviation (SD)) (n = 3, mean ± SD) (one-way analysis of variance (ANOVA), Tukey's 
post-tests, * P  ≤ 0.05). , % in the basal compartment at 240 min; , % on cells at 240 min; , % in cells at 
240 min. 
 
Surface morphology of Calu-3 cells grown via air-liquid interface (ALI) culture 
Scanning electron microscopy was used to study the surface of the cells after 11 days in ALI 
culture (Figure 5.13), the point at which the TEER maintained its maximum resistance of 
approximately 750 - 1,000 Ω cm2 and the cell layer was presumed to be ‘intact’ with fully 
formed tight junction proteins accompanied with mucus production. The boundaries between 
cells were also observed as clearly shown. 
Calu-3 cells were clearly shown to express cilia after 7 days in culture (Figure 5.14A & B); a 
characteristic trait which is only present in a differentiated pseudostratified epithelium. Around 
95% of all cells in each sample displayed cilia; however, some cell populations displayed a 
diverse degree of differentiation. The shape and length of cilia also varied between cells and 
some displayed a “clumping” characteristic which has also been described by Proctor (Proctor 
2013) who reasoned it to be due to the fixing method.  
* 
* 
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Figure 5.15 displays highly magnified images visualising the particles present on the cell 
surface post- pMDI fire. Particle size delivered by the pMDI were formulation dependent. The 
particles have been determined by SEM visualisation and indicated that, in general, the particles 
were well dispersed 60 seconds post-fire. LP1 displayed a more striated dispersion (Figure 
5.16A & B) whereas agglomerates were preferentially seen for LP2. (Figure 5.16C). Images 
are representative of n=2 independent experiments. 
 
Figure 5.13: (A) Linezolid particles deposited on top of the cells for Stage 2; (B) Examples of tight junction belt 
fractures after freeze-drying for SEM. 
 
Figure 5.14: SEM images of Calu-3 epithelial layers grown at ALI where cilia on the surface is visible as well as 
a mucosal layer. 
 
Figure 5.15: SEM images visualising the deposition of Synsurf® and Linezolid on the Calu-3 epithelial layers 
grown at ALI immediately post pMDI-fire. Droplets were measured between 500 nm and 1 µm. 
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Figure 5.16: SEM images visualising the deposition of Synsurf® on the Calu-3 epithelial layers grown at ALI. 
Unique spreading properties over the mucosal layers are visible 60 seconds post pMDI-fire for (A & B) LP1 and 
(C) LP2. 
  
A B C 
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5.4 Discussion 
 
In this study we compared the diffusion kinetics of linezolid formulated alone and within two 
preparations of a synthetic surfactant (Synsurf) based pMDI (LP1 & LP2) across a Calu-3 
cell Transwell© culture. The different surfactant drug combinations allow for an evaluation of 
the significance of the experimental model system, as well as assessment of the formulations 
providing a possible non-invasive, site-specific, delivery model via pMDI. From a drug 
delivery perspective this is valuable in the potential development and characterization of a 
drug-loaded synthetic surfactant. 
 
Under our experimental conditions with a total dose of 500 μg (C0), fired from the pMDI, the 
concentration delivered was calculated in the different regions of the lung (Copley Scientific 
2017). The same reasoning could be used for the deposition of the compound at the different 
stages of the NGITM. In the large conducting airways (Stage 1 of the NGITM), the potential 
deposited concentration could amount from 30 to 300 ng/cm2. The peak concentration in the 
segmental bronchi (Stage 2) and the small conducting airways (Stage 3) could be 30 ng/cm2 
and in the alveoli, the concentration was shown to be 0.1 – 1 ng/cm2 (Stage 4-5), which 
correlated with the total mass deposited on the Calu-3 cell surface (Figure 5.6).  
 
In studies conducted with Caco-2 cells it was shown that the apparent permeability coefficients 
of compounds with different physicochemical properties and mechanisms of permeation, have 
a very distinctive effect on the rate of transport. Moreover, drug permeability under Fick’s law 
(Equation 5.1) assumes that the driving force is a concentration gradient difference between 
the single barrier of the cell monolayer. This either leads to the sequestration of lipophilic drugs 
into the phospholipid membranes, in transcellular diffusion, or partitioning of hydrophilic drugs 
into aqueous tight-junctional areas by paracellular diffusion (Mathias, Timoszyk et al. 2002, 
Hilgers, Conradi et al. 1990). On the other hand, high passive permeability is not necessarily 
synonymous with high lipophilicity because hydrogen bonding or the presence of an unstirred 
water layer for a group of compounds can delimit permeability to such an extent that the 
compounds would exhibit a low permeability (Sun, Pang 2007). This theory may be the 
explanation for the decreased permeability of linezolid in LP2 containing cholesterol for stage 
2 and 3 compared to that of L and LP1. The 2 wt% cholesterol addition to Synsurf® Prep 2, 
may have contributed to the more lipophilic nature of the compound LP2 as a whole. However, 
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our data show that LP2 displayed the lowest Papp value, albeit not all significant, of all three 
compounds over all three stages of the NGI™ (Figures 5.7 – 5.9). These findings differ to that 
from a report by Foster and colleagues that found a linear relationship between the log Papp and 
the log octanol/ water partition coefficient (Foster, Avery et al. 2000). The moderate 
lipophilicity of linezolid is demonstrated in Figures 5.10 – 5.12 where the remaining 
concentration values are conveyed for all three pMDI preparations over all 3 stages. Linezolid 
displays the highest concentration for remaining drug on the surface of the Calu-3 monolayer 
at stages 2 and 3 compared to that of linezolid in combination with either of the Synsurf® 
preparations (LP1 & LP2). One can thus speculate that linezolid alone and LP2 has the ability 
to embed within the cell as their lysate concentration values were found to be similar. In such 
a situation, electrostatic and hydrophobic interactions are enhanced and may reinforce each 
other. The different particle sizes among the stages should also to be taken into consideration 
when deliberating the remaining surface drug of cell lysate concentrations; as there could very 
well be a higher concentration of drug in a certain particle size distribution and thus more 
deposited in a certain stage than others.  
 
Synthetic particles of diverse forms have gained increasing attention, as evident from recent 
studies, which suggested that morphology could influence the mechanisms of drug delivery in 
many ways (Champion, Katare et al. 2007, Simone, Dziubla et al. 2008, Yoo, Doshi et al. 2011, 
Kim, Dobson 2009, Venkataraman, Hedrick et al. 2011). In studies conducted by Lu et al., it 
was shown that key parameters such as altering surfactant concentration might alter solution 
viscoelasticity and surface tension that will change the morphology of the preparation such as 
filament forming between drops. Instead of filaments breaking up rapidly, they change from a 
spherical to a spindle-like appearance (Lu, Hou et al. 2015). Under our experimental conditions, 
we found a more agglomerated and “ribbon-like” nature of LP2 (Figure 5.16C) compared to 
that of cholesterol-devoid LP1 (Figure 5.16B) that; displayed more perpendicular spreading 
like characteristics. Moreover, the temperature at which DPPC transitions from the gel phase 
to the rippled phase (Tp = 36 °C ) could also be of significance where DPPC based liposomes 
form vesicle pearling filaments as seen in Figure 5.16A and B (Lu, Hou et al. 2015, Arai, 
Yoshimoto et al. 2016). This is reflected for both Synsurf®/linezolid preparations that 
displayed similar supra-molecular entanglements with the incorporation of droplets and beaded 
filaments.  
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The delivered particles and drug dose showed a high dependency from the preparation that has 
been aerosolised. The Synsurf®/linezolid preparations (LP1 & LP2) showed an assortment of 
particle ranges from 500 nm to 2 μm in the emitted dose which have been similarly reported by 
Zanen et. al. and other studies (Zanen, Go et al. 1996, Blank, Rothen-Rutishauser et al. 2006, 
Meindl, Stranzinger et al. 2015). It is generally accepted that to be therapeutically effective, the 
particles should be in the range of 1 to 5μm since particles > 5μm will generally impact on the 
mucosa of the oropharynx and be swallowed whereas those < 1μm may remain entrained in the 
airstream and be exhaled during the next breathing cycle (Copley Scientific 2017). The smaller 
particles may be deposited peripherally and may be more effective since surfactant is present 
and functions in the alveolar region. The LP1 and LP2 pMDI particle diameters measured with 
SEM imaging revealed suitable size distribution to achieve desired lung distribution and still 
be deemed therapeutically effective. However, fast inhalations (>60 L/min) such as illustrated 
with a pMDI, result in a reduced peripheral deposition because the aerosol is more readily 
deposited by inertial impaction in the conducting airway and oropharyngeal regions (Labiris, 
Dolovich 2003b).  
 
In summary, a synthetic surfactant Synsurf®-based pMDI was investigated to deliver the anti-
tubercular drug linezolid. Our data shows that linezolid can be aerosolised in desired particle 
ranges for optimal lung deposition. The use of the NGITM and the Calu-3 cell line for the 
assessment of linezolid dissolution and transport after particle co-deposition has allowed for a 
more realistic investigation with respect to the in vivo situation. This report is the ﬁrst to 
studySynsurf® in a pMDI in the evolution of surfactant therapy and drug delivery.  
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6 Concluding Remarks 
 
This study outlined three main themed questions crucial to understanding surfactant pulmonary 
drug delivery: 1) Is surfactant a suitable inhalable drug carrier within a pMDI, 2) Does 
surfactant influence anti-tubercular drug activity in vitro, and 3) to what extent exogenous 
surfactants influence alveolar macrophage immunomodulatory characteristics? Moreover, 
investigating comparable exogenous surfactants indicate that the synthetic surfactant Synsurf® 
may be a worthy competitor to the natural surfactants, Curosurf® and Liposurf®. Considering 
this study’s unique findings, the elucidation of the possible mechanisms involved in the cyto-
protective nature of pulmonary surfactants may offer a window into a patient-specific, 
individualised treatment option for inflammatory pulmonary disorders.  
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7 LIST OF ABBREVIATIONS 
 
%   percentage 
=   equal 
~   approximately 
>  greater than 
≥   greater than or equal to 
<  less than 
≤   less than or equal to 
±   plus or minus 
v/v:  volume per volume 
w/v:  weight per volume 
w/w:  weight per weight 
wt%:  weight percentage 
Å   angstrom 
°C   degrees Celsius 
ε   barrier porosity 
µ   micro 
ρ  pico 
η   viscosity 
Ω   ohm 
λex   excitation wavelength 
λem   emission wavelength 
®   registered trademark 
 
ACI:   Andersen cascade impactor 
AGC:  Automatic gain control 
AIC:   Air interface culture 
ALI:  Acute lung injury 
AM:   Alveolar Macrophages  
ANOVA:  Analysis of variance 
APC:   Antigen-presenting cell 
APCI:   Atmospheric pressure chemical ionization 
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API:  Active pharmaceutical ingredient 
ARDS: Adult respiratory distress syndrome 
ATCC:  American Type Culture Collection 
BAL:   Bronchoalveolar lavage 
BALF:  Bronchoalveolar lavage fluid 
BCG:   Mycobacterium bovis bacille Calmette-Guérin 
BE:  Cystic fibrosis bronchiectasis 
BMRC:  British Medical Research Council 
Ca2+:   Calcium 
CCD22: Coiled-coil domain-containing protein 22 
CCL5:  Chemokine (C-C motif) ligand 5 
CF:  Cystic fibrosis 
CFC:  Chlorofluorocarbon 
CFU:   Colony-forming unit 
CH3CN: Acetonitrile 
Cm:  Centimeter 
CO2:   Carbon dioxide 
COMMD1: Copper Metabolism Domain Containing 1 
COPD: Chronic obstructive pulmonary disease 
CPAP:  Continuous positive airway pressure 
CRD:  Rhodamine dextran concentration 
CREB:  cAMP response element binding protein 
CUL1:  Cullin–RING  
Da:   Dalton 
DAN:   2, 3-diaminonaphthalene 
DC:   Dendritic cells  
DCF:   2′,7′ –Dichlorofluorescein 
DCFH-DA:  2′,7′ –Dichlorofluorescein acetate 
DDW:  Deionized distilled water 
Di:  Diffusion coefficient 
DMEM:  Dulbecco’s modified eagle’s medium 
DMF:  Dimethylformamide 
DMSO: Dimethyl sulfoxide  
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DOTS:  Directly observed treatment short-course 
DPIs:   Dry powered inhalers 
DPPC:  Dipalmitoyl-L-α-phosphatidylcholine 
DPI:  Dry powder inhaler 
Drp1:  Dynamin-1-like protein  
e.g.   For example 
EGF:   Epidermal growth factor 
ELISA:  Enzyme-linked immunosorbent assay 
ESBL:  Extended spectrum β-lactamase-Klebsiella 
et al.:  And others 
EVOM: EVOM voltohmmeter 
F-12:   Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 
FA:  Formic acid 
FBS:  Fetal bovine serum 
FDA:  US Food and Drug Administration 
FDR:  False discovery rate 
FHC:  Ferritin Heavy Chain 
FP:  Fluticasone propionate 
g  Gram 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GBS:   Group B streptococcus 
GI:   Growth Index 
GM-CSF: Granulocyte macrophage colony stimulating factor 
h   Hour 
HBSS:  Hank’s buffered salt solution 
HCD:  Higher energy collisional dissociation 
H&E:  Hematoxylin and Eosin 
HEPES: N-[2-hydroxy-ethyl]piperazine-N’-[2-ethanesulfonic acid] 
HFA:  Hydrofluoroalkane 
HIV:  Human immunodeficiency virus 
HMDS: Hexamethyldisilazane 
HPLC:  High performance liquid chromatography 
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HPLC-MS/MS: High performance liquid chromatography coupled with tandem mass 
spectrometry 
IAP:  Inhibitor of apoptosis protein 
ICS:  Inhaled corticosteroid 
i.e.   That is 
IL-1β:   Interleukin-1 beta 
IL-2:  Interleukin-2 
IL-6:   Interleukin 6 
IL-8:  Interleukin-8 
IL-10:  Interleukin-10 
IL-12:  Interleukin-12 
IFN-γ:  Interferon gamma 
INH:  Isoniazid 
iNOS  Inducible nitric oxide synthase 
IRAK:  Interleukin-1 receptor-associated kinase 
IRF3:  Interferon regulatory transcription factor 
ITIM  Immunoreceptor tyrosine-based inhibitory motif 
J:   Initial rate for mass permeation 
JAK/STAT: Janus kinase/Signal transducer and activator of transcription 
KC-GRO: Keratinocyte chemoattractant-human growth-regulated oncogene 
KEGG: Kyoto encyclopedia of genes and genomes 
L:  Liter 
LDPI:  Liposomal dry powder formulations for inhalation 
LJ:  Lowenstein Jensen 
Log P:  Octanol-water partition coefficient 
LP1:  Synsurf®/linezolid preparation 1 
LP2:  Synsurf®/linezolid preparation 2 
LPS:   Lipopolysaccharide 
LUVs:  Large unilamellar vesicles 
m:  Meter 
M:  Molarity 
M:  Methionine 
MCP1:  Monocyte chemotactic protein 1 (CCL2) 
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MDR TB: Multidrug drug-resistant TB 
Mg2+:   Magnesium 
MGIT :  Mycobacteria Growth Indicator tubes 
MIC:   Minimum inhibitory concentration 
MIP-1α: Macrophage Inflammatory Proteins 
MLVs:  Multilamellar vesicles 
MMTS: Methane methylthiosulphonate 
mN/m:  millinewton/meter 
MOMP Mitochondrial outer membrane permeabilisation 
MRNA: Messenger ribonucliac acid 
MRSA:  Methicillin-resistant Staphylococcus aureus 
MTB:   Mycobacterium tuberculosis 
MTT:  3-(4,5-Dmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW:  Molecular weight 
MyD88: Myeloid differentiation primary response 88 
n:  Nano 
NEAA:  Non-essential amino acid 
NFκB:  Nuclear factor kappa B 
NGI:  Next generation impactor 
NK:  Natural killer cells 
NO:   Nitric oxide 
NQ:  Asparagine/glutamine 
nRDS:  Neonatal respiratory distress syndrome 
ORAC:  Oxygen radical absorbance capacity  
PANPs: Pathogen-associated molecular patterns 
Papp:  Apparent permeability coefficient 
PAS:  Para-aminosalicylic acid 
PBMC: Peripheral blood monocytes 
PBS:  Phosphate-buffered saline 
PC:  Phosphatidylcholine 
PCP:  Pnumocystis pneumonia 
PCS:   Polymer-containing surfactant 
PDA:  photo diode array detector 
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PDD:   Pulmonary drug delivery 
PE:  Phosphatidylethanolamin 
PENSTREP: Penicillin-Streptomycin 
PG:   Phosphatidyl glycerol 
pH:  Negative log of hydrogen ion concentration or activity 
PI:  Phosphatidylinositol 
pMDI:  Pressurized metered dose inhaler 
PPI:  Protein-protein interaction 
PRRs:  Pattern recognition receptors 
Prx1:  Peroxiredoxin-1 
PS:  Phosphatidylserine 
Px:  Pixels 
PZA:  Pyrazinamide 
RANTES: Regulated on activation, normal T cell expressed and secreted 
RDS:   Respiratory distress syndrome 
RelA:  Rel-like domain-containing proteins 
RHOA: Ras homolog gene family, member A 
RIF:  Rifampicin 
RNA:   Ribonucleic acid 
ROI  Reactive oxygen intermediates 
ROS   Reactive oxygen species 
Rpm:  Revolutions per minute 
RPMI-1640:  Roswell Park Memorial Institute medium 1640 
RR-TB: Rifampicim-resistant tuberculosis 
RSV:  Respiratory syncytial virus 
RT:  Respiratory tract 
s:  Second 
SD:  Standard deviation 
SE:  Standard error 
SEM:  Scanning electron microscopy 
SEM:   Standard error of the mean 
SIRPα:  Signal inhibitory regulatory protein α 
SM:  Sphingomyolin 
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SM:  Streptomyocin 
SNO:   Denitrosylation 
SOCS1: Suppressor of cytokine signalling 1 
SOCS3: Suppressor of cytokine signalling 3 
SP-A:   Surfactant protein A 
SP-B:   Surfactant protein B 
SP-C:   Surfactant protein C 
SP-D:   Surfactant protein D 
SPDE:  Monoclonal Mouse anti-SFTPD / Surfactant Protein D Antibody 
STRING Search Tool for the Retrieval of Interacting Genes 
SU:  Stellenbosch University 
SUVs:  Small unilamellar vesicles 
TB:   Tuberculosis 
TBS:  Tris buffered saline 
TC:   T cells 
TCEP:  Triscarboxyethyl phosphine 
TDM:  Trehalose dimycolate 
TDR-TB: Totally drug-resistant tuberculosis 
TEAB:  Triethylammonium bicarbonate 
TEER:  Transepithelial electrical resistance 
TLR:  Toll-like receptor 
TM:  Trade mark 
TNF-α:  Tumor necrosis factor alpha 
Tp:  Temperature 
Trx1:  Thioredoxin 1 
V:  Volt 
vs.:  Versus 
WHO:  World Health Organization 
XDR-TB: Extensively drug-resistant TB 
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8 APPENDIX A: MTT Cell Viability Assay Protocol 
 
Method: 
Three independent experiments were conducted in triplicate. 
 An Isopropanol solution (1%): containing 1 ml concentrated HCl and 99 ml Isopropanol 
was made.  
 Triton solution (0.1 %): 0.1 ml Trition-X-100 + 99 ml dH20 
 An Isopropanol / Triton solution was made in a 50:1 ratio, where 50 ml of 1% 
Isopropanol was added to 1 ml of 0.1% Triton  
 MTT (0.01 g/1 ml PBS) solution was made up just before use. MTT is photosensitive, 
thus the solution was covered in foil. 
 Medium was removed from treated cells. 
 PBS (1.5 ml) and MTT (500 µl) was added and allowed to incubate, in 6 well plates 
covered with foil for 2 hours at 37ºC. 
  
NOTE: 0.01g/1 ml PBS (+3 ml PBS)   ---> 4mL PBS 
  4 mL is enough for 8 wells of a 24-well (500 µl per well) 
  24 wells x 9 plates = 216 wells 
  216 wells / 8 wells = 27 mL PBS 
0.01 x 27 = 0.27g in 27 ml PBS 
 
Then FILTER 
Then add another 81 mL PBS 
 
Reference: 
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of immunological methods, 65(1-2), pp.55-63. 
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9 APPENDIX B: Phalloidin Staining Protocol 
 
Sigma Aldrich Phalloidin from Amanita phalloides – TRITC (P1951) 
Emission: 540-545 nm 
Excitation: 570-573 nm 
Storage: -20⁰C (Freezer in Histology) 
Light sensitive – keep in brown bottle, covered with foil  
Stock solution: 
 1mg made up to 0.5 mg/ml in 2ml methanol  
 Vortex and store in freezer 
Working solution: 50 µg/ml 
For 1 ml:  
 100µl stock solution of Phalloidin (10x diluted) 
 10µl DMSO (1%) 
 890 µl PBS (89%) 
Stainingprocedure: 
 
 Wash cells with PBS  
 Fix cells for 10 min in 3.7-4% paraformaldehyde made up in PBS 
 Wash cells 3 x 5 min with PBS 
 Permeabilise cells for 6 min with 0.1 % Triton X-100 in PBS 
 Wash cells 3 x 5 min in PBS 
 Blocking (optional): 5% goat serum – 30 min / overnight in fridge (4ºC) 
 Wash cells 3 x 5 min with PBS 
 Stain with Phalloidin-TRITC (50 µg/ml) for 40 min @ room temperature 
 Wash3 x 5 min with PBS 
 Add Hoechst (1:8000) for 5 min @ room temperature  
 Wash 3 x 5 min with PBS 
 Let slides air dry for a few minutes 
 Mount upside down on microscope slides (moviol / fluorescent mounting media) 
 Air dry slides for at least an hour before freezing (Histology freezer).  
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10 APPENDIX C: ROS Flow Cytometry Protocol 
 
General ROS - DCF (Sigma): 
Fluorescent probe 2′,7′ –dichlorofluorescein acetate (DCFH-DA, final concentration 25 µM). 
MW: 401.20 g/mol 
 
1.  Culture cells in T75 flasks and plate in 12 well plates 
2. When cells are 70-80% confluent, begin treatment protocol 
3. At the end of treatment protocol, remove media 
4. Trypsinise all wells, aspirate in eppi’s and centrifuge @ 1500 rpm for 3 min 
5. Re-suspend in (300-500 µl) of PBS 
(Note: the amount of PBS you re-suspend in should be confirmed with CAF staff prior 
to your experiment:± 1 x 106 cells per mL) 
6. Add required amount of dye to the PBS cell suspension (5 µl) 
7. Incubate cells for 15 mins before taking cells to CAF unit for analysis. 
 
Make a 2 mM concentration of stock solution by weighing out the dye and dissolving in PBS.  
Dissolve 0.02g of solute in 25 mL to yield 2mM (or 0.04012g in 50mL) 
 
 
Therefore 5 µl in 250 µl cell sample to yield 25µM 
*DCF is light sensitive so wrap in foil when working with it. 
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11 APPENDIX D: Mycoplasma Testing Protocol 
 
When to test: All new cell lines (e.g. gifts from other labs) should be tested as soon as possible 
(preferably before freezing down to build up stock – might be wasting time and consumables). 
Frozen stock that has not yet been tested should also be tested once thawed. With continuous 
culture, routine testing should be performed. This can vary, every 1 - 3 months, and can depend 
on the amount of work being done – e.g. maybe test just before performing a set of important 
experiments. Also, important to remember, the more people working in a lab, the greater the 
risk for contamination.  
To test cells, maintain a separate flask in antibiotic-free media – maintain and passage flask 2-
3 times. This will allow a “low infection” to proliferate, making it easier to identify.  
Day 1 
Plate cells: 
 Place a clean coverslip (UV sterilised, or dipped in EtOH and allowed to air-dry) in a 
35mm dish (or in a well of 6-well plate, however the dish will be easier to handle) 
 Seed cells into dish in antibiotic-free media – avoid seeding cells to dense, there should 
still be spaces between cells on day 3 
Day 3 
Fixing cells:  
 Add 1ml of fixing solution (Metanol:Acetic Acid 3:1) to dish (don’t remove media) 
 Wait 10 sec, pour off into waste bottle 
 Add another 1 ml fixing solution 
 Wait 10 sec, pour off into waste bottle 
 Rinse 3x gently with dH20 
 Place dish upside down on a paper towel to dry 
Stain cells: 
 Make sure the coverslip is dry 
 Add 100 – 200 µl (just enough to cover coverslip) of Hoechst stain and incubate 
(covered) for 10 min 
 Pour off staining solution 
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 Rinse 3x gently with dH20 
Mount: 
 Place one drop of mounting fluid on a glass microscope slide 
 Pick up coverslip with tweezers and dab side on paper towel to remove excess H20. 
Place upside down on glass slide 
View under fluorescent microscope under blue filter (Ex 360 nm, Em 430 – 490 nm, on Leica 
Microscope use filter A) – first use 10x then 40X (actual 100x and 400x).  
 
Example: a) clean vs. b) infected 
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12 APPENDIX E: List of conference contributions, 
publications and awards 
 
 
2017  Faculty of Medicine and Health Sciences 60th Academic Year Day 
Oral Presentation Title: Investigating the Possible Immunoactive and 
Immunomodulatory properties of various Surfactants 
L van Rensburg1, J van Zyl2, and J Smith3 
1, 2. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg, 3. Department of Pediatrics 
and Child Health, Tygerberg Children’s Hospital, Faculty of Medicine and Health 
Sciences, Stellenbosch University 
 
2016  Faculty of Medicine and Health Sciences 60th Academic Year Day 
Poster Presentation Title: Investigating the Possible Immunoactive and anti-
mycobacterial properties of various Surfactants 
L van Rensburg1, J van Zyl2, and J Smith3 
1, 2. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg, 3. Department of Pediatrics 
and Child Health, Tygerberg Children’s Hospital, Faculty of Medicine and Health 
Sciences, Stellenbosch University 
 
2016  Golden Key honorary society member (Stellenbosch Chapter) 
 
2016 International Conference: 2016 All Africa Congress on Pharmacology and 
Pharmacy 
Misty Hills Hotel and Conference Centre, Muldersdrift, Gauteng, South Africa. 
Oral Presentation Title: Investigating the Possible Immunoactive and anti-
mycobacterial properties of various Surfactants 
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2015 National Conference: South African Society of Basic and Clinical 
Pharmacology (SASBCP) and Toxicology SA (ToxSA), held atThe Wits 
Club, Johannesburg hosted by The Wits Division of Pharmacology. 
Oral Presentation Title: Establishing the Calu-3 Cell line: A model for the investigation 
of the delivery and deposition of a Surfactant-drug based pressurised metered-dose 
inhaler (pMDI) 
L van Rensburg1, J van Zyl2, and J Smith3 
1, 2. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg, 3. Department of Pediatrics 
and Child Health, Tygerberg Children’s Hospital, Faculty of Medicine and Health 
Sciences, Stellenbosch University 
 
2015  Faculty of Medicine and Health Sciences 59th Academic Year Day 
  Poster Presentation Title: Establishing the Calu-3 Cell line: A model for the 
investigation of the delivery and deposition of a Surfactant-drug based pressurised 
metered-dose inhaler (pMDI) 
L van Rensburg1, J van Zyl2, and J Smith3 
1, 2. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg, 3. Department of Pediatrics 
and Child Health, Tygerberg Children’s Hospital, Faculty of Medicine and Health 
Sciences, Stellenbosch University 
 
2015-2016 NRF Doctoral Freestanding, Innovation, Scarce Skills Scholarship award  
 
2014  IUPHAR’s 17th World Congress of Basic and Clinical Pharmacology 
(WCP2014) 
Poster Presentation Title: Drug Susceptibility testing of Mycobacterium 
tuberculosis to Isoniazid and fluoroquinolone entrapped 1,2 Dipalmitoyl-L-α-
phosphatidylcholine liposomes  
Lyné van Rensburg¹, Johann van Zyl², I anWiid³ 
¹´²Division of Pharmacology, ³Division Molecular Biology and Human 
Genetics Faculty of Medicine and Health Sciences, Stellenbosch University, 
Tygerberg, 7505, South Africa 
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2014  University of Bath Global Partner Research scholarship award 
Completed a 6-month research visit to the University of Bath (United Kingdom) 
under the supervision of Prof. Robert Price. 
 
 
Peer-reviewed Papers 
 
Pressurised Metered Dose inhaler (pMDI) Deposition of Linezolid combined with a 
synthetic surfactant Synsurf®: A Calu-3 Model 
 
Lyné van Rensburg1, Johann M van Zyl2, and Johan Smith3 
1, 2. Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Tygerberg, 7505, South Africa; 3. Department of Pediatrics, 
Tygerberg Children’s Hospital, Faculty of Medicine and Health Sciences, Stellenbosch 
University, Stellenbosch University, Tygerberg, 7505, South Africa 
 
Submitted to Drug Design, Development and Therapy, DovePress 
 
The Comparative Effect of Pulmonary Surfactants in combination with Linezolid on the 
Susceptibility of Mycobacterium tuberculosis in vitro. 
 
Lyné van Rensburg1, Johan M van Zyl2, Andile H Ngwane3, and Johan Smith4 
1, 2 Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch 
University, Tygerberg, 7505, South Africa; 3 DST/NRF Centre of Excellence for Biomedical 
Tuberculosis Research/MRC Centre for Tuberculosis Research, Division of Molecular Biology 
and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, 
Tygerberg, 7505, South Africa. 4 Department of Pediatrics, Tygerberg Children’s Hospital, 
Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch University, 
Tygerberg, 7505, South Africa 
 
Submitted to Experimental and Therapeutic Medicine, Spandidos Publications 
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Immunoactive properties of Synsurf®, Curosurf® and Liposurf® 
 
Lyné van Rensburg1, Johann M van Zyl2, and Johan Smith3 
1, 2 Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch 
University, Tygerberg, 7505, South Africa; 3 Department of Pediatrics, Tygerberg Children’s 
Hospital, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch 
University, Tygerberg, 7505, South Africa 
 
Submitted to Frontiers in Pharmacology, Inflammation Pharmacology. 
 
Patents 
 
Further Medical Use of Synsurf® Surfactant - PCT International Patent Application  
No. PCT/IB2017/056119 
Stellenbosch University  https://scholar.sun.ac.za
